JP5918217B2 - 特定のアミノピリダジン、その組成物、及びこれらの使用方法 - Google Patents
特定のアミノピリダジン、その組成物、及びこれらの使用方法 Download PDFInfo
- Publication number
- JP5918217B2 JP5918217B2 JP2013506327A JP2013506327A JP5918217B2 JP 5918217 B2 JP5918217 B2 JP 5918217B2 JP 2013506327 A JP2013506327 A JP 2013506327A JP 2013506327 A JP2013506327 A JP 2013506327A JP 5918217 B2 JP5918217 B2 JP 5918217B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridazin
- amino
- fluoro
- methyl
- pyridyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title description 114
- 238000000034 method Methods 0.000 title description 15
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical class NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 title description 7
- -1 3-fluorocyclobutyl Chemical group 0.000 claims description 569
- 150000001875 compounds Chemical class 0.000 claims description 327
- 125000000217 alkyl group Chemical group 0.000 claims description 210
- 125000001424 substituent group Chemical group 0.000 claims description 126
- 229910052736 halogen Inorganic materials 0.000 claims description 109
- 150000002367 halogens Chemical class 0.000 claims description 109
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 105
- 150000003839 salts Chemical class 0.000 claims description 92
- 125000003118 aryl group Chemical group 0.000 claims description 81
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 75
- 239000001257 hydrogen Substances 0.000 claims description 74
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 74
- 229910052799 carbon Inorganic materials 0.000 claims description 73
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 72
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 68
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 62
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 59
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 54
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 53
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 50
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 47
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 47
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 47
- 210000003205 muscle Anatomy 0.000 claims description 44
- 201000010099 disease Diseases 0.000 claims description 43
- 150000002431 hydrogen Chemical class 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 36
- 125000003342 alkenyl group Chemical group 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 125000001188 haloalkyl group Chemical group 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 229910052757 nitrogen Inorganic materials 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 17
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 17
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 16
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 206010028417 myasthenia gravis Diseases 0.000 claims description 13
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 12
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 12
- 206010049565 Muscle fatigue Diseases 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 11
- 125000002883 imidazolyl group Chemical group 0.000 claims description 11
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 11
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 11
- 125000002971 oxazolyl group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 11
- 125000000335 thiazolyl group Chemical group 0.000 claims description 11
- 125000001544 thienyl group Chemical group 0.000 claims description 11
- 125000001425 triazolyl group Chemical group 0.000 claims description 11
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 10
- 208000021642 Muscular disease Diseases 0.000 claims description 9
- 201000009623 Myopathy Diseases 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 201000000585 muscular atrophy Diseases 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000005412 pyrazyl group Chemical group 0.000 claims description 8
- 125000005495 pyridazyl group Chemical group 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 7
- 206010028289 Muscle atrophy Diseases 0.000 claims description 7
- 208000018360 neuromuscular disease Diseases 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000020763 muscle atrophy Effects 0.000 claims description 4
- YDCAQDYGXSWTBH-UHFFFAOYSA-N n-[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-imidazol-2-yl]acetamide Chemical compound N1C(NC(=O)C)=NC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 YDCAQDYGXSWTBH-UHFFFAOYSA-N 0.000 claims description 4
- SPYWHVYKYUSAOQ-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 SPYWHVYKYUSAOQ-UHFFFAOYSA-N 0.000 claims description 3
- UQHNZAJPCPAKFL-UHFFFAOYSA-N 3-[5-cyano-6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(C(=C1)C#N)=NN=C1C1=CC=CC(C(N)=O)=C1 UQHNZAJPCPAKFL-UHFFFAOYSA-N 0.000 claims description 3
- XBVAEBNCRCKKBF-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(C(N)=O)C=N1 XBVAEBNCRCKKBF-UHFFFAOYSA-N 0.000 claims description 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- QLJZUQVFZHZTRN-UHFFFAOYSA-N n-[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazol-3-yl]acetamide Chemical compound C1=C2C(NC(=O)C)=NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 QLJZUQVFZHZTRN-UHFFFAOYSA-N 0.000 claims description 3
- ZEGWHKOYFNEIOE-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-n-methylacetamide Chemical compound S1C(CC(=O)NC)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZEGWHKOYFNEIOE-UHFFFAOYSA-N 0.000 claims description 2
- MUHNGCZYAXXZEE-UHFFFAOYSA-N 2-fluoro-5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 MUHNGCZYAXXZEE-UHFFFAOYSA-N 0.000 claims description 2
- NINXQUZKJNBQML-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzonitrile Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C#N)N=N1 NINXQUZKJNBQML-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 150000002222 fluorine compounds Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 150000003857 carboxamides Chemical class 0.000 claims 16
- 230000003796 beauty Effects 0.000 claims 15
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 4
- VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 4
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 3
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 3
- 229940124530 sulfonamide Drugs 0.000 claims 3
- WEAXWBRPRMMBHI-UHFFFAOYSA-N 3-[6-[(3-fluoro-1-pyridin-2-ylcyclobutyl)methylamino]pyridazin-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3N=CC=CC=3)=CC=2)=C1 WEAXWBRPRMMBHI-UHFFFAOYSA-N 0.000 claims 2
- SKKULIKXLRZWDR-UHFFFAOYSA-N 3-[[[6-(1h-indazol-6-yl)pyridazin-3-yl]amino]methyl]-3-pyridin-2-ylcyclobutan-1-ol Chemical compound C1C(O)CC1(C=1N=CC=CC=1)CNC1=CC=C(C=2C=C3NN=CC3=CC=2)N=N1 SKKULIKXLRZWDR-UHFFFAOYSA-N 0.000 claims 2
- SNFYDJKOAVMCBY-UHFFFAOYSA-N C1C(NN)CC1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 Chemical compound C1C(NN)CC1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 SNFYDJKOAVMCBY-UHFFFAOYSA-N 0.000 claims 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims 2
- INVVHZZJPXMAPH-UHFFFAOYSA-N N-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-(4-hydrazinylcyclohexyl)pyridazin-3-amine Chemical compound C1CC(NN)CCC1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 INVVHZZJPXMAPH-UHFFFAOYSA-N 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims 2
- LGFPRDMSWSLRPD-UHFFFAOYSA-N n-[[2-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]acetamide Chemical compound S1C(CNC(=O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 LGFPRDMSWSLRPD-UHFFFAOYSA-N 0.000 claims 2
- KHJYUNIXWFRNTI-OAHLLOKOSA-N (2r)-2-amino-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-3-hydroxypropanamide Chemical compound S1C(CNC(=O)[C@@H](CO)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KHJYUNIXWFRNTI-OAHLLOKOSA-N 0.000 claims 1
- XHPTVARSLWOMMU-CYBMUJFWSA-N (2r)-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-hydroxypropanamide Chemical compound S1C(CNC(=O)[C@H](O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 XHPTVARSLWOMMU-CYBMUJFWSA-N 0.000 claims 1
- KHJYUNIXWFRNTI-HNNXBMFYSA-N (2s)-2-amino-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-3-hydroxypropanamide Chemical compound S1C(CNC(=O)[C@H](CO)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KHJYUNIXWFRNTI-HNNXBMFYSA-N 0.000 claims 1
- XHPTVARSLWOMMU-ZDUSSCGKSA-N (2s)-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-hydroxypropanamide Chemical compound S1C(CNC(=O)[C@@H](O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 XHPTVARSLWOMMU-ZDUSSCGKSA-N 0.000 claims 1
- DKJDJKXVQSCYMB-IBGZPJMESA-N (2s)-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-4-methylsulfonylpiperazine-2-carboxamide Chemical compound C1N(S(=O)(=O)C)CCN[C@@H]1C(=O)NCC1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 DKJDJKXVQSCYMB-IBGZPJMESA-N 0.000 claims 1
- NHVNWOGXVOJJLK-UHFFFAOYSA-N 1,1,1-trifluoro-2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]propan-2-ol Chemical compound S1C(C(O)(C)C(F)(F)F)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 NHVNWOGXVOJJLK-UHFFFAOYSA-N 0.000 claims 1
- YTPFAIZMNQVACE-UHFFFAOYSA-N 1-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]ethanol Chemical compound S1C(C(O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 YTPFAIZMNQVACE-UHFFFAOYSA-N 0.000 claims 1
- XOJPOTHNVNRMMN-UHFFFAOYSA-N 1-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]ethanone Chemical compound S1C(C(=O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 XOJPOTHNVNRMMN-UHFFFAOYSA-N 0.000 claims 1
- ZFXYYSIXAQKZSK-UHFFFAOYSA-N 1-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-5-yl]ethanone Chemical compound S1C=2CN(C(=O)C)CCC=2N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZFXYYSIXAQKZSK-UHFFFAOYSA-N 0.000 claims 1
- HITLHAKRRPAPPC-UHFFFAOYSA-N 1-[3-(3-fluoropyridin-2-yl)-3-[[[6-(1h-indazol-5-yl)pyridazin-3-yl]amino]methyl]azetidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C3C=NNC3=CC=2)N=N1 HITLHAKRRPAPPC-UHFFFAOYSA-N 0.000 claims 1
- MOVAZOFTKCMFQK-UHFFFAOYSA-N 1-[3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]azetidin-1-yl]ethanone Chemical compound C1N(C(=O)C)CC1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 MOVAZOFTKCMFQK-UHFFFAOYSA-N 0.000 claims 1
- OGCCQFUFBIAOCM-UHFFFAOYSA-N 1-[3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]-3-methylurea Chemical compound CNC(=O)NC1=CC=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 OGCCQFUFBIAOCM-UHFFFAOYSA-N 0.000 claims 1
- XSIMZZWCBOWTPQ-UHFFFAOYSA-N 1-[3-fluoro-4-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]-3-methylurea Chemical compound FC1=CC(NC(=O)NC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 XSIMZZWCBOWTPQ-UHFFFAOYSA-N 0.000 claims 1
- HXZCFKWOSJIZQI-UHFFFAOYSA-N 1-[4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 HXZCFKWOSJIZQI-UHFFFAOYSA-N 0.000 claims 1
- YBHRONBIYXVPNQ-UHFFFAOYSA-N 1-[4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-3,6-dihydro-2h-pyridin-1-yl]ethanone Chemical compound C1N(C(=O)C)CCC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 YBHRONBIYXVPNQ-UHFFFAOYSA-N 0.000 claims 1
- GIYMFEPULPSEPP-UHFFFAOYSA-N 1-[4-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]-3-methylurea Chemical compound C1=CC(NC(=O)NC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 GIYMFEPULPSEPP-UHFFFAOYSA-N 0.000 claims 1
- GIMLFOJEFAUVOI-UHFFFAOYSA-N 1-[4-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CC1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 GIMLFOJEFAUVOI-UHFFFAOYSA-N 0.000 claims 1
- ROLYOGWURMFDEP-UHFFFAOYSA-N 1-[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-2h-indazol-3-yl]ethane-1,2-diol Chemical compound C=1C=C(C=2C=C3C(C(O)CO)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 ROLYOGWURMFDEP-UHFFFAOYSA-N 0.000 claims 1
- VOSLMNXPFYEQMW-UHFFFAOYSA-N 1-amino-1-[4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]-2-methylpropan-2-ol Chemical compound C1=CC(C(N)C(C)(O)C)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 VOSLMNXPFYEQMW-UHFFFAOYSA-N 0.000 claims 1
- OTWQXLQCDXCQCE-UHFFFAOYSA-N 1-amino-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]cyclopropane-1-carboxamide Chemical compound C=1N=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)SC=1CNC(=O)C1(N)CC1 OTWQXLQCDXCQCE-UHFFFAOYSA-N 0.000 claims 1
- SKCYCEIOEZLGIL-UHFFFAOYSA-N 2,2,2-trifluoro-1-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]ethane-1,1-diol Chemical compound S1C(C(O)(O)C(F)(F)F)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 SKCYCEIOEZLGIL-UHFFFAOYSA-N 0.000 claims 1
- XPAFNPSSLZCMHM-UHFFFAOYSA-N 2,2-difluoro-1-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]ethanol Chemical compound S1C(C(C(F)F)O)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 XPAFNPSSLZCMHM-UHFFFAOYSA-N 0.000 claims 1
- OHDCLBUCMKYETH-UHFFFAOYSA-N 2-[1-[[[6-(1h-indazol-5-yl)pyridazin-3-yl]amino]methyl]cyclobutyl]-1h-pyridin-4-one Chemical compound OC1=CC=NC(C2(CNC=3N=NC(=CC=3)C=3C=C4C=NNC4=CC=3)CCC2)=C1 OHDCLBUCMKYETH-UHFFFAOYSA-N 0.000 claims 1
- XMJMXORIHRVTMM-UHFFFAOYSA-N 2-[1-[[[6-(1h-indazol-5-yl)pyridazin-3-yl]amino]methyl]cyclobutyl]pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(C2(CNC=3N=NC(=CC=3)C=3C=C4C=NNC4=CC=3)CCC2)=C1 XMJMXORIHRVTMM-UHFFFAOYSA-N 0.000 claims 1
- UASQTMKWMOMZKN-UHFFFAOYSA-N 2-[1-[[[6-(1h-indazol-6-yl)pyridazin-3-yl]amino]methyl]cyclobutyl]-1h-pyridin-4-one Chemical compound OC1=CC=NC(C2(CNC=3N=NC(=CC=3)C=3C=C4NN=CC4=CC=3)CCC2)=C1 UASQTMKWMOMZKN-UHFFFAOYSA-N 0.000 claims 1
- NBRSZHMVMCWZIN-UHFFFAOYSA-N 2-[2-[6-[[1-(3-chloropyridin-2-yl)-3-fluorocyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-n-methylacetamide Chemical compound S1C(CC(=O)NC)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)Cl)CC(F)C1 NBRSZHMVMCWZIN-UHFFFAOYSA-N 0.000 claims 1
- IPWDPOMIZSZGAI-UHFFFAOYSA-N 2-[2-[6-[[1-(3-chloropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-n-methylacetamide Chemical compound S1C(CC(=O)NC)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)Cl)CCC1 IPWDPOMIZSZGAI-UHFFFAOYSA-N 0.000 claims 1
- TZDVDDBSXNJLIC-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]-4-methylpyridazin-3-yl]-1,3-thiazol-5-yl]-n-methylacetamide Chemical compound S1C(CC(=O)NC)=CN=C1C(C(=C1)C)=NN=C1NCC1(C=2C(=CC=CN=2)F)CCC1 TZDVDDBSXNJLIC-UHFFFAOYSA-N 0.000 claims 1
- KCQJDAJBNXPYIB-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]-4-methylpyridazin-3-yl]-1,3-thiazol-5-yl]acetic acid Chemical compound N=1N=C(C=2SC(CC(O)=O)=CN=2)C(C)=CC=1NCC1(C=2C(=CC=CN=2)F)CCC1 KCQJDAJBNXPYIB-UHFFFAOYSA-N 0.000 claims 1
- OZEMAFKDDWIGRR-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-2-methylpropanenitrile Chemical compound S1C(C(C)(C#N)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 OZEMAFKDDWIGRR-UHFFFAOYSA-N 0.000 claims 1
- BMQWXZNNXPWIAE-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-n,n-dimethylacetamide Chemical compound S1C(CC(=O)N(C)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 BMQWXZNNXPWIAE-UHFFFAOYSA-N 0.000 claims 1
- VGAJVQQQVRTPCY-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]acetic acid Chemical compound S1C(CC(=O)O)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 VGAJVQQQVRTPCY-UHFFFAOYSA-N 0.000 claims 1
- ZHPFZNNQDDYZDA-UHFFFAOYSA-N 2-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]propan-2-ol Chemical compound S1C(C(C)(O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZHPFZNNQDDYZDA-UHFFFAOYSA-N 0.000 claims 1
- ZXHSYDDIFHPGPA-UHFFFAOYSA-N 2-[3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=NC=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZXHSYDDIFHPGPA-UHFFFAOYSA-N 0.000 claims 1
- IZZIGACLVUTDCT-UHFFFAOYSA-N 2-[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-2h-indazol-3-yl]propan-2-ol Chemical compound C1=C2C(C(C)(O)C)=NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 IZZIGACLVUTDCT-UHFFFAOYSA-N 0.000 claims 1
- QRQJAOWTDGNQLP-UHFFFAOYSA-N 2-[6-[(1-pyridin-2-ylcyclobutyl)methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2N=CC=CC=2)CCC1 QRQJAOWTDGNQLP-UHFFFAOYSA-N 0.000 claims 1
- FAHVUAPMBJVUQJ-UHFFFAOYSA-N 2-[6-[(1-pyridin-2-ylcyclobutyl)methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(=O)O)=CN=C1C(N=N1)=CC=C1NCC1(C=2N=CC=CC=2)CCC1 FAHVUAPMBJVUQJ-UHFFFAOYSA-N 0.000 claims 1
- FPLLLBGFLGZDFI-UHFFFAOYSA-N 2-[6-[2-(3-chloropyridin-2-yl)propan-2-ylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound N=1C=CC=C(Cl)C=1C(C)(C)NC(N=N1)=CC=C1C1=NC=C(C(N)=O)S1 FPLLLBGFLGZDFI-UHFFFAOYSA-N 0.000 claims 1
- NJGDSRCEXPFNBA-UHFFFAOYSA-N 2-[6-[2-[6-(difluoromethoxy)pyridin-2-yl]propan-2-ylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC(OC(F)F)=NC=1C(C)(C)NC(N=N1)=CC=C1C1=NC=C(C(N)=O)S1 NJGDSRCEXPFNBA-UHFFFAOYSA-N 0.000 claims 1
- XTURTYJGJPIKGP-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)N)=CN=C1C(N=N1)=CC=C1NC1(C=2C(=CC=CN=2)F)CCC1 XTURTYJGJPIKGP-UHFFFAOYSA-N 0.000 claims 1
- YRRRJHMHRSGQRJ-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]-4-methylpyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound N=1N=C(C=2SC(=CN=2)C(N)=O)C(C)=CC=1NCC1(C=2C(=CC=CN=2)F)CCC1 YRRRJHMHRSGQRJ-UHFFFAOYSA-N 0.000 claims 1
- YBZJCJRNWLNEOH-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-oxazole-4-carboxamide Chemical compound NC(=O)C1=COC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 YBZJCJRNWLNEOH-UHFFFAOYSA-N 0.000 claims 1
- AJOZOQPDWCXRGK-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 AJOZOQPDWCXRGK-UHFFFAOYSA-N 0.000 claims 1
- XKIPOZFPMSMNOC-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-4-carboxamide Chemical compound NC(=O)C1=CSC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 XKIPOZFPMSMNOC-UHFFFAOYSA-N 0.000 claims 1
- AJHCCTOAWNXUEI-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carbonitrile Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C#N)CCC1 AJHCCTOAWNXUEI-UHFFFAOYSA-N 0.000 claims 1
- UYKQRRADYZCRFV-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carbothioamide Chemical compound S1C(C(=S)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 UYKQRRADYZCRFV-UHFFFAOYSA-N 0.000 claims 1
- HICRVIPMNBIKPL-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(=O)O)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 HICRVIPMNBIKPL-UHFFFAOYSA-N 0.000 claims 1
- XYDOLYYIGHWZOI-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-sulfonamide Chemical compound S1C(S(=O)(=O)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 XYDOLYYIGHWZOI-UHFFFAOYSA-N 0.000 claims 1
- DAURAAWJPZSHSO-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1-methylimidazole-4-carboxamide Chemical compound CN1C=C(C(N)=O)N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DAURAAWJPZSHSO-UHFFFAOYSA-N 0.000 claims 1
- PZLDMXJNRNWUNF-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-3-methylimidazole-4-carboxamide Chemical compound CN1C(C(N)=O)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 PZLDMXJNRNWUNF-UHFFFAOYSA-N 0.000 claims 1
- DVERWYUWWTVSLL-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4,5-dihydro-1h-imidazole-5-carboxamide Chemical compound N1C(C(=O)N)CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DVERWYUWWTVSLL-UHFFFAOYSA-N 0.000 claims 1
- PNKZGTXPGYNKJN-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4,5-dihydro-1h-imidazole-5-carboxylic acid Chemical compound N1C(C(=O)O)CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 PNKZGTXPGYNKJN-UHFFFAOYSA-N 0.000 claims 1
- KRHQGGULWGTBBH-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4,5-dihydrothieno[2,3-c]pyrrol-6-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC=3C(=O)NCC=3C=2)CCC1 KRHQGGULWGTBBH-UHFFFAOYSA-N 0.000 claims 1
- KAJTUYNWASTTNU-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxy-1,3-thiazole-5-carbonitrile Chemical compound S1C(C#N)=C(O)N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KAJTUYNWASTTNU-UHFFFAOYSA-N 0.000 claims 1
- GOMBDJNTJZGANV-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxy-1,3-thiazole-5-carboxamide Chemical compound OC1=C(C(=O)N)SC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 GOMBDJNTJZGANV-UHFFFAOYSA-N 0.000 claims 1
- PHMYKLHUHBISLU-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-methoxy-1,3-thiazole-5-carboxamide Chemical compound S1C(C(N)=O)=C(OC)N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 PHMYKLHUHBISLU-UHFFFAOYSA-N 0.000 claims 1
- QDLLQJONPHOONV-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-methoxy-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(OC)N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QDLLQJONPHOONV-UHFFFAOYSA-N 0.000 claims 1
- MAZZFEPRDWXRPZ-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-methyl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(N)=O)=C(C)N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 MAZZFEPRDWXRPZ-UHFFFAOYSA-N 0.000 claims 1
- KEBZBHWJYHWALE-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-5,6-dihydro-4h-cyclopenta[d][1,3]thiazole-4-carboxamide Chemical compound N=1C=2C(C(=O)N)CCC=2SC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KEBZBHWJYHWALE-UHFFFAOYSA-N 0.000 claims 1
- QDVCQIPEYOACGX-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-5,6-dihydro-4h-cyclopenta[d][1,3]thiazole-4-carboxylic acid Chemical compound N=1C=2C(C(=O)O)CCC=2SC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QDVCQIPEYOACGX-UHFFFAOYSA-N 0.000 claims 1
- BNHMKFPJTDCACB-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxamide Chemical compound S1C=2CN(C(=O)N)CCC=2N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 BNHMKFPJTDCACB-UHFFFAOYSA-N 0.000 claims 1
- DZAAKRCOGCERQP-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n,n-dimethyl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)N(C)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DZAAKRCOGCERQP-UHFFFAOYSA-N 0.000 claims 1
- YCNBRVXTKOCRNJ-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(2-hydroxyethyl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 YCNBRVXTKOCRNJ-UHFFFAOYSA-N 0.000 claims 1
- RKYDUUBHRCKMCW-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(2-methylsulfonylethyl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCS(=O)(=O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 RKYDUUBHRCKMCW-UHFFFAOYSA-N 0.000 claims 1
- FVBRZRRDKPOGPC-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(2-oxopyrrolidin-3-yl)-1,3-thiazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C(=O)NC2C(NCC2)=O)CCC1 FVBRZRRDKPOGPC-UHFFFAOYSA-N 0.000 claims 1
- MBLQGHAHDCAOBU-CQSZACIVSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(3r)-pyrrolidin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C(=O)N[C@H]2CNCC2)CCC1 MBLQGHAHDCAOBU-CQSZACIVSA-N 0.000 claims 1
- MBLQGHAHDCAOBU-AWEZNQCLSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(3s)-pyrrolidin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C(=O)N[C@@H]2CNCC2)CCC1 MBLQGHAHDCAOBU-AWEZNQCLSA-N 0.000 claims 1
- JSLCAULNWVCYSJ-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NC(C)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 JSLCAULNWVCYSJ-UHFFFAOYSA-N 0.000 claims 1
- ZYZCITDTMNJAQX-UHFFFAOYSA-N 2-[6-[[1-(4-fluorophenyl)cyclobutyl]amino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)N)=CN=C1C(N=N1)=CC=C1NC1(C=2C=CC(F)=CC=2)CCC1 ZYZCITDTMNJAQX-UHFFFAOYSA-N 0.000 claims 1
- KTLFSFPTZOBZDG-UHFFFAOYSA-N 2-[6-[[2-(3-fluoropyridin-2-yl)-2-methylpropyl]amino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound N=1C=CC=C(F)C=1C(C)(C)CNC(N=N1)=CC=C1C1=NC=C(C(N)=O)S1 KTLFSFPTZOBZDG-UHFFFAOYSA-N 0.000 claims 1
- XNUPGHHNJNBTPB-UHFFFAOYSA-N 2-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-2h-1,3,4-oxadiazol-5-one Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1OC(=O)N=N1 XNUPGHHNJNBTPB-UHFFFAOYSA-N 0.000 claims 1
- WQDRNMRSPSCJOS-UHFFFAOYSA-N 2-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC=C1C(N)=O WQDRNMRSPSCJOS-UHFFFAOYSA-N 0.000 claims 1
- FXGLXJJNIMAUKW-UHFFFAOYSA-N 2-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-4-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC(C(N)=O)=CC=N1 FXGLXJJNIMAUKW-UHFFFAOYSA-N 0.000 claims 1
- FLRBWRIBJFFCFE-UHFFFAOYSA-N 2-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methylamino]ethanol Chemical compound S1C(CNCCO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 FLRBWRIBJFFCFE-UHFFFAOYSA-N 0.000 claims 1
- QZUBSMIUQNBWOW-UHFFFAOYSA-N 2-[[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazol-3-yl]amino]ethanol Chemical compound C=1C=C(C=2C=C3C(NCCO)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 QZUBSMIUQNBWOW-UHFFFAOYSA-N 0.000 claims 1
- HRFQGFDBAZEKSU-UHFFFAOYSA-N 2-amino-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-n,2-dimethylpropanamide Chemical compound S1C(CN(C)C(=O)C(C)(C)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 HRFQGFDBAZEKSU-UHFFFAOYSA-N 0.000 claims 1
- CBQTWMVOQYKXBG-UHFFFAOYSA-N 2-amino-n-[[2-[6-[[2-(3-chloropyridin-2-yl)-2-methylpropyl]amino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-methylpropanamide Chemical compound S1C(CNC(=O)C(C)(N)C)=CN=C1C(N=N1)=CC=C1NCC(C)(C)C1=NC=CC=C1Cl CBQTWMVOQYKXBG-UHFFFAOYSA-N 0.000 claims 1
- NPDMIOFRKJOQMA-UHFFFAOYSA-N 2-fluoro-4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzoic acid Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(C(O)=O)C(F)=C1 NPDMIOFRKJOQMA-UHFFFAOYSA-N 0.000 claims 1
- SXHBPMAFZUYWQP-UHFFFAOYSA-N 2-fluoro-5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 SXHBPMAFZUYWQP-UHFFFAOYSA-N 0.000 claims 1
- JJFJHBDFBUQZNG-UHFFFAOYSA-N 2-fluoro-5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylbenzamide Chemical compound C1=C(F)C(C(=O)NC)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 JJFJHBDFBUQZNG-UHFFFAOYSA-N 0.000 claims 1
- UQNQBLSMUWZAKB-UHFFFAOYSA-N 2-fluoro-5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzoic acid Chemical compound C1=C(F)C(C(=O)O)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 UQNQBLSMUWZAKB-UHFFFAOYSA-N 0.000 claims 1
- JYWNCHIQGRAPLQ-UHFFFAOYSA-N 3-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-2h-1,2,4-oxadiazol-5-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C=2NOC(=O)N=2)CCC1 JYWNCHIQGRAPLQ-UHFFFAOYSA-N 0.000 claims 1
- VDWCVWXCKWNOCU-UHFFFAOYSA-N 3-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-3,4-dihydro-1,2,4-triazol-5-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C2N=NC(=O)N2)CCC1 VDWCVWXCKWNOCU-UHFFFAOYSA-N 0.000 claims 1
- DVAZCILUAJREGQ-UHFFFAOYSA-N 3-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]propanoic acid Chemical compound S1C(CCC(=O)O)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DVAZCILUAJREGQ-UHFFFAOYSA-N 0.000 claims 1
- AHEDYGLMKAXIQX-UHFFFAOYSA-N 3-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]thiophen-2-yl]-3,4-dihydro-1,2,4-triazol-5-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CC=2)C2N=NC(=O)N2)CCC1 AHEDYGLMKAXIQX-UHFFFAOYSA-N 0.000 claims 1
- GVWTUQFBMAPWBG-UHFFFAOYSA-N 3-[6-(2-phenylpropan-2-ylamino)pyridazin-3-yl]benzonitrile Chemical compound C=1C=CC=CC=1C(C)(C)NC(N=N1)=CC=C1C1=CC=CC(C#N)=C1 GVWTUQFBMAPWBG-UHFFFAOYSA-N 0.000 claims 1
- BVWMZEFSZOMJQB-UHFFFAOYSA-N 3-[6-[(1-pyridin-2-ylcyclobutyl)methylamino]pyridazin-3-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2N=NC(NCC3(CCC3)C=3N=CC=CC=3)=CC=2)=C1 BVWMZEFSZOMJQB-UHFFFAOYSA-N 0.000 claims 1
- GKVIBHOFNRJSOP-UHFFFAOYSA-N 3-[6-[(2-methyl-2-pyrimidin-2-ylpropyl)amino]pyridazin-3-yl]benzamide Chemical compound N=1C=CC=NC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 GKVIBHOFNRJSOP-UHFFFAOYSA-N 0.000 claims 1
- XANNJBAKWVXIFC-UHFFFAOYSA-N 3-[6-[2-(3-chloropyridin-2-yl)propan-2-ylamino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound N=1C=CC=C(Cl)C=1C(C)(C)NC(N=N1)=CC=C1C1=CC(C(N)=O)=CC=C1F XANNJBAKWVXIFC-UHFFFAOYSA-N 0.000 claims 1
- YSWZJGXSKANAOI-UHFFFAOYSA-N 3-[6-[2-[6-(difluoromethoxy)pyridin-2-yl]propan-2-ylamino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound C=1C=CC(OC(F)F)=NC=1C(C)(C)NC(N=N1)=CC=C1C1=CC(C(N)=O)=CC=C1F YSWZJGXSKANAOI-UHFFFAOYSA-N 0.000 claims 1
- GBUUAMDKGWSRCT-UHFFFAOYSA-N 3-[6-[[1-(3-bromopyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3C(=CC=CN=3)Br)=CC=2)=C1 GBUUAMDKGWSRCT-UHFFFAOYSA-N 0.000 claims 1
- LZHYJIQYRDROJK-UHFFFAOYSA-N 3-[6-[[1-(3-chloropyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3C(=CC=CN=3)Cl)=CC=2)=C1 LZHYJIQYRDROJK-UHFFFAOYSA-N 0.000 claims 1
- NRLGSPOMWKOEML-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]-4-methylpyridazin-3-yl]benzonitrile Chemical compound N=1N=C(C=2C=C(C=CC=2)C#N)C(C)=CC=1NCC1(C=2C(=CC=CN=2)F)CCC1 NRLGSPOMWKOEML-UHFFFAOYSA-N 0.000 claims 1
- KGPYMUDSPSBPTD-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2,4-oxadiazole-5-carboxamide Chemical compound O1C(C(=O)N)=NC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 KGPYMUDSPSBPTD-UHFFFAOYSA-N 0.000 claims 1
- GJUZAUWFCCFCCF-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-1,2,4-triazole-5-carboxamide Chemical compound N1C(C(=O)N)=NC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 GJUZAUWFCCFCCF-UHFFFAOYSA-N 0.000 claims 1
- NQMRYANEBKFJMU-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-5-methylbenzamide Chemical compound Cc1cc(C(N)=O)c(O)c(c1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 NQMRYANEBKFJMU-UHFFFAOYSA-N 0.000 claims 1
- YEUKWNSXPDHWAK-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-5-methylbenzonitrile Chemical compound Cc1cc(C#N)c(O)c(c1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 YEUKWNSXPDHWAK-UHFFFAOYSA-N 0.000 claims 1
- CCKTVSNHSYHOEX-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1cccc(c1O)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 CCKTVSNHSYHOEX-UHFFFAOYSA-N 0.000 claims 1
- HAEIRLKPOOBAEP-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-3,4-dihydro-1,2,4-triazol-5-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C2N=NC(=O)N2)CCC1 HAEIRLKPOOBAEP-UHFFFAOYSA-N 0.000 claims 1
- JBNIAOVCORYJHF-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4,4-dimethyl-1h-pyrazol-5-one Chemical compound CC1(C)C(=O)NN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 JBNIAOVCORYJHF-UHFFFAOYSA-N 0.000 claims 1
- YSZGYWFOUXHUFP-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxy-N-methylbenzamide Chemical compound FC=1C(=NC=CC1)C1(CCC1)CNC1=CC=C(N=N1)C=1C=C(C=CC1O)C(=O)NC YSZGYWFOUXHUFP-UHFFFAOYSA-N 0.000 claims 1
- CEUNVNWVLHFBBU-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxybenzamide Chemical compound NC(=O)c1ccc(O)c(c1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 CEUNVNWVLHFBBU-UHFFFAOYSA-N 0.000 claims 1
- VJZGTEODNUAKIR-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxybenzoic acid Chemical compound OC(=O)c1ccc(O)c(c1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 VJZGTEODNUAKIR-UHFFFAOYSA-N 0.000 claims 1
- KUVZKCLSMPTNOO-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(N)=O)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KUVZKCLSMPTNOO-UHFFFAOYSA-N 0.000 claims 1
- SJZYJKXTEXVMBT-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 SJZYJKXTEXVMBT-UHFFFAOYSA-N 0.000 claims 1
- SIIOPZLSWXMRHX-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzenecarboximidamide Chemical compound NC(=N)C1=CC=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 SIIOPZLSWXMRHX-UHFFFAOYSA-N 0.000 claims 1
- KNTLDHOAOVHREN-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyridine-2-carbonitrile Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2C(=NC=CC=2)C#N)CCC1 KNTLDHOAOVHREN-UHFFFAOYSA-N 0.000 claims 1
- OSHIWULWFLAMGB-UHFFFAOYSA-N 3-[6-[[1-(4-cyanopyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3N=CC=C(C=3)C#N)=CC=2)=C1 OSHIWULWFLAMGB-UHFFFAOYSA-N 0.000 claims 1
- NBRMCOMKQVBXPI-UHFFFAOYSA-N 3-[6-[[1-(4-cyanopyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CCC3)C=3N=CC=C(C=3)C#N)=CC=2)=C1 NBRMCOMKQVBXPI-UHFFFAOYSA-N 0.000 claims 1
- ACWOWTYMJFURGQ-UHFFFAOYSA-N 3-[6-[[1-(5-cyanopyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3N=CC(=CC=3)C#N)=CC=2)=C1 ACWOWTYMJFURGQ-UHFFFAOYSA-N 0.000 claims 1
- XBKDPJFPFONNIC-UHFFFAOYSA-N 3-[6-[[1-(6-cyanopyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3N=C(C=CC=3)C#N)=CC=2)=C1 XBKDPJFPFONNIC-UHFFFAOYSA-N 0.000 claims 1
- HSURUYFUMYZFJF-UHFFFAOYSA-N 3-[6-[[1-[5-(difluoromethoxy)pyridin-2-yl]cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3N=CC(OC(F)F)=CC=3)=CC=2)=C1 HSURUYFUMYZFJF-UHFFFAOYSA-N 0.000 claims 1
- BOZUKCBGJQCLMB-UHFFFAOYSA-N 3-[6-[[1-[6-(difluoromethoxy)pyridin-2-yl]cyclobutyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3N=C(OC(F)F)C=CC=3)=CC=2)=C1 BOZUKCBGJQCLMB-UHFFFAOYSA-N 0.000 claims 1
- GHMBHZFWFYJOQH-UHFFFAOYSA-N 3-[6-[[2-(2,4-difluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=C(F)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 GHMBHZFWFYJOQH-UHFFFAOYSA-N 0.000 claims 1
- ODJODMQIVWVQBK-UHFFFAOYSA-N 3-[6-[[2-(2-chlorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=CC=C(Cl)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 ODJODMQIVWVQBK-UHFFFAOYSA-N 0.000 claims 1
- XOGZSTMDQVBQDI-UHFFFAOYSA-N 3-[6-[[2-(2-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=CC=C(F)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 XOGZSTMDQVBQDI-UHFFFAOYSA-N 0.000 claims 1
- YDCREAFRFQLSTF-UHFFFAOYSA-N 3-[6-[[2-(3-chloropyridin-2-yl)-2-methylpropyl]amino]pyridazin-3-yl]-4-fluorobenzamide Chemical compound N=1C=CC=C(Cl)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CC(C(N)=O)=CC=C1F YDCREAFRFQLSTF-UHFFFAOYSA-N 0.000 claims 1
- HDCQOGQBTKZKEZ-UHFFFAOYSA-N 3-[6-[[2-(3-chloropyridin-2-yl)-2-methylpropyl]amino]pyridazin-3-yl]-4-fluorobenzonitrile Chemical compound N=1C=CC=C(Cl)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CC(C#N)=CC=C1F HDCQOGQBTKZKEZ-UHFFFAOYSA-N 0.000 claims 1
- QTHNTRCVBMYKIP-UHFFFAOYSA-N 3-[6-[[2-(3-chloropyridin-2-yl)-2-methylpropyl]amino]pyridazin-3-yl]benzonitrile Chemical compound N=1C=CC=C(Cl)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C#N)=C1 QTHNTRCVBMYKIP-UHFFFAOYSA-N 0.000 claims 1
- GAOSVXNYERTJKH-UHFFFAOYSA-N 3-[6-[[2-(3-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=CC(F)=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 GAOSVXNYERTJKH-UHFFFAOYSA-N 0.000 claims 1
- HSJBGLUMFILIML-UHFFFAOYSA-N 3-[6-[[2-(4-chlorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(Cl)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 HSJBGLUMFILIML-UHFFFAOYSA-N 0.000 claims 1
- UIMMVIMUZSLSMC-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]-4-methylpyridazin-3-yl]benzonitrile Chemical compound N=1N=C(C=2C=C(C=CC=2)C#N)C(C)=CC=1NCC(C)(C)C1=CC=C(F)C=C1 UIMMVIMUZSLSMC-UHFFFAOYSA-N 0.000 claims 1
- ATAJGQPLONEONI-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]-5-methylpyridazin-3-yl]benzamide Chemical compound CC1=CC(C=2C=C(C=CC=2)C(N)=O)=NN=C1NCC(C)(C)C1=CC=C(F)C=C1 ATAJGQPLONEONI-UHFFFAOYSA-N 0.000 claims 1
- OAZWZELVEFGFCK-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]-5-methylpyridazin-3-yl]benzonitrile Chemical compound CC1=CC(C=2C=C(C=CC=2)C#N)=NN=C1NCC(C)(C)C1=CC=C(F)C=C1 OAZWZELVEFGFCK-UHFFFAOYSA-N 0.000 claims 1
- AGJXCWVWBXYVPA-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1,2,4-oxadiazole-5-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=NOC(C(N)=O)=N1 AGJXCWVWBXYVPA-UHFFFAOYSA-N 0.000 claims 1
- ILCQLXQXHQPFIM-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-pyridin-2-one Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CN=C1O ILCQLXQXHQPFIM-UHFFFAOYSA-N 0.000 claims 1
- CMGYAMLRGXNRPR-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-n-(2-hydroxyethyl)benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(=O)NCCO)=C1 CMGYAMLRGXNRPR-UHFFFAOYSA-N 0.000 claims 1
- MRKGGNNOADZEDC-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 MRKGGNNOADZEDC-UHFFFAOYSA-N 0.000 claims 1
- DVUWOCPRFMAQRQ-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=C1 DVUWOCPRFMAQRQ-UHFFFAOYSA-N 0.000 claims 1
- JGUQGBKMONIUPM-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzonitrile Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C#N)=C1 JGUQGBKMONIUPM-UHFFFAOYSA-N 0.000 claims 1
- IBAATCWPTFASKT-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-N,5-dimethylbenzamide Chemical compound FC1CC(C1)(C1=NC=CC=C1F)CNC1=CC=C(N=N1)C=1C(=C(C=C(C1)C)C(=O)NC)O IBAATCWPTFASKT-UHFFFAOYSA-N 0.000 claims 1
- SPGSGLREBKVIBJ-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-N-methylbenzamide Chemical compound FC1CC(C1)(C1=NC=CC=C1F)CNC1=CC=C(N=N1)C=1C(=C(C=CC1)C(=O)NC)O SPGSGLREBKVIBJ-UHFFFAOYSA-N 0.000 claims 1
- LBNPEGIPHPGGOU-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1cccc(c1O)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 LBNPEGIPHPGGOU-UHFFFAOYSA-N 0.000 claims 1
- PMOMMNNFSBXIIX-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzoic acid Chemical compound OC(=O)c1cccc(c1O)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 PMOMMNNFSBXIIX-UHFFFAOYSA-N 0.000 claims 1
- OTZYCMRXGLHKAK-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzonitrile Chemical compound Oc1c(cccc1-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1)C#N OTZYCMRXGLHKAK-UHFFFAOYSA-N 0.000 claims 1
- QAJFIDFHYWRMHQ-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzamide Chemical compound COC1=C(C(N)=O)C=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 QAJFIDFHYWRMHQ-UHFFFAOYSA-N 0.000 claims 1
- KLRAHVCBWBMTHN-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzonitrile Chemical compound COC1=C(C#N)C=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 KLRAHVCBWBMTHN-UHFFFAOYSA-N 0.000 claims 1
- MUKQZNDYPXHKGP-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxy-N-methylbenzamide Chemical compound FC1CC(C1)(C1=NC=CC=C1F)CNC1=CC=C(N=N1)C=1C=C(C=CC1O)C(=O)NC MUKQZNDYPXHKGP-UHFFFAOYSA-N 0.000 claims 1
- ACQZHEBHQHFYOJ-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxybenzamide Chemical compound NC(=O)c1ccc(O)c(c1)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 ACQZHEBHQHFYOJ-UHFFFAOYSA-N 0.000 claims 1
- VFNFHFQQGTXELF-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-5-hydroxybenzamide Chemical compound NC(=O)C1=CC(O)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 VFNFHFQQGTXELF-UHFFFAOYSA-N 0.000 claims 1
- UZHRAZXYXYBBRE-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-5-methylbenzamide Chemical compound CC1=CC(C(N)=O)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 UZHRAZXYXYBBRE-UHFFFAOYSA-N 0.000 claims 1
- FNMDQUCNJBUJNP-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n,5-dimethylbenzamide Chemical compound CNC(=O)C1=CC(C)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 FNMDQUCNJBUJNP-UHFFFAOYSA-N 0.000 claims 1
- BKVHFRFRTITUDC-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(1-methylazetidin-3-yl)benzamide Chemical compound C1N(C)CC1NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 BKVHFRFRTITUDC-UHFFFAOYSA-N 0.000 claims 1
- RNFXVUIUMGAIEM-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(1-methylsulfonylazetidin-3-yl)benzamide Chemical compound C1N(S(=O)(=O)C)CC1NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 RNFXVUIUMGAIEM-UHFFFAOYSA-N 0.000 claims 1
- VESDJFXJPKGJKC-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(3-hydroxy-3-methylcyclobutyl)benzamide Chemical compound C1C(C)(O)CC1NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 VESDJFXJPKGJKC-UHFFFAOYSA-N 0.000 claims 1
- LKWRYJJTZFFXJE-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(3-hydroxycyclobutyl)benzamide Chemical compound C1C(O)CC1NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 LKWRYJJTZFFXJE-UHFFFAOYSA-N 0.000 claims 1
- YRICFEULZJYHSU-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(oxetan-3-yl)benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C(=O)NC2COC2)N=N1 YRICFEULZJYHSU-UHFFFAOYSA-N 0.000 claims 1
- QBLXICUNYLIAJY-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(1-hydroxycyclopropyl)methyl]benzamide Chemical compound C=1C=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=CC=1C(=O)NCC1(O)CC1 QBLXICUNYLIAJY-UHFFFAOYSA-N 0.000 claims 1
- UKOJNNONNCQMSH-FAFRJYIDSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(3r)-oxolan-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C(=O)N[C@H]2COCC2)N=N1 UKOJNNONNCQMSH-FAFRJYIDSA-N 0.000 claims 1
- FDSDJWVOWHBOTO-HJQGZVKSSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(3s,4s)-4-hydroxy-1,1-dioxothiolan-3-yl]benzamide Chemical compound O[C@@H]1CS(=O)(=O)C[C@H]1NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 FDSDJWVOWHBOTO-HJQGZVKSSA-N 0.000 claims 1
- JKTPCFHXUWAUFD-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 JKTPCFHXUWAUFD-UHFFFAOYSA-N 0.000 claims 1
- ACQQLOSCPNPGLG-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 ACQQLOSCPNPGLG-UHFFFAOYSA-N 0.000 claims 1
- KFZWDDZBECARPY-UHFFFAOYSA-N 3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 KFZWDDZBECARPY-UHFFFAOYSA-N 0.000 claims 1
- OCFOQBFVPCKGNR-UHFFFAOYSA-N 3-amino-5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-n,n-dimethylindazole-1-carboxamide Chemical compound C=1C=C2N(C(=O)N(C)C)N=C(N)C2=CC=1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 OCFOQBFVPCKGNR-UHFFFAOYSA-N 0.000 claims 1
- UAVZKNGSJIKKKS-UHFFFAOYSA-N 3-amino-5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzonitrile Chemical compound NC1=CC(C#N)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 UAVZKNGSJIKKKS-UHFFFAOYSA-N 0.000 claims 1
- KHPYIHAXMGQJCV-UHFFFAOYSA-N 3-amino-n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]oxetane-3-carboxamide Chemical compound C=1N=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)SC=1CNC(=O)C1(N)COC1 KHPYIHAXMGQJCV-UHFFFAOYSA-N 0.000 claims 1
- WVFWASQKCREKES-UHFFFAOYSA-N 3-fluoro-5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC(F)=CC(C(N)=O)=C1 WVFWASQKCREKES-UHFFFAOYSA-N 0.000 claims 1
- GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 claims 1
- NSZPLTMINLNQLF-UHFFFAOYSA-N 4-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carbonyl]piperazin-2-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C(=O)N2CC(=O)NCC2)CCC1 NSZPLTMINLNQLF-UHFFFAOYSA-N 0.000 claims 1
- RYMIKYDMYBJQRT-UHFFFAOYSA-N 4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-dihydroindol-2-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2C=3CC(=O)NC=3C=CC=2)CCC1 RYMIKYDMYBJQRT-UHFFFAOYSA-N 0.000 claims 1
- OXUMYOMYYALGPL-UHFFFAOYSA-N 4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-2-carboxamide Chemical compound S1C(C(=O)N)=NC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 OXUMYOMYYALGPL-UHFFFAOYSA-N 0.000 claims 1
- OEHRSOHXFDFDPM-UHFFFAOYSA-N 4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1-methylimidazole-2-carboxamide Chemical compound N1=C(C(N)=O)N(C)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 OEHRSOHXFDFDPM-UHFFFAOYSA-N 0.000 claims 1
- ICMUBJABFXIQLF-UHFFFAOYSA-N 4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)N)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ICMUBJABFXIQLF-UHFFFAOYSA-N 0.000 claims 1
- XTVFDYLLOMMNMP-UHFFFAOYSA-N 4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzamide Chemical compound C1=C(C(N)=O)C(OC)=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 XTVFDYLLOMMNMP-UHFFFAOYSA-N 0.000 claims 1
- JTHUBLRJHIHDSH-UHFFFAOYSA-N 4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 JTHUBLRJHIHDSH-UHFFFAOYSA-N 0.000 claims 1
- RZKYFHICNFTTLO-UHFFFAOYSA-N 4-[6-[[1-(4-fluorophenyl)cyclobutyl]amino]pyridazin-3-yl]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(C=2N=NC(NC3(CCC3)C=3C=CC(F)=CC=3)=CC=2)=C1 RZKYFHICNFTTLO-UHFFFAOYSA-N 0.000 claims 1
- NADMXKFOJOOZQQ-UHFFFAOYSA-N 4-[6-[[1-(4-fluorophenyl)cyclobutyl]amino]pyridazin-3-yl]pyridine-2-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(NC=2N=NC(=CC=2)C=2C=C(N=CC=2)C#N)CCC1 NADMXKFOJOOZQQ-UHFFFAOYSA-N 0.000 claims 1
- JWLIYCOCMKSGOC-UHFFFAOYSA-N 4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1,2,3,6-tetrahydropyridine-6-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC(C(N)=O)NCC1 JWLIYCOCMKSGOC-UHFFFAOYSA-N 0.000 claims 1
- DBFQSKIGDYUHJF-UHFFFAOYSA-N 4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(C(N)=O)C=C1 DBFQSKIGDYUHJF-UHFFFAOYSA-N 0.000 claims 1
- HFKAYCSGMOTOGH-UHFFFAOYSA-N 4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzonitrile Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(C#N)C=C1 HFKAYCSGMOTOGH-UHFFFAOYSA-N 0.000 claims 1
- CGAVSYCFJUHPCJ-UHFFFAOYSA-N 4-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2,3-dihydroisoindol-1-one Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=3CNC(=O)C=3C=CC=2)N=N1 CGAVSYCFJUHPCJ-UHFFFAOYSA-N 0.000 claims 1
- KERVYTVUYGIAFH-UHFFFAOYSA-N 4-fluoro-3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]benzonitrile Chemical compound FC1=CC=C(C#N)C=C1C(N=N1)=CC=C1NC1(C=2C(=CC=CN=2)F)CCC1 KERVYTVUYGIAFH-UHFFFAOYSA-N 0.000 claims 1
- OEOLSYLRMHBRTL-UHFFFAOYSA-N 4-fluoro-3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1ccc(F)c(c1O)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 OEOLSYLRMHBRTL-UHFFFAOYSA-N 0.000 claims 1
- CLSLFMDJWOYIST-UHFFFAOYSA-N 4-fluoro-3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 CLSLFMDJWOYIST-UHFFFAOYSA-N 0.000 claims 1
- SMJUCNORBRQRCI-UHFFFAOYSA-N 4-fluoro-3-[6-[[1-(4-fluorophenyl)cyclobutyl]amino]pyridazin-3-yl]-n-(2-hydroxy-2-methylpropyl)benzamide Chemical compound CC(C)(O)CNC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3C=CC(F)=CC=3)=CC=2)=C1 SMJUCNORBRQRCI-UHFFFAOYSA-N 0.000 claims 1
- GDEOWFCTGSRNQD-UHFFFAOYSA-N 4-fluoro-3-[6-[[1-(4-fluorophenyl)cyclobutyl]amino]pyridazin-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3C=CC(F)=CC=3)=CC=2)=C1 GDEOWFCTGSRNQD-UHFFFAOYSA-N 0.000 claims 1
- INGCWGXLNNDDIY-UHFFFAOYSA-N 4-fluoro-3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC(C(N)=O)=CC=C1F INGCWGXLNNDDIY-UHFFFAOYSA-N 0.000 claims 1
- NRKXPGHKPYOLCV-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-(4-fluorophenyl)-3-methylbutanoyl]-[(2-methylpropan-2-yl)oxy]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(C=2C(=CC=C(C=2)C(N)=O)F)N=NC=1N(OC(C)(C)C)C(=O)CC(C)(C)C1=CC=C(F)C=C1 NRKXPGHKPYOLCV-UHFFFAOYSA-N 0.000 claims 1
- ZYLWYVQFIHYSBQ-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1O ZYLWYVQFIHYSBQ-UHFFFAOYSA-N 0.000 claims 1
- JKQSIDNNSSJVEL-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 JKQSIDNNSSJVEL-UHFFFAOYSA-N 0.000 claims 1
- CWDRHFDTKPHKPC-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(1-methylazetidin-3-yl)benzamide Chemical compound C1N(C)CC1NC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 CWDRHFDTKPHKPC-UHFFFAOYSA-N 0.000 claims 1
- IBWDAOVKXMVSHZ-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-(2,2,2-trifluoroethyl)benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C(=O)NCC(F)(F)F)F)N=N1 IBWDAOVKXMVSHZ-UHFFFAOYSA-N 0.000 claims 1
- MSNLCGSDGOMNEJ-JHZJELJQSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(3r)-pyrrolidin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C(=O)N[C@H]2CNCC2)F)N=N1 MSNLCGSDGOMNEJ-JHZJELJQSA-N 0.000 claims 1
- MSNLCGSDGOMNEJ-SFFMRIQBSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-[(3s)-pyrrolidin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C(=O)N[C@@H]2CNCC2)F)N=N1 MSNLCGSDGOMNEJ-SFFMRIQBSA-N 0.000 claims 1
- KDMBIGHMEINNMR-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 KDMBIGHMEINNMR-UHFFFAOYSA-N 0.000 claims 1
- QUTSMFXDCYFJAI-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-propan-2-ylbenzamide Chemical compound CC(C)NC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 QUTSMFXDCYFJAI-UHFFFAOYSA-N 0.000 claims 1
- BGKNZTCESAGKSM-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 BGKNZTCESAGKSM-UHFFFAOYSA-N 0.000 claims 1
- VKJZDRRPRVKSJM-UHFFFAOYSA-N 4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzonitrile Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C#N)F)N=N1 VKJZDRRPRVKSJM-UHFFFAOYSA-N 0.000 claims 1
- IFQQXENDTNHPCI-UHFFFAOYSA-N 4-fluoro-5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1cc(c(F)cc1O)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 IFQQXENDTNHPCI-UHFFFAOYSA-N 0.000 claims 1
- XQBQQOJTZGUGCD-UHFFFAOYSA-N 4-fluoro-5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-N-methylbenzamide Chemical compound FC1=CC(=C(C=C1C=1N=NC(=CC1)NCC1(CC(C1)F)C1=NC=CC=C1F)C(=O)NC)O XQBQQOJTZGUGCD-UHFFFAOYSA-N 0.000 claims 1
- YSNTVDAVHMSYMP-UHFFFAOYSA-N 4-fluoro-5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1cc(c(F)cc1O)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 YSNTVDAVHMSYMP-UHFFFAOYSA-N 0.000 claims 1
- UAUXDZQGBLCTMJ-UHFFFAOYSA-N 4-fluoro-n-(2-fluoroethyl)-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound FCCNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 UAUXDZQGBLCTMJ-UHFFFAOYSA-N 0.000 claims 1
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 claims 1
- DEXIZPJYUASIRA-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound C1=C(O)C(C(=O)N)=CC(C=2N=NC(NC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 DEXIZPJYUASIRA-UHFFFAOYSA-N 0.000 claims 1
- OLLQPQNQZLZUSS-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]amino]pyridazin-3-yl]thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C(N=N1)=CC=C1NC1(C=2C(=CC=CN=2)F)CCC1 OLLQPQNQZLZUSS-UHFFFAOYSA-N 0.000 claims 1
- SSPGCHBCFHFFRA-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2,4-oxadiazole-3-carboxamide Chemical compound NC(=O)C1=NOC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 SSPGCHBCFHFFRA-UHFFFAOYSA-N 0.000 claims 1
- SKYBWTQJAFBYKS-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2-dihydropyrazol-3-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2NNC(=O)C=2)CCC1 SKYBWTQJAFBYKS-UHFFFAOYSA-N 0.000 claims 1
- KFWYPGURXXANLA-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2-oxazole-3-carboxylic acid Chemical compound O1N=C(C(=O)O)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KFWYPGURXXANLA-UHFFFAOYSA-N 0.000 claims 1
- CNGVIPXDEQIWBD-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3,4-oxadiazole-2-carboxamide Chemical compound O1C(C(=O)N)=NN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 CNGVIPXDEQIWBD-UHFFFAOYSA-N 0.000 claims 1
- LPIJFXASVPTMBF-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3,4-thiadiazole-2-carboxamide Chemical compound S1C(C(=O)N)=NN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 LPIJFXASVPTMBF-UHFFFAOYSA-N 0.000 claims 1
- QZFXRHWBFJDQRW-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-dihydroindol-2-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2C=C3CC(=O)NC3=CC=2)CCC1 QZFXRHWBFJDQRW-UHFFFAOYSA-N 0.000 claims 1
- UVLIHRKUTBQFFR-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-oxazole-2-carboxamide Chemical compound O1C(C(=O)N)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 UVLIHRKUTBQFFR-UHFFFAOYSA-N 0.000 claims 1
- SAQIYHVJXSLLFZ-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-2-carboxamide Chemical compound S1C(C(=O)N)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 SAQIYHVJXSLLFZ-UHFFFAOYSA-N 0.000 claims 1
- TYPIYBDMBQYILM-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(N)=O)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 TYPIYBDMBQYILM-UHFFFAOYSA-N 0.000 claims 1
- OSMHYIOTEZKFGZ-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1cc(ccc1O)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 OSMHYIOTEZKFGZ-UHFFFAOYSA-N 0.000 claims 1
- DDZOJIDIGPEDLK-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzamide Chemical compound C1=C(C(N)=O)C(OC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DDZOJIDIGPEDLK-UHFFFAOYSA-N 0.000 claims 1
- YRRDGGZFZYJRSJ-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzoic acid Chemical compound C1=C(C(O)=O)C(OC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 YRRDGGZFZYJRSJ-UHFFFAOYSA-N 0.000 claims 1
- QXULTNAFRFAVRW-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxypyridine-3-carbonitrile Chemical compound C1=C(C#N)C(OC)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QXULTNAFRFAVRW-UHFFFAOYSA-N 0.000 claims 1
- ODZMZJWQUBXBMB-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxypyridine-3-carboxamide Chemical compound C1=C(C(N)=O)C(OC)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ODZMZJWQUBXBMB-UHFFFAOYSA-N 0.000 claims 1
- DCECPDOAVIMFJN-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methylpyrazole-3-carboxamide Chemical compound C1=C(C(N)=O)N(C)N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DCECPDOAVIMFJN-UHFFFAOYSA-N 0.000 claims 1
- JHQNRVZQTIZXPY-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-methyl-1,2-dihydropyrazol-3-one Chemical compound N1NC(=O)C(C)=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 JHQNRVZQTIZXPY-UHFFFAOYSA-N 0.000 claims 1
- YAATVVLAAUQBBO-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methylthiophene-2-carboxamide Chemical compound S1C(C(=O)NC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 YAATVVLAAUQBBO-UHFFFAOYSA-N 0.000 claims 1
- KHQCRUWDHVLNGY-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzene-1,3-dicarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 KHQCRUWDHVLNGY-UHFFFAOYSA-N 0.000 claims 1
- XSLXHJSZVBJEGO-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]thiophene-2-carbonitrile Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CC=2)C#N)CCC1 XSLXHJSZVBJEGO-UHFFFAOYSA-N 0.000 claims 1
- QFZANDGXCBMLAZ-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QFZANDGXCBMLAZ-UHFFFAOYSA-N 0.000 claims 1
- SZBDDPBYCLEAPX-UHFFFAOYSA-N 5-[6-[[1-(4-fluorophenyl)cyclopropyl]methylamino]pyridazin-3-yl]pyridine-3-carbonitrile Chemical compound C1=CC(F)=CC=C1C1(CNC=2N=NC(=CC=2)C=2C=C(C=NC=2)C#N)CC1 SZBDDPBYCLEAPX-UHFFFAOYSA-N 0.000 claims 1
- HPVFXAUIFYTMFZ-UHFFFAOYSA-N 5-[6-[[2-(2-chlorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-3-carbonitrile Chemical compound C=1C=CC=C(Cl)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CN=CC(C#N)=C1 HPVFXAUIFYTMFZ-UHFFFAOYSA-N 0.000 claims 1
- SSLYJCHFFYJNJL-UHFFFAOYSA-N 5-[6-[[2-(2-chlorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CC=C(Cl)C=1C(C)(C)CNC(N=N1)=CC=C1C1=CN=CC(C(N)=O)=C1 SSLYJCHFFYJNJL-UHFFFAOYSA-N 0.000 claims 1
- AJHPQELSUXAZHW-UHFFFAOYSA-N 5-[6-[[2-(3-fluoropyridin-2-yl)-2-methylpropyl]amino]pyridazin-3-yl]-1,3-dihydrobenzimidazol-2-one Chemical compound C=1C=C(C=2C=C3NC(O)=NC3=CC=2)N=NC=1NCC(C)(C)C1=NC=CC=C1F AJHPQELSUXAZHW-UHFFFAOYSA-N 0.000 claims 1
- BJAUKQHXGCRXAA-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1H-indazole-3-carboximidamide Chemical compound C=1C=C(C=2C=C3C(C(N)=N)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 BJAUKQHXGCRXAA-UHFFFAOYSA-N 0.000 claims 1
- YBPKPQIJCIFMQU-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazole-3-carbonitrile Chemical compound C=1C=C(C=2C=C3C(C#N)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 YBPKPQIJCIFMQU-UHFFFAOYSA-N 0.000 claims 1
- YVQIGSLKULVORF-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazole-3-carboxamide Chemical compound C=1C=C(C=2C=C3C(C(N)=O)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 YVQIGSLKULVORF-UHFFFAOYSA-N 0.000 claims 1
- UCMWGMPHAOBADJ-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazole-7-carboxamide Chemical compound C=1C=C(C=2C=C3C=NNC3=C(C(N)=O)C=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 UCMWGMPHAOBADJ-UHFFFAOYSA-N 0.000 claims 1
- FFHCUHSBQUAHLL-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-n,n-dimethyl-1h-indazol-3-amine Chemical compound C1=C2C(N(C)C)=NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 FFHCUHSBQUAHLL-UHFFFAOYSA-N 0.000 claims 1
- JSILZFCPQNVDHX-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-2-carbonitrile Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(C#N)N=C1 JSILZFCPQNVDHX-UHFFFAOYSA-N 0.000 claims 1
- OKWCUNCUXDADOY-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(C(N)=O)N=C1 OKWCUNCUXDADOY-UHFFFAOYSA-N 0.000 claims 1
- WFFVZGGNVFGFID-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-3-carbonitrile Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CN=CC(C#N)=C1 WFFVZGGNVFGFID-UHFFFAOYSA-N 0.000 claims 1
- NCZKHCVZAQEMIR-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CN=CC(C(N)=O)=C1 NCZKHCVZAQEMIR-UHFFFAOYSA-N 0.000 claims 1
- ZHYAKDAOVUUQTE-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-indole-2-carboxylic acid Chemical compound C=1C=C2NC(C(=O)O)=CC2=CC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 ZHYAKDAOVUUQTE-UHFFFAOYSA-N 0.000 claims 1
- KVOOBZVAOJZSAZ-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2,3-dihydroisoindol-1-one Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C3CNC(=O)C3=CC=2)N=N1 KVOOBZVAOJZSAZ-UHFFFAOYSA-N 0.000 claims 1
- IQUROEBGBQSHIO-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-N,N-dimethylbenzamide Chemical compound CN(C)C(=O)c1cc(ccc1O)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 IQUROEBGBQSHIO-UHFFFAOYSA-N 0.000 claims 1
- ISMVGPQWXJWRPC-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-N-methylbenzamide Chemical compound FC1CC(C1)(C1=NC=CC=C1F)CNC1=CC=C(N=N1)C=1C=CC(=C(C1)C(=O)NC)O ISMVGPQWXJWRPC-UHFFFAOYSA-N 0.000 claims 1
- AZHONCZZOJKONM-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzamide Chemical compound NC(=O)c1cc(ccc1O)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 AZHONCZZOJKONM-UHFFFAOYSA-N 0.000 claims 1
- XHYHDFNZEUPZJK-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxybenzoic acid Chemical compound OC(=O)c1cc(ccc1O)-c1ccc(NCC2(CC(F)C2)c2ncccc2F)nn1 XHYHDFNZEUPZJK-UHFFFAOYSA-N 0.000 claims 1
- XQRTZYQVWRPYRN-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-methoxybenzamide Chemical compound C1=C(C(N)=O)C(OC)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 XQRTZYQVWRPYRN-UHFFFAOYSA-N 0.000 claims 1
- XZYYGQGVJWHPNQ-UHFFFAOYSA-N 5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-n-methyl-1h-indole-2-carboxamide Chemical compound C=1C=C2NC(C(=O)NC)=CC2=CC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CC(F)C1 XZYYGQGVJWHPNQ-UHFFFAOYSA-N 0.000 claims 1
- PCLZAKHSYYFBBT-UHFFFAOYSA-N 5-bromo-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2-hydroxy-N-methylbenzamide Chemical compound BrC=1C=C(C(=C(C1)C(=O)NC)O)C=1N=NC(=CC1)NCC1(CC(C1)F)C1=NC=CC=C1F PCLZAKHSYYFBBT-UHFFFAOYSA-N 0.000 claims 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims 1
- VXCJLONLBOCWFX-UHFFFAOYSA-N 6-(2-fluoro-4-hydrazinylphenyl)-N-[1-(3-fluoropyridin-2-yl)cyclobutyl]pyridazin-3-amine Chemical compound FC1=CC(NN)=CC=C1C(N=N1)=CC=C1NC1(C=2C(=CC=CN=2)F)CCC1 VXCJLONLBOCWFX-UHFFFAOYSA-N 0.000 claims 1
- AMEYNDPUNBVMND-UHFFFAOYSA-N 6-(2-fluoro-5-hydrazinylphenyl)-N-[1-(3-fluoropyridin-2-yl)cyclobutyl]pyridazin-3-amine Chemical compound NNC1=CC=C(F)C(C=2N=NC(NC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 AMEYNDPUNBVMND-UHFFFAOYSA-N 0.000 claims 1
- JPUXAROWQOVFKK-UHFFFAOYSA-N 6-(3-carbamoylphenyl)-3-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazine-4-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(C(=C1)C(N)=O)=NN=C1C1=CC=CC(C(N)=O)=C1 JPUXAROWQOVFKK-UHFFFAOYSA-N 0.000 claims 1
- CRRNBOMJWUYPDQ-UHFFFAOYSA-N 6-[1-[[[6-(1h-indazol-5-yl)pyridazin-3-yl]amino]methyl]cyclobutyl]-1h-pyridin-2-one Chemical compound OC1=CC=CC(C2(CNC=3N=NC(=CC=3)C=3C=C4C=NNC4=CC=3)CCC2)=N1 CRRNBOMJWUYPDQ-UHFFFAOYSA-N 0.000 claims 1
- HTQWIKBTFPTIMV-UHFFFAOYSA-N 6-[1-[[[6-(1h-indazol-5-yl)pyridazin-3-yl]amino]methyl]cyclobutyl]pyridine-2-carbonitrile Chemical compound N#CC1=CC=CC(C2(CNC=3N=NC(=CC=3)C=3C=C4C=NNC4=CC=3)CCC2)=N1 HTQWIKBTFPTIMV-UHFFFAOYSA-N 0.000 claims 1
- KDOAUDMAFZNSJG-UHFFFAOYSA-N 6-[1-[[[6-(1h-indazol-6-yl)pyridazin-3-yl]amino]methyl]cyclobutyl]-1h-pyridin-2-one Chemical compound OC1=CC=CC(C2(CNC=3N=NC(=CC=3)C=3C=C4NN=CC4=CC=3)CCC2)=N1 KDOAUDMAFZNSJG-UHFFFAOYSA-N 0.000 claims 1
- SETGYRQIVRGYEQ-UHFFFAOYSA-N 6-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-dihydroindol-2-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2C=C3NC(=O)CC3=CC=2)CCC1 SETGYRQIVRGYEQ-UHFFFAOYSA-N 0.000 claims 1
- BVLUJXARTRQSLS-UHFFFAOYSA-N 6-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2,3-dihydroimidazo[2,1-b][1,3]thiazole-3-carboxylic acid Chemical compound C=1N2C(C(=O)O)CSC2=NC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 BVLUJXARTRQSLS-UHFFFAOYSA-N 0.000 claims 1
- UCAJAHWSGSVITE-UHFFFAOYSA-N 6-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-3,3-dimethyl-1h-indol-2-one Chemical compound C=1C=C2C(C)(C)C(=O)NC2=CC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 UCAJAHWSGSVITE-UHFFFAOYSA-N 0.000 claims 1
- CZCFZYMBMBYWBB-UHFFFAOYSA-N 6-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyrazine-2-carbonitrile Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2N=C(C=NC=2)C#N)CCC1 CZCFZYMBMBYWBB-UHFFFAOYSA-N 0.000 claims 1
- ORSKOSRAUUSRDI-UHFFFAOYSA-N 6-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyridin-3-ol Chemical compound Oc1ccc(nc1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 ORSKOSRAUUSRDI-UHFFFAOYSA-N 0.000 claims 1
- WAWNEJCSBGNGGF-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1,4-dihydroquinoxaline-2,3-dione Chemical compound C=1C=C(C=2C=C3NC(=O)C(=O)NC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 WAWNEJCSBGNGGF-UHFFFAOYSA-N 0.000 claims 1
- JYNJDJJKNAUUFP-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-pyridin-2-one Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(O)=N1 JYNJDJJKNAUUFP-UHFFFAOYSA-N 0.000 claims 1
- ZYXKFTYESJZYRD-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-quinazoline-2,4-dione Chemical compound C=1C=C(C=2C=C3C(=O)NC(=O)NC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 ZYXKFTYESJZYRD-UHFFFAOYSA-N 0.000 claims 1
- WIRPFBGMRJHNFK-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-3,3-dimethyl-1h-indol-2-one Chemical compound C=1C=C(C=2C=C3C(C(C(=O)N3)(C)C)=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 WIRPFBGMRJHNFK-UHFFFAOYSA-N 0.000 claims 1
- FQDJJQLISARWDB-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridin-3-ol Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(O)C=N1 FQDJJQLISARWDB-UHFFFAOYSA-N 0.000 claims 1
- DVGFDGHWQYIKBD-UHFFFAOYSA-N 6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-2-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(N)=O)=N1 DVGFDGHWQYIKBD-UHFFFAOYSA-N 0.000 claims 1
- NAQCCAIPADNGON-UHFFFAOYSA-N 6-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-2,3-dihydroisoindol-1-one Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C3C(=O)NCC3=CC=2)N=N1 NAQCCAIPADNGON-UHFFFAOYSA-N 0.000 claims 1
- KBILRIVSGDFLBL-UHFFFAOYSA-N C1=C2C(NN)=NNC2=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 Chemical compound C1=C2C(NN)=NNC2=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KBILRIVSGDFLBL-UHFFFAOYSA-N 0.000 claims 1
- CLOQJWOPHXCCGK-UHFFFAOYSA-N C1=CC(NN)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 Chemical compound C1=CC(NN)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 CLOQJWOPHXCCGK-UHFFFAOYSA-N 0.000 claims 1
- IHLTWGZFWLRNMU-UHFFFAOYSA-N Fc1ccc(cc1-c1ccc(NCC2(CCC2)c2ncccc2F)nn1)C1NC(=O)N=N1 Chemical compound Fc1ccc(cc1-c1ccc(NCC2(CCC2)c2ncccc2F)nn1)C1NC(=O)N=N1 IHLTWGZFWLRNMU-UHFFFAOYSA-N 0.000 claims 1
- QVRMWMLTDHKCIQ-UHFFFAOYSA-N Fc1cccnc1C1(CNc2ccc(nn2)-c2cccc(c2)C2NC(=O)N=N2)CCC1 Chemical compound Fc1cccnc1C1(CNc2ccc(nn2)-c2cccc(c2)C2NC(=O)N=N2)CCC1 QVRMWMLTDHKCIQ-UHFFFAOYSA-N 0.000 claims 1
- DDEIETRXTGPWEE-UHFFFAOYSA-N Fc1cccnc1C1(CNc2ccc(nn2)-c2ncc(s2)C2OC(=O)N=N2)CCC1 Chemical compound Fc1cccnc1C1(CNc2ccc(nn2)-c2ncc(s2)C2OC(=O)N=N2)CCC1 DDEIETRXTGPWEE-UHFFFAOYSA-N 0.000 claims 1
- IILNLYJTAXPYCS-UHFFFAOYSA-N N-[1-(3-fluoropyridin-2-yl)cyclobutyl]-6-(4-hydrazinylphenyl)pyridazin-3-amine Chemical compound C1=CC(NN)=CC=C1C(N=N1)=CC=C1NC1(C=2C(=CC=CN=2)F)CCC1 IILNLYJTAXPYCS-UHFFFAOYSA-N 0.000 claims 1
- ILIXIKWHLRTHHG-UHFFFAOYSA-N N-[1-(4-fluorophenyl)cyclobutyl]-6-(4-hydrazinylphenyl)pyridazin-3-amine Chemical compound C1=CC(NN)=CC=C1C(N=N1)=CC=C1NC1(C=2C=CC(F)=CC=2)CCC1 ILIXIKWHLRTHHG-UHFFFAOYSA-N 0.000 claims 1
- ZKMOBGQJAZIRGI-UHFFFAOYSA-N N-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]-4-methylpyridazin-3-yl]benzamide Chemical compound C(C1=CC=CC=C1)(=O)NC=1N=NC(=CC=1C)NCC(C)(C)C1=CC=C(C=C1)F ZKMOBGQJAZIRGI-UHFFFAOYSA-N 0.000 claims 1
- ATDZQGZNFNUABH-UHFFFAOYSA-N N-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-(3-hydrazinylphenyl)pyridazin-3-amine Chemical compound NNC1=CC=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 ATDZQGZNFNUABH-UHFFFAOYSA-N 0.000 claims 1
- KXINGAVRYWMCSU-UHFFFAOYSA-N N-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-(4-hydrazinylcyclohexen-1-yl)pyridazin-3-amine Chemical compound C1C(NN)CCC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 KXINGAVRYWMCSU-UHFFFAOYSA-N 0.000 claims 1
- FOXAPRPPAZPGKD-UHFFFAOYSA-N N-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-(6-hydrazinylpyridin-3-yl)pyridazin-3-amine Chemical compound C1=NC(NN)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 FOXAPRPPAZPGKD-UHFFFAOYSA-N 0.000 claims 1
- LUJXNDAQGVOMIK-UHFFFAOYSA-N NC1(NNC2=CC=C(C=C12)C=1N=NC(=CC1)NCC1(CCC1)C1=NC=CC=C1F)C(=O)N Chemical compound NC1(NNC2=CC=C(C=C12)C=1N=NC(=CC1)NCC1(CCC1)C1=NC=CC=C1F)C(=O)N LUJXNDAQGVOMIK-UHFFFAOYSA-N 0.000 claims 1
- CSCGATCNUUZIMI-UHFFFAOYSA-N NNc1ccc(cc1)-c1ccc(NCC2(CC(F)(F)C2)c2ncccc2F)nn1 Chemical compound NNc1ccc(cc1)-c1ccc(NCC2(CC(F)(F)C2)c2ncccc2F)nn1 CSCGATCNUUZIMI-UHFFFAOYSA-N 0.000 claims 1
- KWEZCWBOHATAKZ-UHFFFAOYSA-N NNc1ncc(cn1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 Chemical compound NNc1ncc(cn1)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 KWEZCWBOHATAKZ-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- WPXDKRSZYXTJQP-MRXNPFEDSA-N [(2r)-1-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]piperazin-2-yl]methanol Chemical compound OC[C@H]1CNCCN1CC1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 WPXDKRSZYXTJQP-MRXNPFEDSA-N 0.000 claims 1
- WPXDKRSZYXTJQP-INIZCTEOSA-N [(2s)-1-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]piperazin-2-yl]methanol Chemical compound OC[C@@H]1CNCCN1CC1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 WPXDKRSZYXTJQP-INIZCTEOSA-N 0.000 claims 1
- DBLPIWAHXBXBIQ-UHFFFAOYSA-N [2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-(3-hydroxypiperidin-1-yl)methanone Chemical compound C1C(O)CCCN1C(=O)C1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 DBLPIWAHXBXBIQ-UHFFFAOYSA-N 0.000 claims 1
- CXXJNWHANYAKSE-UHFFFAOYSA-N [2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-(3-hydroxypyrrolidin-1-yl)methanone Chemical compound C1C(O)CCN1C(=O)C1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 CXXJNWHANYAKSE-UHFFFAOYSA-N 0.000 claims 1
- RVZKUXUIMAPMTR-UHFFFAOYSA-N [2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-(4-hydroxypiperidin-1-yl)methanone Chemical compound C1CC(O)CCN1C(=O)C1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 RVZKUXUIMAPMTR-UHFFFAOYSA-N 0.000 claims 1
- JCWAMEPYRBROIO-UHFFFAOYSA-N [2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]-morpholin-4-ylmethanone Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C(=O)N2CCOCC2)CCC1 JCWAMEPYRBROIO-UHFFFAOYSA-N 0.000 claims 1
- BAPWRMWYBSSDMC-UHFFFAOYSA-N [2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methanol Chemical compound S1C(CO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 BAPWRMWYBSSDMC-UHFFFAOYSA-N 0.000 claims 1
- WIQKHTNDYGSJFH-UHFFFAOYSA-N [2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]methanol Chemical compound OCC1=CC=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 WIQKHTNDYGSJFH-UHFFFAOYSA-N 0.000 claims 1
- INHIXXOXGPFJPO-UHFFFAOYSA-N [3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyridin-2-yl]methanol Chemical compound OCC1=NC=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 INHIXXOXGPFJPO-UHFFFAOYSA-N 0.000 claims 1
- AJJMGESSOOAXDE-UHFFFAOYSA-N [3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]phenyl]-phenylmethanone Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C(C=1)=CC=CC=1C(=O)C1=CC=CC=C1 AJJMGESSOOAXDE-UHFFFAOYSA-N 0.000 claims 1
- KCNBOIQTHZXOIX-UHFFFAOYSA-N [3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]phenyl]-piperidin-1-ylmethanone Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C(C=1)=CC=CC=1C(=O)N1CCCCC1 KCNBOIQTHZXOIX-UHFFFAOYSA-N 0.000 claims 1
- UQNCLMKLZAGCCQ-UHFFFAOYSA-N [3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]phenyl]methanol Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(CO)=C1 UQNCLMKLZAGCCQ-UHFFFAOYSA-N 0.000 claims 1
- VCASBYZXJCTEDN-UHFFFAOYSA-N [3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]methanol Chemical compound OCC1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 VCASBYZXJCTEDN-UHFFFAOYSA-N 0.000 claims 1
- LGOOWZBPSUDNDA-UHFFFAOYSA-N [4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]phenyl]-phenylmethanone Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 LGOOWZBPSUDNDA-UHFFFAOYSA-N 0.000 claims 1
- NGYWPUSVQUKKHF-UHFFFAOYSA-N [5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-2h-indazol-3-yl]methanol Chemical compound C=1C=C(C=2C=C3C(CO)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 NGYWPUSVQUKKHF-UHFFFAOYSA-N 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 125000004273 azetidin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- DFYAKUJCZPULIC-UHFFFAOYSA-N ethyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 DFYAKUJCZPULIC-UHFFFAOYSA-N 0.000 claims 1
- CXXKJUASGJMWSK-UHFFFAOYSA-N ethyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-hydroxy-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)c1sc(nc1O)-c1ccc(NCC2(CCC2)c2ncccc2F)nn1 CXXKJUASGJMWSK-UHFFFAOYSA-N 0.000 claims 1
- GMZSKKUWFIYNTL-UHFFFAOYSA-N ethyl 2-fluoro-5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzoate Chemical compound C1=C(F)C(C(=O)OCC)=CC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 GMZSKKUWFIYNTL-UHFFFAOYSA-N 0.000 claims 1
- MLZQAQHPONQEQX-UHFFFAOYSA-N ethyl 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-5-oxo-1,2-dihydropyrazole-4-carboxylate Chemical compound N1NC(=O)C(C(=O)OCC)=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 MLZQAQHPONQEQX-UHFFFAOYSA-N 0.000 claims 1
- OFUBVFDINBVHOD-UHFFFAOYSA-N ethyl 5-chloro-2-[5-chloro-6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-4-carboxylate Chemical compound S1C(Cl)=C(C(=O)OCC)N=C1C(N=N1)=CC(Cl)=C1NCC1(C=2C(=CC=CN=2)F)CCC1 OFUBVFDINBVHOD-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- URGVPWHWEYZBRA-UHFFFAOYSA-N methyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 URGVPWHWEYZBRA-UHFFFAOYSA-N 0.000 claims 1
- WYGFLMNJWMFALH-UHFFFAOYSA-N methyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-oxazole-5-carboxylate Chemical compound O1C(C(=O)OC)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 WYGFLMNJWMFALH-UHFFFAOYSA-N 0.000 claims 1
- BKOSNBKRZUHYCP-UHFFFAOYSA-N methyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-4-carboxylate Chemical compound COC(=O)C1=CSC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 BKOSNBKRZUHYCP-UHFFFAOYSA-N 0.000 claims 1
- JUNBBIVBQMNUFY-UHFFFAOYSA-N methyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1-methylimidazole-4-carboxylate Chemical compound COC(=O)C1=CN(C)C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 JUNBBIVBQMNUFY-UHFFFAOYSA-N 0.000 claims 1
- OQFYJUXBUBAJPQ-UHFFFAOYSA-N methyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4,5-dihydro-1h-imidazole-5-carboxylate Chemical compound N1C(C(=O)OC)CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 OQFYJUXBUBAJPQ-UHFFFAOYSA-N 0.000 claims 1
- NVAXDXOOCIEQEU-UHFFFAOYSA-N methyl 3-amino-5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1,2-dihydroindazole-3-carboxylate Chemical compound C1=C2C(C(=O)OC)(N)NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 NVAXDXOOCIEQEU-UHFFFAOYSA-N 0.000 claims 1
- RDRIEMMXYAGZHN-UHFFFAOYSA-N methyl 4-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1,2,3,6-tetrahydropyridine-6-carboxylate Chemical compound COC(=O)C1NCCC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 RDRIEMMXYAGZHN-UHFFFAOYSA-N 0.000 claims 1
- APNXKXJRHXMMPF-UHFFFAOYSA-N methyl 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-3-(methoxycarbonylamino)-1,2-dihydroindazole-3-carboxylate Chemical compound C1=C2C(NC(=O)OC)(C(=O)OC)NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 APNXKXJRHXMMPF-UHFFFAOYSA-N 0.000 claims 1
- VHPPUESSTHXGKI-UHFFFAOYSA-N methyl 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridine-3-carboxylate Chemical compound COC(=O)C1=CN=CC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 VHPPUESSTHXGKI-UHFFFAOYSA-N 0.000 claims 1
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 1
- ZBULIFUAGUXUFF-UHFFFAOYSA-N methyl n-[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-5,6-dihydro-4h-cyclopenta[d][1,3]thiazol-4-yl]carbamate Chemical compound N=1C=2C(NC(=O)OC)CCC=2SC=1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZBULIFUAGUXUFF-UHFFFAOYSA-N 0.000 claims 1
- LRFDGSNKJGKESZ-UHFFFAOYSA-N methyl n-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyrimidin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 LRFDGSNKJGKESZ-UHFFFAOYSA-N 0.000 claims 1
- JUNMOTUPNKRTAQ-UHFFFAOYSA-N methyl n-[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazol-3-yl]carbamate Chemical compound C1=C2C(NC(=O)OC)=NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 JUNMOTUPNKRTAQ-UHFFFAOYSA-N 0.000 claims 1
- REJDGIBJTGSLHY-UHFFFAOYSA-N methyl n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]carbamate Chemical compound S1C(CNC(=O)OC)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 REJDGIBJTGSLHY-UHFFFAOYSA-N 0.000 claims 1
- QJRCDYIVAKUKLB-UHFFFAOYSA-N n'-cyano-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboximidamide Chemical compound S1C(C(=NC#N)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QJRCDYIVAKUKLB-UHFFFAOYSA-N 0.000 claims 1
- XOAAUWSYNWLMJN-UHFFFAOYSA-N n-(1,1-dioxothietan-3-yl)-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C(=O)NC2CS(=O)(=O)C2)N=N1 XOAAUWSYNWLMJN-UHFFFAOYSA-N 0.000 claims 1
- JBHXCUKRXCCEAA-UHFFFAOYSA-N n-(1,1-dioxothiolan-3-yl)-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CN=2)C(=O)NC2CS(=O)(=O)CC2)CCC1 JBHXCUKRXCCEAA-UHFFFAOYSA-N 0.000 claims 1
- GSPDLUUFWSMSPN-UHFFFAOYSA-N n-(1,1-dioxothiolan-3-yl)-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C(=O)NC2CS(=O)(=O)CC2)N=N1 GSPDLUUFWSMSPN-UHFFFAOYSA-N 0.000 claims 1
- YTGKQGDHEXJNOI-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound OCC(CO)NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 YTGKQGDHEXJNOI-UHFFFAOYSA-N 0.000 claims 1
- MCHGGGQWBNCHKU-UHFFFAOYSA-N n-(1-acetylazetidin-3-yl)-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1N(C(=O)C)CC1NC(=O)C1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 MCHGGGQWBNCHKU-UHFFFAOYSA-N 0.000 claims 1
- CWLUQNNVZCJTNF-UHFFFAOYSA-N n-(1-acetylazetidin-3-yl)-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1N(C(=O)C)CC1NC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 CWLUQNNVZCJTNF-UHFFFAOYSA-N 0.000 claims 1
- OJXMVPXGNRWYKA-UHFFFAOYSA-N n-(2,2-difluoro-3-hydroxypropyl)-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCC(F)(F)CO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 OJXMVPXGNRWYKA-UHFFFAOYSA-N 0.000 claims 1
- ZCHXIZNFQFQYAW-UHFFFAOYSA-N n-(2,2-difluoroethyl)-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound FC(F)CNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 ZCHXIZNFQFQYAW-UHFFFAOYSA-N 0.000 claims 1
- OVTUOXHYFGEWMX-UHFFFAOYSA-N n-(2,3-dihydroxypropyl)-3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(=O)NCC(O)CO)=C1 OVTUOXHYFGEWMX-UHFFFAOYSA-N 0.000 claims 1
- APLASMXWEJBQPT-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCC(=O)N)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 APLASMXWEJBQPT-UHFFFAOYSA-N 0.000 claims 1
- QJKKGQCEAKARER-UHFFFAOYSA-N n-(2-amino-3,3,3-trifluoropropyl)-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCC(N)C(F)(F)F)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QJKKGQCEAKARER-UHFFFAOYSA-N 0.000 claims 1
- KKZCMJMMFIBHCO-UHFFFAOYSA-N n-(2-aminoethyl)-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCN)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 KKZCMJMMFIBHCO-UHFFFAOYSA-N 0.000 claims 1
- HZAARNVSXQZAAX-UHFFFAOYSA-N n-(2-aminoethyl)-3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(=O)NCCN)=C1 HZAARNVSXQZAAX-UHFFFAOYSA-N 0.000 claims 1
- DBYUFOHYECHMGH-UHFFFAOYSA-N n-(3,3-difluorocyclobutyl)-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C(=O)NC2CC(F)(F)C2)F)N=N1 DBYUFOHYECHMGH-UHFFFAOYSA-N 0.000 claims 1
- PVYFLVUGQVOZOB-UHFFFAOYSA-N n-(3-amino-2,2-difluoropropyl)-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCC(F)(F)CN)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 PVYFLVUGQVOZOB-UHFFFAOYSA-N 0.000 claims 1
- KAPSMXVDRJNOGB-UHFFFAOYSA-N n-(3-aminopropyl)-3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC(C(=O)NCCCN)=C1 KAPSMXVDRJNOGB-UHFFFAOYSA-N 0.000 claims 1
- MTWBKVLTFIUYLI-UHFFFAOYSA-N n-(azetidin-3-yl)-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C(=O)NC2CNC2)N=N1 MTWBKVLTFIUYLI-UHFFFAOYSA-N 0.000 claims 1
- RDPXBVVMYSBYPZ-CYBMUJFWSA-N n-[(2r)-2,3-dihydroxypropyl]-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NC[C@@H](O)CO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 RDPXBVVMYSBYPZ-CYBMUJFWSA-N 0.000 claims 1
- WSMGGVNVQIVUHN-DMISQSQKSA-N n-[(2r)-2,3-dihydroxypropyl]-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound OC[C@H](O)CNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 WSMGGVNVQIVUHN-DMISQSQKSA-N 0.000 claims 1
- RDPXBVVMYSBYPZ-ZDUSSCGKSA-N n-[(2s)-2,3-dihydroxypropyl]-2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NC[C@H](O)CO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 RDPXBVVMYSBYPZ-ZDUSSCGKSA-N 0.000 claims 1
- WSMGGVNVQIVUHN-LYAYERMMSA-N n-[(2s)-2,3-dihydroxypropyl]-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 WSMGGVNVQIVUHN-LYAYERMMSA-N 0.000 claims 1
- ZAZIOCZWGLMDFW-UHFFFAOYSA-N n-[2-(4-fluorophenyl)-2-methylpropyl]-6-(1-methylsulfonyl-3,6-dihydro-2h-pyridin-4-yl)pyridazin-3-amine Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CCN(S(C)(=O)=O)CC1 ZAZIOCZWGLMDFW-UHFFFAOYSA-N 0.000 claims 1
- KYXUBSRXIFQTMB-UHFFFAOYSA-N n-[3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 KYXUBSRXIFQTMB-UHFFFAOYSA-N 0.000 claims 1
- HPURCMZNULWLDR-UHFFFAOYSA-N n-[4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 HPURCMZNULWLDR-UHFFFAOYSA-N 0.000 claims 1
- FAUVLWHBDIZZJU-UHFFFAOYSA-N n-[4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyrimidin-2-yl]acetamide Chemical compound CC(=O)NC1=NC=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 FAUVLWHBDIZZJU-UHFFFAOYSA-N 0.000 claims 1
- FTXNCXPAYCZELA-UHFFFAOYSA-N n-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-imidazol-2-yl]acetamide Chemical compound N1C(NC(=O)C)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 FTXNCXPAYCZELA-UHFFFAOYSA-N 0.000 claims 1
- XNZUKYQAVPFYBM-UHFFFAOYSA-N n-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-indazol-3-yl]acetamide Chemical compound C1=C2C(NC(=O)C)=NNC2=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 XNZUKYQAVPFYBM-UHFFFAOYSA-N 0.000 claims 1
- LAMBUYRNBSTXOX-UHFFFAOYSA-N n-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyrimidin-2-yl]acetamide Chemical compound C1=NC(NC(=O)C)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 LAMBUYRNBSTXOX-UHFFFAOYSA-N 0.000 claims 1
- CJKUTXGKPRRPPO-UHFFFAOYSA-N n-[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridin-2-yl]acetamide Chemical compound C1=NC(NC(=O)C)=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 CJKUTXGKPRRPPO-UHFFFAOYSA-N 0.000 claims 1
- CRBHCDWPOWBZFW-UHFFFAOYSA-N n-[6-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-benzimidazol-2-yl]acetamide Chemical compound C=1C=C2NC(NC(=O)C)=NC2=CC=1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 CRBHCDWPOWBZFW-UHFFFAOYSA-N 0.000 claims 1
- ZKVWVUUAXWINKG-UHFFFAOYSA-N n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-(5-methylsulfonyl-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridin-2-yl)pyridazin-3-amine Chemical compound S1C=2CN(S(=O)(=O)C)CCC=2N=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZKVWVUUAXWINKG-UHFFFAOYSA-N 0.000 claims 1
- BNUAQTRUHKCJRQ-UHFFFAOYSA-N n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-[5-[(4-methylsulfonylpiperazin-1-yl)methyl]-1,3-thiazol-2-yl]pyridazin-3-amine Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CN=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)S1 BNUAQTRUHKCJRQ-UHFFFAOYSA-N 0.000 claims 1
- GPXGCABTVNQWPJ-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-1h-1,2,4-triazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C=3NN=CN=3)=CN=2)CCC1 GPXGCABTVNQWPJ-UHFFFAOYSA-N 0.000 claims 1
- RQMSDKJIPJOERW-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-1h-imidazole-2-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C=3NC=CN=3)=CN=2)CCC1 RQMSDKJIPJOERW-UHFFFAOYSA-N 0.000 claims 1
- MUOQQMHCLLADDO-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-1h-imidazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C=3NC=NC=3)=CN=2)CCC1 MUOQQMHCLLADDO-UHFFFAOYSA-N 0.000 claims 1
- IODYOGCOSDCMFR-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-1h-pyrazole-4-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C3=CNN=C3)=CN=2)CCC1 IODYOGCOSDCMFR-UHFFFAOYSA-N 0.000 claims 1
- PCTILYKGXYQVMH-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-1h-pyrazole-5-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C=3NN=CC=3)=CN=2)CCC1 PCTILYKGXYQVMH-UHFFFAOYSA-N 0.000 claims 1
- QSDZOVPNDLYDRB-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-hydroxy-2-methylpropanamide Chemical compound S1C(CNC(=O)C(C)(O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QSDZOVPNDLYDRB-UHFFFAOYSA-N 0.000 claims 1
- VYUBGCRIZPGGDZ-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-hydroxy-n-methylacetamide Chemical compound S1C(CN(C)C(=O)CO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 VYUBGCRIZPGGDZ-UHFFFAOYSA-N 0.000 claims 1
- PFVSWMGPMPUBAD-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-methylpropanamide Chemical compound S1C(CNC(=O)C(C)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 PFVSWMGPMPUBAD-UHFFFAOYSA-N 0.000 claims 1
- NVJBJWKCRVQVHG-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-methylpropane-2-sulfinamide Chemical compound S1C(CNS(=O)C(C)(C)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 NVJBJWKCRVQVHG-UHFFFAOYSA-N 0.000 claims 1
- SRZWDLASDQRNOD-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-oxo-1,3-dihydroimidazole-4-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C=3NC(=O)NC=3)=CN=2)CCC1 SRZWDLASDQRNOD-UHFFFAOYSA-N 0.000 claims 1
- HMPXTVBRNRHLBI-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2h-triazole-4-carboxamide Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(CNC(=O)C3=NNN=C3)=CN=2)CCC1 HMPXTVBRNRHLBI-UHFFFAOYSA-N 0.000 claims 1
- ZNOXWQJEPWLMDM-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]acetamide Chemical compound S1C(CNC(=O)C)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZNOXWQJEPWLMDM-UHFFFAOYSA-N 0.000 claims 1
- MSALHUHMKALZLO-UHFFFAOYSA-N n-[[3-(3-fluoropyridin-2-yl)-1-methylsulfonylazetidin-3-yl]methyl]-6-(1h-indazol-5-yl)pyridazin-3-amine Chemical compound C1N(S(=O)(=O)C)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C3C=NNC3=CC=2)N=N1 MSALHUHMKALZLO-UHFFFAOYSA-N 0.000 claims 1
- QURYGGCFIIXXQI-UHFFFAOYSA-N n-[[3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 QURYGGCFIIXXQI-UHFFFAOYSA-N 0.000 claims 1
- KHEBLWPDIRXKKY-UHFFFAOYSA-N n-[[4-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-2-yl]methyl]acetamide Chemical compound S1C(CNC(=O)C)=NC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=C1 KHEBLWPDIRXKKY-UHFFFAOYSA-N 0.000 claims 1
- SWZQIMRRDXYQOV-UHFFFAOYSA-N n-[[4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 SWZQIMRRDXYQOV-UHFFFAOYSA-N 0.000 claims 1
- QYMBJDSGEYFLID-UHFFFAOYSA-N n-[[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-2-yl]methyl]acetamide Chemical compound S1C(CNC(=O)C)=NC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 QYMBJDSGEYFLID-UHFFFAOYSA-N 0.000 claims 1
- USGBIXFGPJXMIC-UHFFFAOYSA-N n-[[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]pyridin-2-yl]methyl]acetamide Chemical compound C1=NC(CNC(=O)C)=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 USGBIXFGPJXMIC-UHFFFAOYSA-N 0.000 claims 1
- ABAQJMBCPHJNHF-UHFFFAOYSA-N n-cyclobutyl-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C(=O)NC2CCC2)F)N=N1 ABAQJMBCPHJNHF-UHFFFAOYSA-N 0.000 claims 1
- RTEJWIKANGLQNV-UHFFFAOYSA-N n-cyclopropyl-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C=C(C=CC=2)C(=O)NC2CC2)N=N1 RTEJWIKANGLQNV-UHFFFAOYSA-N 0.000 claims 1
- MSTHMTPRKPYAOZ-UHFFFAOYSA-N n-cyclopropyl-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1C(F)CC1(C=1C(=CC=CN=1)F)CNC1=CC=C(C=2C(=CC=C(C=2)C(=O)NC2CC2)F)N=N1 MSTHMTPRKPYAOZ-UHFFFAOYSA-N 0.000 claims 1
- RNIIIINMYGLQEI-UHFFFAOYSA-N n-ethyl-2-fluoro-5-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound C1=C(F)C(C(=O)NCC)=CC(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 RNIIIINMYGLQEI-UHFFFAOYSA-N 0.000 claims 1
- JLOYKZQPSOPPLT-UHFFFAOYSA-N n-ethyl-4-fluoro-3-[6-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzamide Chemical compound CCNC(=O)C1=CC=C(F)C(C=2N=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=CC=2)=C1 JLOYKZQPSOPPLT-UHFFFAOYSA-N 0.000 claims 1
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims 1
- BRYCUMKDWMEGMK-UHFFFAOYSA-N piperazine-2-carboxamide Chemical compound NC(=O)C1CNCCN1 BRYCUMKDWMEGMK-UHFFFAOYSA-N 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- VQUWCVSMHHSTIB-UHFFFAOYSA-N tert-butyl N-[2-(4-fluorophenyl)-2-methylpropyl]carbamate Chemical compound C(C)(C)(C)OC(=O)NCC(C)(C)C1=CC=C(C=C1)F VQUWCVSMHHSTIB-UHFFFAOYSA-N 0.000 claims 1
- BKKDUUATHOPXDZ-UHFFFAOYSA-N tert-butyl n-[2-(3-fluoropyridin-2-yl)-2-methylpropyl]-n-[6-(2-oxo-1,3-dihydrobenzimidazol-5-yl)pyridazin-3-yl]carbamate Chemical compound C=1C=C(C=2C=C3NC(O)=NC3=CC=2)N=NC=1N(C(=O)OC(C)(C)C)CC(C)(C)C1=NC=CC=C1F BKKDUUATHOPXDZ-UHFFFAOYSA-N 0.000 claims 1
- ANGYJTLRKVZZRD-UHFFFAOYSA-N tert-butyl n-[2-[[5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazol-3-yl]amino]ethyl]carbamate Chemical compound C1=C2C(NCCNC(=O)OC(C)(C)C)=NNC2=CC=C1C(N=N1)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 ANGYJTLRKVZZRD-UHFFFAOYSA-N 0.000 claims 1
- LTKNVPMSYQSUOP-UHFFFAOYSA-N tert-butyl n-[3-[[3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzoyl]amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC(=O)C1=CC=CC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 LTKNVPMSYQSUOP-UHFFFAOYSA-N 0.000 claims 1
- JVNPBXAICCBZRU-UHFFFAOYSA-N tert-butyl n-[6-(2,3-dioxo-1,4-dihydroquinoxalin-6-yl)pyridazin-3-yl]-n-[2-(4-fluorophenyl)-2-methylpropyl]carbamate Chemical compound C=1C=C(C=2C=C3NC(=O)C(=O)NC3=CC=2)N=NC=1N(C(=O)OC(C)(C)C)CC(C)(C)C1=CC=C(F)C=C1 JVNPBXAICCBZRU-UHFFFAOYSA-N 0.000 claims 1
- VWLHQEJZEAJHMB-UHFFFAOYSA-N tert-butyl n-[[3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]phenyl]methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C=2N=NC(NCC(C)(C)C=3C=CC(F)=CC=3)=CC=2)=C1 VWLHQEJZEAJHMB-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 249
- 235000019439 ethyl acetate Nutrition 0.000 description 105
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 105
- 238000006243 chemical reaction Methods 0.000 description 104
- 239000007787 solid Substances 0.000 description 81
- 239000012044 organic layer Substances 0.000 description 74
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
- 239000000243 solution Substances 0.000 description 63
- 239000011541 reaction mixture Substances 0.000 description 58
- 239000011734 sodium Substances 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- 210000002027 skeletal muscle Anatomy 0.000 description 45
- 239000012267 brine Substances 0.000 description 42
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 42
- 238000010898 silica gel chromatography Methods 0.000 description 41
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 210000001087 myotubule Anatomy 0.000 description 34
- 125000001624 naphthyl group Chemical group 0.000 description 33
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 31
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 102000003505 Myosin Human genes 0.000 description 27
- 239000003921 oil Substances 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 26
- 125000003367 polycyclic group Chemical group 0.000 description 26
- 108060008487 Myosin Proteins 0.000 description 25
- 238000007792 addition Methods 0.000 description 25
- 210000002235 sarcomere Anatomy 0.000 description 24
- 238000000746 purification Methods 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 22
- 239000000460 chlorine Chemical group 0.000 description 22
- 229920006395 saturated elastomer Polymers 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 20
- 102000004903 Troponin Human genes 0.000 description 20
- 108090001027 Troponin Proteins 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- 102000007469 Actins Human genes 0.000 description 18
- 108010085238 Actins Proteins 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 16
- 108010030743 Tropomyosin Proteins 0.000 description 16
- 102000005937 Tropomyosin Human genes 0.000 description 16
- 102000013534 Troponin C Human genes 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 206010028372 Muscular weakness Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000011737 fluorine Substances 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 14
- 208000010428 Muscle Weakness Diseases 0.000 description 13
- 238000003419 tautomerization reaction Methods 0.000 description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 102000013394 Troponin I Human genes 0.000 description 12
- 108010065729 Troponin I Chemical group 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229910052717 sulfur Inorganic materials 0.000 description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 11
- 102000004987 Troponin T Human genes 0.000 description 11
- 108090001108 Troponin T Proteins 0.000 description 11
- 150000001721 carbon Chemical group 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 239000012453 solvate Substances 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 229910001424 calcium ion Inorganic materials 0.000 description 9
- 206010016256 fatigue Diseases 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 9
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 8
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 8
- 108010029485 Protein Isoforms Proteins 0.000 description 8
- 102000001708 Protein Isoforms Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 125000003386 piperidinyl group Chemical group 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010006895 Cachexia Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 210000003632 microfilament Anatomy 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 230000004118 muscle contraction Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- DHGRRSSFDBJARB-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-methylpropan-1-amine Chemical compound NCC(C)(C)C1=CC=C(F)C=C1 DHGRRSSFDBJARB-UHFFFAOYSA-N 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 210000002161 motor neuron Anatomy 0.000 description 6
- 230000004220 muscle function Effects 0.000 description 6
- 201000006938 muscular dystrophy Diseases 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 208000033808 peripheral neuropathy Diseases 0.000 description 6
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- MAZYJDRQVMDEIA-UHFFFAOYSA-N tert-butyl n-(6-chloropyridazin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(Cl)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 MAZYJDRQVMDEIA-UHFFFAOYSA-N 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- KTHVNDNYOHUVAF-UHFFFAOYSA-N 6-chloro-n-[2-(4-fluorophenyl)-2-methylpropyl]pyridazin-3-amine Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC1=CC=C(Cl)N=N1 KTHVNDNYOHUVAF-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 208000036119 Frailty Diseases 0.000 description 5
- 208000029578 Muscle disease Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 210000003128 head Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000030175 lameness Diseases 0.000 description 5
- 210000003365 myofibril Anatomy 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229960000581 salicylamide Drugs 0.000 description 5
- 208000001076 sarcopenia Diseases 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940125913 troponin activator Drugs 0.000 description 5
- DIMBLPFESAVLBI-UHFFFAOYSA-N 2-bromo-1-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]ethanone Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC1=CC=C(C(=O)CBr)N=N1 DIMBLPFESAVLBI-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- XZPNLYMTKNDIIV-UHFFFAOYSA-N 6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazine-3-carbonitrile Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C#N)CCC1 XZPNLYMTKNDIIV-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- 101150003085 Pdcl gene Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
- BJACDHCRWGPBLA-UHFFFAOYSA-N tert-butyl n-[6-[5-(chloromethyl)-1,3-thiazol-2-yl]pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(CCl)=CN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 BJACDHCRWGPBLA-UHFFFAOYSA-N 0.000 description 4
- XKQMBNDZSNXHAW-UHFFFAOYSA-N tert-butyl n-[6-[5-(cyanomethyl)-1,3-thiazol-2-yl]pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(CC#N)=CN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 XKQMBNDZSNXHAW-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- GNTKFUARIPLYGN-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)cyclobutan-1-amine Chemical compound N=1C=CC=C(F)C=1C1(N)CCC1 GNTKFUARIPLYGN-UHFFFAOYSA-N 0.000 description 3
- DLDPBPUXBQGZPH-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)cyclobutane-1-carboxamide Chemical compound N=1C=CC=C(F)C=1C1(C(=O)N)CCC1 DLDPBPUXBQGZPH-UHFFFAOYSA-N 0.000 description 3
- ROKGHLCDAGGOPN-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridazin-3-yl]-4-methoxy-2,5-dihydro-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)C(OC)=NC1C1=CC=C(N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=N1 ROKGHLCDAGGOPN-UHFFFAOYSA-N 0.000 description 3
- DCDSAWIIPKIQRS-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]propan-2-ol Chemical compound N1=NC(C(C)(O)C)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DCDSAWIIPKIQRS-UHFFFAOYSA-N 0.000 description 3
- WCKNMSWOWPROGD-UHFFFAOYSA-N 2-bromo-5-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=C(Br)N=C1 WCKNMSWOWPROGD-UHFFFAOYSA-N 0.000 description 3
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- YBLZNTUPPOLKIC-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-3h-1,3,4-oxadiazol-2-one Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=NNC(=O)O1 YBLZNTUPPOLKIC-UHFFFAOYSA-N 0.000 description 3
- OMHWRBXMXIHICG-UHFFFAOYSA-N 6-(2-chloropyridin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyridazin-3-amine Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2C(=NC=CC=2)Cl)CCC1 OMHWRBXMXIHICG-UHFFFAOYSA-N 0.000 description 3
- HOKHYFZLKSGFAX-UHFFFAOYSA-N 6-(5-aminopyridin-2-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyridazin-3-amine Chemical compound N1=CC(N)=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 HOKHYFZLKSGFAX-UHFFFAOYSA-N 0.000 description 3
- OLYQDBSTNCTCJF-UHFFFAOYSA-N 6-chloro-n-[2-(4-fluorophenyl)-2-methylpropyl]-5-methylpyridazin-3-amine Chemical compound N1=C(Cl)C(C)=CC(NCC(C)(C)C=2C=CC(F)=CC=2)=N1 OLYQDBSTNCTCJF-UHFFFAOYSA-N 0.000 description 3
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 3
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- FHHLEXHAVFYXDK-UHFFFAOYSA-N benzyl n-[2-[[2-fluoro-5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]benzoyl]amino]ethyl]carbamate Chemical compound FC1=CC=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)C=C1C(=O)NCCNC(=O)OCC1=CC=CC=C1 FHHLEXHAVFYXDK-UHFFFAOYSA-N 0.000 description 3
- AQFQKBURGVBXEK-UHFFFAOYSA-N benzyl n-[2-[[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-indazol-3-yl]amino]ethyl]carbamate Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2C=C3C(NCCNC(=O)OCC=4C=CC=CC=4)=NNC3=CC=2)CCC1 AQFQKBURGVBXEK-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000010779 crude oil Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- SSYZIFCEOSSERB-UHFFFAOYSA-N methyl n-[1-(3-fluoropyridin-2-yl)cyclobutyl]carbamate Chemical compound N=1C=CC=C(F)C=1C1(NC(=O)OC)CCC1 SSYZIFCEOSSERB-UHFFFAOYSA-N 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- IPDBWOKGEUFVQP-UHFFFAOYSA-N n'-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-indazol-3-yl]ethane-1,2-diamine Chemical compound C1=C2C(NCCN)=NNC2=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 IPDBWOKGEUFVQP-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 210000000715 neuromuscular junction Anatomy 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011698 potassium fluoride Substances 0.000 description 3
- 235000003270 potassium fluoride Nutrition 0.000 description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 229960004181 riluzole Drugs 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000849 selective androgen receptor modulator Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- NHPJZMHAGLDRHV-UHFFFAOYSA-N tert-butyl n-(6-carbamothioylpyridazin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C(N)=S)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 NHPJZMHAGLDRHV-UHFFFAOYSA-N 0.000 description 3
- LDOGBTBNGPFVMX-UHFFFAOYSA-N tert-butyl n-[6-(1-ethoxyethenyl)pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound N1=NC(C(=C)OCC)=CC=C1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 LDOGBTBNGPFVMX-UHFFFAOYSA-N 0.000 description 3
- XHCKCKZOKSZHMC-UHFFFAOYSA-N tert-butyl n-[6-(5-carbamoyl-4-methoxy-2,5-dihydro-1,3-thiazol-2-yl)pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound S1C(C(N)=O)C(OC)=NC1C1=CC=C(N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=N1 XHCKCKZOKSZHMC-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- YRBRJLWZJHRXBG-SSDOTTSWSA-N (2s)-2-(4-fluorophenyl)propan-1-amine Chemical compound NC[C@@H](C)C1=CC=C(F)C=C1 YRBRJLWZJHRXBG-SSDOTTSWSA-N 0.000 description 2
- DLIGEPKOWMTQQI-SSDOTTSWSA-N (2s)-2-(4-fluorophenyl)propan-1-ol Chemical compound OC[C@@H](C)C1=CC=C(F)C=C1 DLIGEPKOWMTQQI-SSDOTTSWSA-N 0.000 description 2
- VBTQNVGPCAESPO-GUYCJALGSA-N (4s)-4-benzyl-3-[(2s)-2-(4-fluorophenyl)propanoyl]-1,3-oxazolidin-2-one Chemical compound C([C@@H]1N(C(OC1)=O)C(=O)[C@@H](C)C=1C=CC(F)=CC=1)C1=CC=CC=C1 VBTQNVGPCAESPO-GUYCJALGSA-N 0.000 description 2
- RKQFDYXUAACCJJ-INIZCTEOSA-N (4s)-4-benzyl-3-[2-(4-fluorophenyl)acetyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(F)=CC=C1CC(=O)N1C(=O)OC[C@@H]1CC1=CC=CC=C1 RKQFDYXUAACCJJ-INIZCTEOSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- TVYCYSWASMVOMJ-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d][1,3]thiazol-3-one Chemical compound N1=CSC2=C1NNC2=O TVYCYSWASMVOMJ-UHFFFAOYSA-N 0.000 description 2
- MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-dihydropyridine Chemical compound C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- NQTUTMXQBMACGI-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)-3-hydroxycyclobutane-1-carbonitrile Chemical compound C1C(O)CC1(C#N)C1=NC=CC=C1F NQTUTMXQBMACGI-UHFFFAOYSA-N 0.000 description 2
- NZSLWHICVBIQTK-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)-3-methylidenecyclobutane-1-carbonitrile Chemical compound FC1=CC=CN=C1C1(C#N)CC(=C)C1 NZSLWHICVBIQTK-UHFFFAOYSA-N 0.000 description 2
- MZLXAQCGNKZLQA-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)-3-oxocyclobutane-1-carbonitrile Chemical compound FC1=CC=CN=C1C1(C#N)CC(=O)C1 MZLXAQCGNKZLQA-UHFFFAOYSA-N 0.000 description 2
- MCHGXLXKBRYWIV-UHFFFAOYSA-N 1-(6-fluoropyridin-2-yl)cyclobutane-1-carbonitrile Chemical compound FC1=CC=CC(C2(CCC2)C#N)=N1 MCHGXLXKBRYWIV-UHFFFAOYSA-N 0.000 description 2
- WYBCGBVYIUQGQT-UHFFFAOYSA-N 1-(6-methoxypyridin-2-yl)cyclobutane-1-carbonitrile Chemical compound COC1=CC=CC(C2(CCC2)C#N)=N1 WYBCGBVYIUQGQT-UHFFFAOYSA-N 0.000 description 2
- YYWGBYAOXPGZQN-UHFFFAOYSA-N 1-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]ethanone Chemical compound N1=NC(C(=O)C)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 YYWGBYAOXPGZQN-UHFFFAOYSA-N 0.000 description 2
- WLMKFPQYBKHCOM-UHFFFAOYSA-N 1-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]pyrrole-3-carboxamide Chemical compound C1=C(C(=O)N)C=CN1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 WLMKFPQYBKHCOM-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- QMNUDYFKZYBWQX-UHFFFAOYSA-N 1H-quinazolin-4-one Chemical compound C1=CC=C2C(=O)N=CNC2=C1 QMNUDYFKZYBWQX-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- MLTZCNARUQTCBM-UHFFFAOYSA-N 2-(3-fluoropyridin-2-yl)acetonitrile Chemical compound FC1=CC=CN=C1CC#N MLTZCNARUQTCBM-UHFFFAOYSA-N 0.000 description 2
- JHQBLYITVCBGTO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetonitrile Chemical compound FC1=CC=C(CC#N)C=C1 JHQBLYITVCBGTO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZCMPBROLWBJECM-LLVKDONJSA-N 2-[(2s)-2-(4-fluorophenyl)propyl]isoindole-1,3-dione Chemical compound C1([C@@H](CN2C(C3=CC=CC=C3C2=O)=O)C)=CC=C(F)C=C1 ZCMPBROLWBJECM-LLVKDONJSA-N 0.000 description 2
- JJIBQIVKUBKOJT-UHFFFAOYSA-N 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-4-oxo-1,3-thiazolidine-5-carboxamide Chemical compound N1=C(O)C(C(=O)N)SC1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 JJIBQIVKUBKOJT-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- SVAZIMBLBHOVIR-UHFFFAOYSA-N 2-chloro-3-fluoropyridine Chemical compound FC1=CC=CN=C1Cl SVAZIMBLBHOVIR-UHFFFAOYSA-N 0.000 description 2
- JPYXZRBYDXOASZ-UHFFFAOYSA-N 2-fluoro-5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]-4-methylpyridazin-3-yl]benzonitrile Chemical compound N=1N=C(C=2C=C(C(F)=CC=2)C#N)C(C)=CC=1NCC(C)(C)C1=CC=C(F)C=C1 JPYXZRBYDXOASZ-UHFFFAOYSA-N 0.000 description 2
- FOMUDWIEYXJSPT-UHFFFAOYSA-N 2-fluoro-5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]benzonitrile Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=C(F)C(C#N)=C1 FOMUDWIEYXJSPT-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- VQNDBXJTIJKJPV-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridine Chemical compound C1=CC=NC2=NNN=C21 VQNDBXJTIJKJPV-UHFFFAOYSA-N 0.000 description 2
- NXVUUPORAZUSGG-UHFFFAOYSA-N 3,6-dichloropyridazine-4-carboxamide Chemical compound NC(=O)C1=CC(Cl)=NN=C1Cl NXVUUPORAZUSGG-UHFFFAOYSA-N 0.000 description 2
- KIMATSNDDCQJLF-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2-oxazole-5-carboxamide Chemical compound O1C(C(=O)N)=CC(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)=N1 KIMATSNDDCQJLF-UHFFFAOYSA-N 0.000 description 2
- YMJRXBIJAQLDLD-UHFFFAOYSA-N 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1h-pyrazole-5-carboxamide Chemical compound N1N=C(C(=O)N)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 YMJRXBIJAQLDLD-UHFFFAOYSA-N 0.000 description 2
- LHNBQZKMOHIPPZ-UHFFFAOYSA-N 3-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]-4-methylpyridazin-3-yl]benzamide Chemical compound N=1N=C(C=2C=C(C=CC=2)C(N)=O)C(C)=CC=1NCC(C)(C)C1=CC=C(F)C=C1 LHNBQZKMOHIPPZ-UHFFFAOYSA-N 0.000 description 2
- KAGZGWUUTROZIC-UHFFFAOYSA-N 3-chloro-6-pyrazol-1-ylpyridazine Chemical compound N1=NC(Cl)=CC=C1N1N=CC=C1 KAGZGWUUTROZIC-UHFFFAOYSA-N 0.000 description 2
- UBOOKRVGOBKDMM-UHFFFAOYSA-N 3h-imidazo[4,5-c]pyridine Chemical compound C1=NC=C2NC=NC2=C1 UBOOKRVGOBKDMM-UHFFFAOYSA-N 0.000 description 2
- BCRHMAZIUFJNEM-UHFFFAOYSA-N 4,5-dihydropyrrolo[3,4-d][1,3]thiazol-6-one Chemical compound N1=CSC2=C1CNC2=O BCRHMAZIUFJNEM-UHFFFAOYSA-N 0.000 description 2
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 2
- AXVUBSVQYGRYQA-UHFFFAOYSA-N 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2-oxazole-3-carboxamide Chemical compound O1N=C(C(=O)N)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 AXVUBSVQYGRYQA-UHFFFAOYSA-N 0.000 description 2
- MYBUHRQEIBVQJH-UHFFFAOYSA-N 5-[6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazin-3-yl]-1h-indazol-3-amine Chemical compound C=1C=C(C=2C=C3C(N)=NNC3=CC=2)N=NC=1NCC(C)(C)C1=CC=C(F)C=C1 MYBUHRQEIBVQJH-UHFFFAOYSA-N 0.000 description 2
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical compound C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 description 2
- JLPICQSJXJKGCH-UHFFFAOYSA-N 6-(2-amino-1h-imidazol-5-yl)-n-[2-(4-fluorophenyl)-2-methylpropyl]pyridazin-3-amine Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CNC(N)=N1 JLPICQSJXJKGCH-UHFFFAOYSA-N 0.000 description 2
- DWFKPEKRWMCMCI-UHFFFAOYSA-N 6-(2-aminopyridin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyridazin-3-amine Chemical compound NC1=NC=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 DWFKPEKRWMCMCI-UHFFFAOYSA-N 0.000 description 2
- OOGMTYLMHBIGEJ-UHFFFAOYSA-N 6-chloro-3-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazine-4-carbonitrile Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC1=NN=C(Cl)C=C1C#N OOGMTYLMHBIGEJ-UHFFFAOYSA-N 0.000 description 2
- BUCJQXKYLZEFRS-UHFFFAOYSA-N 6-chloro-3-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazine-4-carboxamide Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC1=NN=C(Cl)C=C1C(N)=O BUCJQXKYLZEFRS-UHFFFAOYSA-N 0.000 description 2
- 102000018918 Activin Receptors Human genes 0.000 description 2
- 108010052946 Activin Receptors Proteins 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 208000006411 Hereditary Sensory and Motor Neuropathy Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 206010068836 Metabolic myopathy Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 108030001204 Myosin ATPases Proteins 0.000 description 2
- 102000005640 Myosin Type II Human genes 0.000 description 2
- 108010045128 Myosin Type II Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010054880 Vascular insufficiency Diseases 0.000 description 2
- 208000010399 Wasting Syndrome Diseases 0.000 description 2
- YAVOMXHKTLHWOE-UHFFFAOYSA-N [1-(3-fluoropyridin-2-yl)cyclobutyl]methanamine Chemical compound N=1C=CC=C(F)C=1C1(CN)CCC1 YAVOMXHKTLHWOE-UHFFFAOYSA-N 0.000 description 2
- HBFKEYQZLXAIRU-UHFFFAOYSA-N [1-(6-methoxypyridin-2-yl)cyclobutyl]methanamine Chemical compound COC1=CC=CC(C2(CN)CCC2)=N1 HBFKEYQZLXAIRU-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 2
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 2
- 201000011474 congenital myopathy Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 201000009338 distal myopathy Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 208000029444 double vision Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- BSNFJRUGPBVGED-UHFFFAOYSA-N ethyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridazin-3-yl]-1,3-thiazole-5-carboxylate Chemical compound S1C(C(=O)OCC)=CN=C1C1=CC=C(N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=N1 BSNFJRUGPBVGED-UHFFFAOYSA-N 0.000 description 2
- VAMBRNJQDKMVEU-UHFFFAOYSA-N ethyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridazin-3-yl]-4-oxo-1,3-thiazolidine-5-carboxylate Chemical compound N1=C(O)C(C(=O)OCC)SC1C1=CC=C(N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=N1 VAMBRNJQDKMVEU-UHFFFAOYSA-N 0.000 description 2
- CNPZMLJCUULLPY-UHFFFAOYSA-N ethyl 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridazin-3-yl]-1h-pyrazole-5-carboxylate Chemical compound N1N=C(C(=O)OCC)C=C1C1=CC=C(N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=N1 CNPZMLJCUULLPY-UHFFFAOYSA-N 0.000 description 2
- SQFPSKJRRPZRQZ-UHFFFAOYSA-N ethyl 5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 SQFPSKJRRPZRQZ-UHFFFAOYSA-N 0.000 description 2
- 230000008921 facial expression Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- PESBHXVSGQQANU-UHFFFAOYSA-N methyl 3-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridazin-3-yl]-1,2-oxazole-5-carboxylate Chemical compound O1C(C(=O)OC)=CC(C=2N=NC(=CC=2)N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)=N1 PESBHXVSGQQANU-UHFFFAOYSA-N 0.000 description 2
- ZJWSHBGRSKBDHO-UHFFFAOYSA-N methyl 6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazine-3-carboxylate Chemical compound N1=NC(C(=O)OC)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZJWSHBGRSKBDHO-UHFFFAOYSA-N 0.000 description 2
- UQSNEYPJYVPFRQ-UHFFFAOYSA-N methyl 6-[[2-(4-fluorophenyl)-2-methylpropyl]amino]pyridazine-3-carboxylate Chemical compound N1=NC(C(=O)OC)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 UQSNEYPJYVPFRQ-UHFFFAOYSA-N 0.000 description 2
- FPKXYXKLOWAIOX-UHFFFAOYSA-N methyl 6-chloropyridazine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=N1 FPKXYXKLOWAIOX-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 208000022084 motor paralysis Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000036473 myasthenia Effects 0.000 description 2
- TVXXPXCQKCWJRS-UHFFFAOYSA-N n-[2-(4-fluorophenyl)-2-methylpropyl]-6-pyrazol-1-ylpyridazin-3-amine Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1N1C=CC=N1 TVXXPXCQKCWJRS-UHFFFAOYSA-N 0.000 description 2
- JPMTVDSEHAHSCD-UHFFFAOYSA-N n-[2-(4-fluorophenyl)-2-methylpropyl]-6-pyridin-2-ylpyridazin-3-amine Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C1=CC=CC=N1 JPMTVDSEHAHSCD-UHFFFAOYSA-N 0.000 description 2
- IZYMWNXNTKVAKQ-UHFFFAOYSA-N n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-6-(2-methoxypyridin-3-yl)pyridazin-3-amine Chemical compound COC1=NC=CC=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 IZYMWNXNTKVAKQ-UHFFFAOYSA-N 0.000 description 2
- ZMWLLDFGUQRHHS-UHFFFAOYSA-N n-[[2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]-1,3-thiazol-5-yl]methyl]-2-hydroxyacetamide Chemical compound S1C(CNC(=O)CO)=CN=C1C(N=N1)=CC=C1NCC1(C=2C(=CC=CN=2)F)CCC1 ZMWLLDFGUQRHHS-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 229960002290 pyridostigmine Drugs 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 230000012232 skeletal muscle contraction Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VAMMWAGXJMPTKG-UHFFFAOYSA-N tert-butyl n-(6-acetylpyridazin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound N1=NC(C(=O)C)=CC=C1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 VAMMWAGXJMPTKG-UHFFFAOYSA-N 0.000 description 2
- RUUVGUVMFGAYHS-UHFFFAOYSA-N tert-butyl n-(6-cyanopyridazin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C#N)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 RUUVGUVMFGAYHS-UHFFFAOYSA-N 0.000 description 2
- VRLKZAAIWPMNQB-UHFFFAOYSA-N tert-butyl n-(6-ethenylpyridazin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=C)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 VRLKZAAIWPMNQB-UHFFFAOYSA-N 0.000 description 2
- RLNZDUIHKNPERV-UHFFFAOYSA-N tert-butyl n-[6-(3-cyanopyrrol-1-yl)pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(N2C=C(C=C2)C#N)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 RLNZDUIHKNPERV-UHFFFAOYSA-N 0.000 description 2
- VXHVZMVQBGSNOB-UHFFFAOYSA-N tert-butyl n-[6-(5-carbamoyl-1,3-thiazol-2-yl)pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(=CN=2)C(N)=O)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 VXHVZMVQBGSNOB-UHFFFAOYSA-N 0.000 description 2
- AUGSBXOSXSJURL-UHFFFAOYSA-N tert-butyl n-[6-(5-cyanopyridin-2-yl)pyridazin-3-yl]-n-[2-(4-fluorophenyl)-2-methylpropyl]carbamate Chemical compound C=1C=C(C=2N=CC(=CC=2)C#N)N=NC=1N(C(=O)OC(C)(C)C)CC(C)(C)C1=CC=C(F)C=C1 AUGSBXOSXSJURL-UHFFFAOYSA-N 0.000 description 2
- WACDUINZUBOYHJ-UHFFFAOYSA-N tert-butyl n-[6-(5-cyanothiophen-2-yl)pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(=CC=2)C#N)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 WACDUINZUBOYHJ-UHFFFAOYSA-N 0.000 description 2
- IGSKLCZTLUIIIQ-UHFFFAOYSA-N tert-butyl n-[6-[5-(2,5-dimethylpyrrol-1-yl)pyridin-2-yl]pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound CC1=CC=C(C)N1C1=CC=C(C=2N=NC(=CC=2)N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=C1 IGSKLCZTLUIIIQ-UHFFFAOYSA-N 0.000 description 2
- VAJCSCQEAVSBSJ-UHFFFAOYSA-N tert-butyl n-[6-[5-(aminomethyl)-1,3-thiazol-2-yl]pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(CN)=CN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 VAJCSCQEAVSBSJ-UHFFFAOYSA-N 0.000 description 2
- MHPIHTYHYRCASJ-UHFFFAOYSA-N tert-butyl n-[6-[5-[[tert-butyl(dimethyl)silyl]oxymethyl]-1,3-thiazol-2-yl]pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(CO[Si](C)(C)C(C)(C)C)=CN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 MHPIHTYHYRCASJ-UHFFFAOYSA-N 0.000 description 2
- BJOBBRDWRUEASO-UHFFFAOYSA-N tert-butyl n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-n-(6-formylpyridazin-3-yl)carbamate Chemical compound C=1C=C(C=O)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 BJOBBRDWRUEASO-UHFFFAOYSA-N 0.000 description 2
- VTJLGAUGJQOQTD-UHFFFAOYSA-N tert-butyl n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-n-[6-[5-(hydroxymethyl)-1,3-thiazol-2-yl]pyridazin-3-yl]carbamate Chemical compound C=1C=C(C=2SC(CO)=CN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 VTJLGAUGJQOQTD-UHFFFAOYSA-N 0.000 description 2
- KUVVANJLEHVHEH-UHFFFAOYSA-N tert-butyl-dimethyl-(1,3-thiazol-5-ylmethoxy)silane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CN=CS1 KUVVANJLEHVHEH-UHFFFAOYSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 102000004217 thyroid hormone receptors Human genes 0.000 description 2
- 108090000721 thyroid hormone receptors Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 208000023577 vascular insufficiency disease Diseases 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NVOLYUXUHWBCRJ-UHFFFAOYSA-N (2-methoxypyridin-3-yl)boronic acid Chemical compound COC1=NC=CC=C1B(O)O NVOLYUXUHWBCRJ-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
- YJEJISGIPNUDBB-UHFFFAOYSA-N (3-bromo-6-fluoro-2-methoxyphenyl)boronic acid Chemical compound COC1=C(Br)C=CC(F)=C1B(O)O YJEJISGIPNUDBB-UHFFFAOYSA-N 0.000 description 1
- OLKIYJDSLMKNLC-UHFFFAOYSA-N (3-cyano-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(C#N)=C1 OLKIYJDSLMKNLC-UHFFFAOYSA-N 0.000 description 1
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-VIFPVBQESA-N (4s)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-VIFPVBQESA-N 0.000 description 1
- ZEOMEPSYIIQIND-UHFFFAOYSA-N (5-cyanothiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C#N)S1 ZEOMEPSYIIQIND-UHFFFAOYSA-N 0.000 description 1
- KNKOUDKOHSNMEL-UHFFFAOYSA-N (7-oxo-5,6-dihydro-4h-1-benzothiophen-4-yl)urea Chemical compound NC(=O)NC1CCC(=O)C2=C1C=CS2 KNKOUDKOHSNMEL-UHFFFAOYSA-N 0.000 description 1
- 125000006721 (C5-C10) heteroaryl (C1-C6) alkyl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical compound C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- QLDQYRDCPNBPII-UHFFFAOYSA-N 1,2-benzoxazol-3-one Chemical compound C1=CC=C2C(O)=NOC2=C1 QLDQYRDCPNBPII-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical compound C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- HUCXRCCJHDFVCI-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-c]pyridin-2-one Chemical compound C1=NC=C2NC(=O)CC2=C1 HUCXRCCJHDFVCI-UHFFFAOYSA-N 0.000 description 1
- IHRRHTILSRVFPW-UHFFFAOYSA-N 1,3-dihydropyrrolo[3,2-b]pyridin-2-one Chemical compound C1=CC=C2NC(=O)CC2=N1 IHRRHTILSRVFPW-UHFFFAOYSA-N 0.000 description 1
- YAUVSURSWJMKFT-UHFFFAOYSA-N 1,3-dihydropyrrolo[3,2-c]pyridin-2-one Chemical compound N1=CC=C2NC(=O)CC2=C1 YAUVSURSWJMKFT-UHFFFAOYSA-N 0.000 description 1
- WKBQQWDVVHGWDB-UHFFFAOYSA-N 1,3-thiazol-5-ylmethanol Chemical compound OCC1=CN=CS1 WKBQQWDVVHGWDB-UHFFFAOYSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- VSOSXKMEQPYESP-UHFFFAOYSA-N 1,6-naphthyridine Chemical compound C1=CN=CC2=CC=CN=C21 VSOSXKMEQPYESP-UHFFFAOYSA-N 0.000 description 1
- MXBVNILGVJVVMH-UHFFFAOYSA-N 1,7-naphthyridine Chemical compound C1=NC=CC2=CC=CN=C21 MXBVNILGVJVVMH-UHFFFAOYSA-N 0.000 description 1
- XVPDCACJJBQDIA-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)cyclobutane-1-carbonitrile Chemical compound FC1=CC=CN=C1C1(C#N)CCC1 XVPDCACJJBQDIA-UHFFFAOYSA-N 0.000 description 1
- NUBQKPWHXMGDLP-UHFFFAOYSA-N 1-[4-benzyl-2-hydroxy-5-[(2-hydroxy-2,3-dihydro-1h-inden-1-yl)amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid Chemical compound OS(O)(=O)=O.C1CN(CC(O)CC(CC=2C=CC=CC=2)C(=O)NC2C3=CC=CC=C3CC2O)C(C(=O)NC(C)(C)C)CN1CC1=CC=CN=C1 NUBQKPWHXMGDLP-UHFFFAOYSA-N 0.000 description 1
- MGKPCLNUSDGXGT-UHFFFAOYSA-N 1-benzofuran-3-one Chemical compound C1=CC=C2C(=O)COC2=C1 MGKPCLNUSDGXGT-UHFFFAOYSA-N 0.000 description 1
- ADHAJDDBRUOZHJ-UHFFFAOYSA-N 1-benzothiophen-3-one Chemical compound C1=CC=C2C(=O)CSC2=C1 ADHAJDDBRUOZHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- DPBKQJOOSMJCFX-UHFFFAOYSA-N 1h-2,1-benzothiazol-3-one Chemical compound C1=CC=C2C(=O)SNC2=C1 DPBKQJOOSMJCFX-UHFFFAOYSA-N 0.000 description 1
- FUAXXVSVFLEVSF-UHFFFAOYSA-N 1h-2,1-benzoxazol-3-one Chemical compound C1=CC=C2C(=O)ONC2=C1 FUAXXVSVFLEVSF-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- VHQVCXSOAGLPRG-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridazine Chemical compound N1=CC=C2C=NNC2=N1 VHQVCXSOAGLPRG-UHFFFAOYSA-N 0.000 description 1
- KNYHISBJRQVMAZ-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C=NNC2=C1 KNYHISBJRQVMAZ-UHFFFAOYSA-N 0.000 description 1
- LLKAAPMRHULVSQ-UHFFFAOYSA-N 1h-pyrazolo[3,4-d][1,3]thiazole Chemical compound N1N=CC2=C1N=CS2 LLKAAPMRHULVSQ-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- NMEPLWZDUIIAAC-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridazine Chemical compound C1=NN=C2C=NNC2=C1 NMEPLWZDUIIAAC-UHFFFAOYSA-N 0.000 description 1
- WCXFPLXZZSWROM-UHFFFAOYSA-N 1h-pyrazolo[4,3-c]pyridine Chemical compound C1=NC=C2C=NNC2=C1 WCXFPLXZZSWROM-UHFFFAOYSA-N 0.000 description 1
- PDRSZUAQTFBWPF-UHFFFAOYSA-N 1h-pyrazolo[4,3-d][1,3]thiazole Chemical compound C1=NNC2=C1N=CS2 PDRSZUAQTFBWPF-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- PCYWMDGJYQAMCR-UHFFFAOYSA-N 1h-pyrrole-3-carbonitrile Chemical compound N#CC=1C=CNC=1 PCYWMDGJYQAMCR-UHFFFAOYSA-N 0.000 description 1
- XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical compound N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 description 1
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- WBRSYBLNSTYNPP-UHFFFAOYSA-N 2,4,6-tris(ethenyl)-1,3,5,2,4,6-trioxatriborinane Chemical compound C=CB1OB(C=C)OB(C=C)O1 WBRSYBLNSTYNPP-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- MBTGBRYMJKYYOE-UHFFFAOYSA-N 2,6-difluoropyridine Chemical compound FC1=CC=CC(F)=N1 MBTGBRYMJKYYOE-UHFFFAOYSA-N 0.000 description 1
- SSNMISUJOQAFRR-UHFFFAOYSA-N 2,6-naphthyridine Chemical compound N1=CC=C2C=NC=CC2=C1 SSNMISUJOQAFRR-UHFFFAOYSA-N 0.000 description 1
- HCMMECMKVPHMDE-UHFFFAOYSA-N 2,7-naphthyridine Chemical compound C1=NC=C2C=NC=CC2=C1 HCMMECMKVPHMDE-UHFFFAOYSA-N 0.000 description 1
- BKOGAZSNJDQTTC-UHFFFAOYSA-N 2-(1,3-thiazol-5-yl)acetamide Chemical compound NC(=O)CC1=CN=CS1 BKOGAZSNJDQTTC-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- UOEIWAZNZTXYSC-UHFFFAOYSA-N 2-(4-fluorophenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)C1=CC=C(F)C=C1 UOEIWAZNZTXYSC-UHFFFAOYSA-N 0.000 description 1
- SIOJFYRPBYGHOO-UHFFFAOYSA-N 2-(4-fluorophenyl)acetyl chloride Chemical compound FC1=CC=C(CC(Cl)=O)C=C1 SIOJFYRPBYGHOO-UHFFFAOYSA-N 0.000 description 1
- JPDCPQSPPPULST-UHFFFAOYSA-N 2-(5-bromo-2-fluoro-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C1=C(Br)C(OC)=CC(F)=C1B1OC(C)(C)C(C)(C)O1 JPDCPQSPPPULST-UHFFFAOYSA-N 0.000 description 1
- DUGMCDWNXXFHDE-VZYDHVRKSA-N 2-amino-2-methyl-n-[(2r)-1-(1-methylsulfonylspiro[2h-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 DUGMCDWNXXFHDE-VZYDHVRKSA-N 0.000 description 1
- WNZQDUSMALZDQF-UHFFFAOYSA-N 2-benzofuran-1(3H)-one Chemical compound C1=CC=C2C(=O)OCC2=C1 WNZQDUSMALZDQF-UHFFFAOYSA-N 0.000 description 1
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- KDFDOINBXBEOLZ-UHFFFAOYSA-N 2-phenylpropan-2-amine Chemical compound CC(C)(N)C1=CC=CC=C1 KDFDOINBXBEOLZ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- ZSYMMINAALNVSH-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=NNN=C21 ZSYMMINAALNVSH-UHFFFAOYSA-N 0.000 description 1
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- ROYHWGZNGMXQEU-UHFFFAOYSA-N 3,6-dichloro-4-methylpyridazine Chemical compound CC1=CC(Cl)=NN=C1Cl ROYHWGZNGMXQEU-UHFFFAOYSA-N 0.000 description 1
- UGKIAJNNQAMSHX-UHFFFAOYSA-N 3,6-dichloropyridazine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC(Cl)=NN=C1Cl UGKIAJNNQAMSHX-UHFFFAOYSA-N 0.000 description 1
- CXGCFHFJFPWUCN-UHFFFAOYSA-N 3-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=CN=C1 CXGCFHFJFPWUCN-UHFFFAOYSA-N 0.000 description 1
- BPKIPHYWHVOWMS-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(C(N)=O)=C1 BPKIPHYWHVOWMS-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- ZRWMAMOBIQQJSA-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carbonitrile Chemical compound C=C1CC(C#N)C1 ZRWMAMOBIQQJSA-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical compound C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 description 1
- ARTAFUJPRUWRJK-UHFFFAOYSA-N 3h-1-benzothiophen-2-one Chemical compound C1=CC=C2SC(=O)CC2=C1 ARTAFUJPRUWRJK-UHFFFAOYSA-N 0.000 description 1
- NSSBUSDEHNCUIY-UHFFFAOYSA-N 3h-2-benzothiophen-1-one Chemical compound C1=CC=C2C(=O)SCC2=C1 NSSBUSDEHNCUIY-UHFFFAOYSA-N 0.000 description 1
- SLGVJLNVPYQNNK-UHFFFAOYSA-N 3h-cinnolin-4-one Chemical compound C1=CC=C2C(=O)CN=NC2=C1 SLGVJLNVPYQNNK-UHFFFAOYSA-N 0.000 description 1
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical compound C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 1
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 1
- ZHWMMBNNMMYAIB-UHFFFAOYSA-N 5,6,7,8-tetrahydrocinnoline Chemical compound N1=CC=C2CCCCC2=N1 ZHWMMBNNMMYAIB-UHFFFAOYSA-N 0.000 description 1
- KJICBBFBFGDSMB-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[2,3-c]pyridazine Chemical compound N1=CC=C2CCCNC2=N1 KJICBBFBFGDSMB-UHFFFAOYSA-N 0.000 description 1
- GSMSTMLNTWYMJY-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[3,2-c]pyridazine Chemical compound C1=NN=C2CCCNC2=C1 GSMSTMLNTWYMJY-UHFFFAOYSA-N 0.000 description 1
- ZOTNHDWPHYWGFM-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[3,4-c]pyridazine Chemical compound C1=NN=C2CNCCC2=C1 ZOTNHDWPHYWGFM-UHFFFAOYSA-N 0.000 description 1
- WPKKYTFIJLZVPP-UHFFFAOYSA-N 5,6,7,8-tetrahydropyrido[4,3-c]pyridazine Chemical compound N1=CC=C2CNCCC2=N1 WPKKYTFIJLZVPP-UHFFFAOYSA-N 0.000 description 1
- RSULGCZVSSSFLN-UHFFFAOYSA-N 5-[5-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyridazin-3-yl]thiophen-2-yl]-1,2-dihydro-1,2,4-triazol-3-one Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(=CC=2)C=2SC(=CC=2)C=2NC(=O)NN=2)CCC1 RSULGCZVSSSFLN-UHFFFAOYSA-N 0.000 description 1
- XZIIBRSVJRQEHT-UHFFFAOYSA-N 5-propylpyridazin-3-amine Chemical group CCCC1=CC(N)=NN=C1 XZIIBRSVJRQEHT-UHFFFAOYSA-N 0.000 description 1
- LBZYKNAEJRHENJ-UHFFFAOYSA-N 5h-pyrrolo[3,2-c]pyridazine Chemical compound N1=CC=C2NC=CC2=N1 LBZYKNAEJRHENJ-UHFFFAOYSA-N 0.000 description 1
- PMPLZTLQJBGDFU-UHFFFAOYSA-N 6,7-dihydro-5h-cyclopenta[c]pyridazine Chemical compound C1=NN=C2CCCC2=C1 PMPLZTLQJBGDFU-UHFFFAOYSA-N 0.000 description 1
- FRTPMZHAGYILGC-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,2-c]pyridazine Chemical compound N1=CC=C2NCCC2=N1 FRTPMZHAGYILGC-UHFFFAOYSA-N 0.000 description 1
- ZVKGDFURDWGFPQ-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[3,4-c]pyridazine Chemical compound N1=CC=C2CNCC2=N1 ZVKGDFURDWGFPQ-UHFFFAOYSA-N 0.000 description 1
- OQGDVQFOSVEYPX-UHFFFAOYSA-N 6-(3-amino-1h-pyrazol-5-yl)-n-[2-(4-fluorophenyl)-2-methylpropyl]pyridazin-3-amine Chemical compound C=1C=C(F)C=CC=1C(C)(C)CNC(N=N1)=CC=C1C=1C=C(N)NN=1 OQGDVQFOSVEYPX-UHFFFAOYSA-N 0.000 description 1
- SAGSWRTZCMVTRA-UHFFFAOYSA-N 6-(4-chlorophenyl)-5-methyl-n-(2-methyl-2-piperidin-1-ylpropyl)pyridazin-3-amine Chemical compound N=1N=C(C=2C=CC(Cl)=CC=2)C(C)=CC=1NCC(C)(C)N1CCCCC1 SAGSWRTZCMVTRA-UHFFFAOYSA-N 0.000 description 1
- FLORCRXFQOHXRD-UHFFFAOYSA-N 6-[5-(2,5-dimethylpyrrol-1-yl)pyridin-2-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyridazin-3-amine Chemical compound CC1=CC=C(C)N1C1=CC=C(C=2N=NC(NCC3(CCC3)C=3C(=CC=CN=3)F)=CC=2)N=C1 FLORCRXFQOHXRD-UHFFFAOYSA-N 0.000 description 1
- XTHKRYHULUJQHN-UHFFFAOYSA-N 6-bromopyridin-3-amine Chemical compound NC1=CC=C(Br)N=C1 XTHKRYHULUJQHN-UHFFFAOYSA-N 0.000 description 1
- XHYGUDGTUJPSNX-UHFFFAOYSA-N 6-bromopyridine-3-carbonitrile Chemical compound BrC1=CC=C(C#N)C=N1 XHYGUDGTUJPSNX-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- VHNSQNYXMUQBEO-UHFFFAOYSA-N 6-chloro-n-(2-phenylpropan-2-yl)pyridazin-3-amine Chemical compound C=1C=CC=CC=1C(C)(C)NC1=CC=C(Cl)N=N1 VHNSQNYXMUQBEO-UHFFFAOYSA-N 0.000 description 1
- HASMXYAMEYCKLN-UHFFFAOYSA-N 6-chloro-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyridazin-3-amine Chemical compound FC1=CC=CN=C1C1(CNC=2N=NC(Cl)=CC=2)CCC1 HASMXYAMEYCKLN-UHFFFAOYSA-N 0.000 description 1
- YMUOLGNUZURDEW-UHFFFAOYSA-N 6-chloropyridazine-3-carbonitrile Chemical compound ClC1=CC=C(C#N)N=N1 YMUOLGNUZURDEW-UHFFFAOYSA-N 0.000 description 1
- ANLKTNDPNJZWLM-UHFFFAOYSA-N 6-ethyl-n-[2-(4-fluorophenyl)-2-methylpropyl]pyridazin-3-amine Chemical compound N1=NC(CC)=CC=C1NCC(C)(C)C1=CC=C(F)C=C1 ANLKTNDPNJZWLM-UHFFFAOYSA-N 0.000 description 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- BXOVRVJPVVRHKP-UHFFFAOYSA-N 7h-pyrrolo[2,3-c]pyridazine Chemical compound C1=NN=C2NC=CC2=C1 BXOVRVJPVVRHKP-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010079335 AMG 745 Proteins 0.000 description 1
- 206010000159 Abnormal loss of weight Diseases 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 239000005964 Acibenzolar-S-methyl Substances 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- SXGAMGNJGVRJAV-UHFFFAOYSA-N C1=CC=CC2=NC(O)=CN=C21.C1=CC=C2N=C(O)C(O)=NC2=C1 Chemical compound C1=CC=CC2=NC(O)=CN=C21.C1=CC=C2N=C(O)C(O)=NC2=C1 SXGAMGNJGVRJAV-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 208000015374 Central core disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 201000006867 Charcot-Marie-Tooth disease type 4 Diseases 0.000 description 1
- 101000936911 Chionoecetes opilio Sarcoplasmic/endoplasmic reticulum calcium ATPase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010015829 Extraocular muscle paresis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010017065 Foster-Kennedy Syndrome Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010020844 Hyperthermia malignant Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000018717 Malignant hyperthermia of anesthesia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108091005975 Myofilaments Proteins 0.000 description 1
- 206010028643 Myopathy endocrine Diseases 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- NUQGVKLGZCUSJX-UHFFFAOYSA-N N-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]pyridazin-3-amine Chemical compound FC=1C(=NC=CC=1)C1(CCC1)CNC1=CC=CN=N1 NUQGVKLGZCUSJX-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- SNOMXEBIFYIRSW-UHFFFAOYSA-N O1C=NC=2C=NC=CC21.O2C=CC=1C=NC=CC12 Chemical compound O1C=NC=2C=NC=CC21.O2C=CC=1C=NC=CC12 SNOMXEBIFYIRSW-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000014993 Pituitary disease Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000030934 Restrictive pulmonary disease Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 102000019027 Ryanodine Receptor Calcium Release Channel Human genes 0.000 description 1
- IRHXGOXEBNJUSN-YOXDLBRISA-N Saquinavir mesylate Chemical compound CS(O)(=O)=O.C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 IRHXGOXEBNJUSN-YOXDLBRISA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100021947 Survival motor neuron protein Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- XUTIDUCSRSNKKP-UHFFFAOYSA-N [1,2]oxazolo[4,5-b]pyridine Chemical compound C1=CN=C2C=NOC2=C1 XUTIDUCSRSNKKP-UHFFFAOYSA-N 0.000 description 1
- AMIWTKBQVQQBBS-UHFFFAOYSA-N [1,2]oxazolo[4,5-c]pyridine Chemical compound C1=NC=C2C=NOC2=C1 AMIWTKBQVQQBBS-UHFFFAOYSA-N 0.000 description 1
- DITTYRBIXKVOTK-UHFFFAOYSA-N [1,2]oxazolo[5,4-b]pyridine Chemical compound C1=CC=C2C=NOC2=N1 DITTYRBIXKVOTK-UHFFFAOYSA-N 0.000 description 1
- WXTRHHSZKLAHHV-UHFFFAOYSA-N [1,2]oxazolo[5,4-c]pyridine Chemical compound N1=CC=C2C=NOC2=C1 WXTRHHSZKLAHHV-UHFFFAOYSA-N 0.000 description 1
- ZTAPFURKEMZRSQ-UHFFFAOYSA-N [1,2]thiazolo[4,5-b]pyridine Chemical compound C1=CN=C2C=NSC2=C1 ZTAPFURKEMZRSQ-UHFFFAOYSA-N 0.000 description 1
- HUMJZSMCTXGAMD-UHFFFAOYSA-N [1,2]thiazolo[4,5-c]pyridine Chemical compound C1=NC=C2C=NSC2=C1 HUMJZSMCTXGAMD-UHFFFAOYSA-N 0.000 description 1
- VTIVYUBSVCXRPI-UHFFFAOYSA-N [1,2]thiazolo[5,4-b]pyridine Chemical compound C1=CC=C2C=NSC2=N1 VTIVYUBSVCXRPI-UHFFFAOYSA-N 0.000 description 1
- BFPLMTPHDFFMTG-UHFFFAOYSA-N [1,3]oxazolo[5,4-b]pyridine Chemical compound C1=CN=C2OC=NC2=C1 BFPLMTPHDFFMTG-UHFFFAOYSA-N 0.000 description 1
- XRVDKIQEFCJTBZ-UHFFFAOYSA-N [1,3]oxazolo[5,4-c]pyridine Chemical compound C1=NC=C2OC=NC2=C1 XRVDKIQEFCJTBZ-UHFFFAOYSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- OZDQBAQCPJNKGG-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]pyridazine Chemical compound N1=CC=C2SC=NC2=N1 OZDQBAQCPJNKGG-UHFFFAOYSA-N 0.000 description 1
- FIPLAFRCDDWERW-UHFFFAOYSA-N [1,3]thiazolo[4,5-c]pyridine Chemical compound N1=CC=C2SC=NC2=C1 FIPLAFRCDDWERW-UHFFFAOYSA-N 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- WJRZTBNFQGTLRC-UHFFFAOYSA-N [1,3]thiazolo[5,4-c]pyridazine Chemical compound C1=NN=C2SC=NC2=C1 WJRZTBNFQGTLRC-UHFFFAOYSA-N 0.000 description 1
- YTFIUHZHMLAERQ-UHFFFAOYSA-N [1-(4-fluorophenyl)cyclobutyl]methanamine Chemical compound C=1C=C(F)C=CC=1C1(CN)CCC1 YTFIUHZHMLAERQ-UHFFFAOYSA-N 0.000 description 1
- XOKZBACDBZUYDB-UHFFFAOYSA-N [[2-(4-fluorophenyl)-2-methylpropyl]amino] pyridazine-3-carboxylate Chemical compound N1=NC(=CC=C1)C(=O)ONCC(C)(C)C1=CC=C(C=C1)F XOKZBACDBZUYDB-UHFFFAOYSA-N 0.000 description 1
- ZBIKORITPGTTGI-UHFFFAOYSA-N [acetyloxy(phenyl)-$l^{3}-iodanyl] acetate Chemical compound CC(=O)OI(OC(C)=O)C1=CC=CC=C1 ZBIKORITPGTTGI-UHFFFAOYSA-N 0.000 description 1
- QKNDAUTYSODFJV-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;sodium Chemical compound [Na].C[Si](C)(C)N[Si](C)(C)C QKNDAUTYSODFJV-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- FPQFYIAXQDXNOR-QDKLYSGJSA-N alpha-Zearalenol Chemical compound O=C1O[C@@H](C)CCC[C@H](O)CCC\C=C\C2=CC(O)=CC(O)=C21 FPQFYIAXQDXNOR-QDKLYSGJSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940052651 anticholinergic tertiary amines Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- QMMFTRJQCCVPCE-UHFFFAOYSA-N benzyl n-(2-aminoethyl)carbamate Chemical compound NCCNC(=O)OCC1=CC=CC=C1 QMMFTRJQCCVPCE-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- VIQRCOQXIHFJND-UHFFFAOYSA-N bicyclo[2.2.2]oct-2-ene Chemical compound C1CC2CCC1C=C2 VIQRCOQXIHFJND-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000005510 but-1-en-2-yl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000022900 cardiac muscle contraction Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- FNJVDWXUKLTFFL-UHFFFAOYSA-N diethyl 2-bromopropanedioate Chemical compound CCOC(=O)C(Br)C(=O)OCC FNJVDWXUKLTFFL-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004890 diethylpropion Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- UXOLDCOJRAMLTQ-ZZXKWVIFSA-N ethyl (2e)-2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(\Cl)=N/O UXOLDCOJRAMLTQ-ZZXKWVIFSA-N 0.000 description 1
- CIPMPQGRFNDLAP-UHFFFAOYSA-N ethyl 1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=CS1 CIPMPQGRFNDLAP-UHFFFAOYSA-N 0.000 description 1
- AVQMANQRZGHPBI-UHFFFAOYSA-N ethyl 2-[6-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]pyridazin-3-yl]-4-methoxy-2,5-dihydro-1,3-thiazole-5-carboxylate Chemical compound N1=C(OC)C(C(=O)OCC)SC1C1=CC=C(N(CC2(CCC2)C=2C(=CC=CN=2)F)C(=O)OC(C)(C)C)N=N1 AVQMANQRZGHPBI-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- ZYXBIOIYWUIXSM-UHFFFAOYSA-N furo[2,3-c]pyridine Chemical compound C1=NC=C2OC=CC2=C1 ZYXBIOIYWUIXSM-UHFFFAOYSA-N 0.000 description 1
- YRTCKZIKGWZNCU-UHFFFAOYSA-N furo[3,2-b]pyridine Chemical compound C1=CC=C2OC=CC2=N1 YRTCKZIKGWZNCU-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 201000003636 hereditary ataxia Diseases 0.000 description 1
- 208000021995 hereditary motor and sensory neuropathy Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- UFBBWLWUIISIPW-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical compound C1=CSC2=NC=CN21 UFBBWLWUIISIPW-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 125000003114 inden-1-yl group Chemical group [H]C1=C([H])C([H])(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960004243 indinavir sulfate Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- LIRDJALZRPAZOR-UHFFFAOYSA-N indolin-3-one Chemical compound C1=CC=C2C(=O)CNC2=C1 LIRDJALZRPAZOR-UHFFFAOYSA-N 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229940033984 lamivudine / zidovudine Drugs 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 201000007004 malignant hyperthermia Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000005545 motor peripheral neuropathy Diseases 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000016334 muscle symptom Diseases 0.000 description 1
- 230000005996 muscular dysfunction Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000029264 myotonic syndrome Diseases 0.000 description 1
- TUXBZDMJKGVKGT-UHFFFAOYSA-N n-(2-methyl-2-piperidin-1-ylpropyl)-6-phenyl-5-propylpyridazin-3-amine Chemical compound N=1N=C(C=2C=CC=CC=2)C(CCC)=CC=1NCC(C)(C)N1CCCCC1 TUXBZDMJKGVKGT-UHFFFAOYSA-N 0.000 description 1
- NGGXACLSAZXJGM-UHFFFAOYSA-N n-(diaminomethylidene)acetamide Chemical compound CC(=O)N=C(N)N NGGXACLSAZXJGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 229960000417 norgestimate Drugs 0.000 description 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- OGIKSURTYJLRMP-UHFFFAOYSA-N oxadiazolo[4,5-b]pyridine Chemical compound C1=CN=C2N=NOC2=C1 OGIKSURTYJLRMP-UHFFFAOYSA-N 0.000 description 1
- LBWZSUHDRDWJEC-UHFFFAOYSA-N oxadiazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=C1N=NO2 LBWZSUHDRDWJEC-UHFFFAOYSA-N 0.000 description 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical compound C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 description 1
- SVMOLIXMHXABPH-UHFFFAOYSA-N oxadiazolo[5,4-c]pyridine Chemical compound C1=NC=CC2=C1ON=N2 SVMOLIXMHXABPH-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000030613 peripheral artery disease Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 230000006584 pituitary dysfunction Effects 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229960000208 pralmorelin Drugs 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 description 1
- YLHJACXHRQQNQR-UHFFFAOYSA-N pyridine;2,4,6-tris(ethenyl)-1,3,5,2,4,6-trioxatriborinane Chemical compound C1=CC=NC=C1.C=CB1OB(C=C)OB(C=C)O1 YLHJACXHRQQNQR-UHFFFAOYSA-N 0.000 description 1
- BEJXOECDIXUTLN-UHFFFAOYSA-N pyrido[2,3-c]pyridazine Chemical compound N1=NC=CC2=CC=CN=C21 BEJXOECDIXUTLN-UHFFFAOYSA-N 0.000 description 1
- OHZYAOYVLLHTGW-UHFFFAOYSA-N pyrido[3,2-c]pyridazine Chemical compound C1=CN=NC2=CC=CN=C21 OHZYAOYVLLHTGW-UHFFFAOYSA-N 0.000 description 1
- DVXYZLCJSYRIPC-UHFFFAOYSA-N pyrido[3,4-c]pyridazine Chemical compound C1=NN=C2C=NC=CC2=C1 DVXYZLCJSYRIPC-UHFFFAOYSA-N 0.000 description 1
- RGWAZXHUULNXGT-UHFFFAOYSA-N pyrido[4,3-c]pyridazine Chemical compound N1=CC=C2C=NC=CC2=N1 RGWAZXHUULNXGT-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 108091052345 ryanodine receptor (TC 1.A.3.1) family Proteins 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- 229960003542 saquinavir mesylate Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003875 slow muscle fiber Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229950007447 sulbenox Drugs 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- YKNFHCXSUHMVST-UHFFFAOYSA-N tert-butyl n-(6-bromopyridazin-3-yl)-n-[2-(4-fluorophenyl)-2-methylpropyl]carbamate Chemical compound C=1C=C(Br)N=NC=1N(C(=O)OC(C)(C)C)CC(C)(C)C1=CC=C(F)C=C1 YKNFHCXSUHMVST-UHFFFAOYSA-N 0.000 description 1
- YPBGFOBXVAHEHB-UHFFFAOYSA-N tert-butyl n-(6-fluoropyridazin-3-yl)-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(F)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 YPBGFOBXVAHEHB-UHFFFAOYSA-N 0.000 description 1
- DYNPDJVUFOHNAP-UHFFFAOYSA-N tert-butyl n-[6-[5-(azidomethyl)-1,3-thiazol-2-yl]pyridazin-3-yl]-n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]carbamate Chemical compound C=1C=C(C=2SC(CN=[N+]=[N-])=CN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 DYNPDJVUFOHNAP-UHFFFAOYSA-N 0.000 description 1
- CWYSHQARQVTESQ-UHFFFAOYSA-N tert-butyl n-[[1-(3-fluoropyridin-2-yl)cyclobutyl]methyl]-n-[6-[5-(5-oxo-1,2-dihydro-1,2,4-triazol-3-yl)thiophen-2-yl]pyridazin-3-yl]carbamate Chemical compound C=1C=C(C=2SC(=CC=2)C=2NC(=O)NN=2)N=NC=1N(C(=O)OC(C)(C)C)CC1(C=2C(=CC=CN=2)F)CCC1 CWYSHQARQVTESQ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- KRRBFUJMQBDDPR-UHFFFAOYSA-N tetrabutylazanium;cyanide Chemical compound N#[C-].CCCC[N+](CCCC)(CCCC)CCCC KRRBFUJMQBDDPR-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- GNXPUXGOQIHJLJ-UHFFFAOYSA-N thiadiazolo[4,5-b]pyridine Chemical compound C1=CN=C2N=NSC2=C1 GNXPUXGOQIHJLJ-UHFFFAOYSA-N 0.000 description 1
- HKMXLNRHGNWKJG-UHFFFAOYSA-N thiadiazolo[4,5-c]pyridine Chemical compound C1=NC=CC2=C1N=NS2 HKMXLNRHGNWKJG-UHFFFAOYSA-N 0.000 description 1
- QKTRRACPJVYJNU-UHFFFAOYSA-N thiadiazolo[5,4-b]pyridine Chemical compound C1=CN=C2SN=NC2=C1 QKTRRACPJVYJNU-UHFFFAOYSA-N 0.000 description 1
- DNWLQCBSEZHTMF-UHFFFAOYSA-N thiadiazolo[5,4-c]pyridine Chemical compound C1=NC=CC2=C1SN=N2 DNWLQCBSEZHTMF-UHFFFAOYSA-N 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical compound C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 description 1
- UYGIYVMPGNRKTG-UHFFFAOYSA-N thieno[2,3-c]pyridazine Chemical compound C1=NN=C2SC=CC2=C1 UYGIYVMPGNRKTG-UHFFFAOYSA-N 0.000 description 1
- GDQBPBMIAFIRIU-UHFFFAOYSA-N thieno[2,3-c]pyridine Chemical compound C1=NC=C2SC=CC2=C1 GDQBPBMIAFIRIU-UHFFFAOYSA-N 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- IZAJCEGIQMYVFM-UHFFFAOYSA-N thieno[3,2-c]pyridazine Chemical compound N1=CC=C2SC=CC2=N1 IZAJCEGIQMYVFM-UHFFFAOYSA-N 0.000 description 1
- MKYRMMMSZSVIGD-UHFFFAOYSA-N thieno[3,2-c]pyridine Chemical compound N1=CC=C2SC=CC2=C1 MKYRMMMSZSVIGD-UHFFFAOYSA-N 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- BPLUKJNHPBNVQL-UHFFFAOYSA-N triphenylarsine Chemical compound C1=CC=CC=C1[As](C=1C=CC=CC=1)C1=CC=CC=C1 BPLUKJNHPBNVQL-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- UPCXAARSWVHVLY-UHFFFAOYSA-N tris(2-hydroxyethyl)azanium;acetate Chemical compound CC(O)=O.OCCN(CCO)CCO UPCXAARSWVHVLY-UHFFFAOYSA-N 0.000 description 1
- 108010013477 troponin-tropomyosin complex Proteins 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960002300 zeranol Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Description
R1は、水素、ハロゲン、CN、C1〜6アルキル、C1〜6ハロアルキル、C(O)ORa、C(O)NRbRc、ORa、NRbRc、C6〜10アリール及び5〜10員ヘテロアリールから選択され、
R2は、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、5〜10員ヘテロアリール及びNRbRcから選択され、前記C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール及び5〜10員ヘテロアリール基のそれぞれが、ハロゲン、CN、オキソ、(CH2)nORa、(CH2)nOC(O)Ra、(CH2)nOC(O)ORa、(CH2)nOC(O)NRbRc、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(O)C(O)NRbRc、(CH2)nNRdC(S)Ra、(CH2)nNRdC(S)ORa、(CH2)nNRdC(S)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)Ra、(CH2)nC(S)ORa、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSRa、(CH2)nS(O)Ra、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、(CH2)nC3〜8シクロアルキル、(CH2)n3〜8員ヘテロシクロアルキル、(CH2)nC6〜10アリール及び(CH2)n5〜10員ヘテロアリールから選択される1、2、3、4又は5個の置換基で場合によって置換されており、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、(CH2)nC3〜8シクロアルキル、(CH2)n3〜8員ヘテロシクロアルキル、(CH2)nC6〜10アリール及び(CH2)n5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRf置換基で場合によって置換されており、
R3は、水素、ハロゲン、CN、C1〜6アルキル、C1〜6ハロアルキル、C(O)ORa、C(O)NRbRc、ORa、NRbRc、C6〜10アリール及び5〜10員ヘテロアリールから選択され、
R4は、水素、C1〜6アルキル、C1〜6ハロアルキル、C(O)Ra、C(O)ORa、C(O)NRbRc及びSO2Raから選択され、
R5及びR6は、それぞれ独立して、水素、ハロゲン、C1〜6アルキル及びC1〜6ハロアルキルから選択され、
又は代替として、R5及びR6は、これらが結合している炭素原子と一緒になって、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル又は3〜8員ヘテロシクロアルケニルを形成しており、それぞれが、ハロゲン、CN、オキソ、ORa、OC(O)Ra、OC(O)ORa、NRbRc、C(O)Ra、C(O)ORa、C(O)NRbRc、S(O)Ra、SO2Ra、SO2NRbRc、C1〜6アルキル及びC1〜6ハロアルキルから選択される1、2、3、4又は5個の置換基で場合によって置換されており、
R7は、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール及び5〜10員ヘテロアリールから選択され、それぞれが、ハロゲン、CN、オキソ、ORa、OC(O)Ra、OC(O)ORa、OC(O)NRbRc、NRbRc、NRdC(O)Ra、NRdC(O)ORa、NRdC(O)NRbRc、NRdC(O)C(O)NRbRc、NRdC(S)Ra、NRdC(S)ORa、NRdC(S)NRbRc、NRdC(NRe)NRbRc、NRdS(O)Ra、NRdSO2Ra、NRdSO2NRbRc、C(O)Ra、C(O)ORa、C(O)NRbRc、C(S)Ra、C(S)ORa、C(S)NRbRc、C(NRe)NRbRc、SRa、S(O)Ra、SO2Ra、SO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル、及び5〜10員ヘテロアリールから選択される1、2、3、4又は5個の置換基で場合によって置換されており、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRf置換基で場合によって置換されており、
R8及びR9は、出現ごとに、それぞれ独立して、水素、ハロゲン及びC1〜6アルキルから選択され、
Xは、結合、-(CH2)p-、-(CH2)pC(O)(CH2)q-、-(CH2)pO(CH2)q-、-(CH2)pS(CH2)q-、-(CH2)pNRd(CH2)q-、-(CH2)pC(O)O(CH2)q-、-(CH2)pOC(O)(CH2)q-、-(CH2)pNRdC(O)(CH2)q-、-(CH2)pC(O)NRd(CH2)q-、-(CH2)pNRdC(O)NRd(CH2)q-、-(CH2)pNRdSO2(CH2)q-、及び-(CH2)pSO2NRd(CH2)q-から選択され、
又は代替として、X、R2及びR3は、これらが結合している炭素原子と一緒になって、酸素、窒素及び硫黄から選択される1個又は複数のヘテロ原子を場合によって含有し、1個又は複数の二重結合を場合によって含有し、1、2、3、4又は5個のRf置換基で場合によって置換されている、5〜6員環を形成しており、
Raは、出現ごとに、独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリールから選択され、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRf置換基で場合によって置換されており、
Rb及びRcは、出現ごとに、それぞれ独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル、5〜10員ヘテロアリール、C(O)Rg、C(O)ORg、C(O)NRiRj及びSO2Rgから選択され、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRf置換基で場合によって置換されており、
Rdは、出現ごとに、独立して、水素及びC1〜6アルキルから選択され、
Reは、出現ごとに、独立して、水素、CN、OH、C1〜6アルコキシ、C1〜6アルキル及びC1〜6ハロアルキルから選択され、
Rfは、出現ごとに、独立して、ハロゲン、CN、ORh、OC(O)Rh、OC(O)ORh、OC(O)NRiRj、NRiRj、NRdC(O)Rh、NRdC(O)ORh、NRdC(O)NRiRj、NRdC(O)C(O)NRiRj、NRdC(S)Rh、NRdC(S)ORh、NRdC(S)NRiRj、NRdC(NRe)NRiRj、NRdS(O)Rh、NRdSO2Rh、NRdSO2NRiRj、C(O)Rh、C(O)ORh、C(O)NRiRj、C(S)Rh、C(S)ORh、C(S)NRiRj、C(NRe)NRiRj、SRh、S(O)Rh、SO2Rh、SO2NRiRj、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリールから選択され、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRk置換基で場合によって置換されており、
又は単一の炭素原子に結合している2個のRf置換基は、これら両方が結合している炭素原子と一緒になって、カルボニル、C3〜8シクロアルキル及び3〜8員ヘテロシクロアルキルから選択される基を形成しており、
Rgは、出現ごとに、独立して、C1〜6アルキル、C1〜6ハロアルキル、フェニル、ナフチル、及びC7〜11アラルキルから選択され、それぞれが、ハロゲン、CN、OH、C1〜6アルコキシ、C1〜6アルキル及びC1〜6ハロアルキルから選択される、1、2、3、4又は5個の置換基で場合によって置換されており、
Rhは、出現ごとに、独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリールから選択され、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRk置換基で場合によって置換されており、
Ri及びRjは、出現ごとに、それぞれ独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル、5〜10員ヘテロアリール、C(O)Rg、及びC(O)ORgから選択され、前記C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれが、ハロゲン、CN、OH、C1〜6アルコキシ、C1〜6アルキル及びC1〜6ハロアルキルから選択される1、2、3、4又は5個の置換基で場合によって置換されており、
Rkは、出現ごとに、ハロゲン、CN、OH、C1〜6アルコキシ、NH2、NH(C1〜6アルキル)、N(C1〜6アルキル)2、NHC(O)C1〜6アルキル、NHC(O)C7〜11アラルキル、NHC(O)OC1〜6アルキル、NHC(O)OC7〜11アラルキル、OC(O)C1〜6アルキル、OC(O)C7〜11アラルキル、OC(O)OC1〜6アルキル、OC(O)OC7〜11アラルキル、C(O)C1〜6アルキル、C(O)C7〜11アラルキル、C(O)OC1〜6アルキル、C(O)OC7〜11アラルキル、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、及びC2〜6アルキニルから独立して選択され、各C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、及びC7〜11アラルキル置換基は、OH、C1〜6アルコキシ、NH2、NH(C1〜6アルキル)、N(C1〜6アルキル)2、NHC(O)C1〜6アルキル、NHC(O)C7〜11アラルキル、NHC(O)OC1〜6アルキル、及びNHC(O)OC7〜11アラルキルから選択される1、2、又は3個の置換基で場合によって置換されており、
又は、単一の炭素原子に結合している2個のRk置換基は、これら両方が結合している炭素原子と一緒になって、カルボニル基を形成しており、
mは、0、1又は2であり、
nは、出現ごとに、独立して、0、1又は2であり、
pは、0、1又は2であり、
qは、0、1又は2である)が提供される。
速骨格筋原線維の調製。ウサギの骨格筋原線維を、Herrmann et al. (Biochem. 32(28):7255-7263(1993)の方法に基づき調製した。Pel-Freez Biologicals(Arkansas)から購入した、氷上で保存されたウサギ腰筋から、注文から2日以内に筋原線維を調製した。Omni-Macroホモジナイザーを使用して、ミンチ状にした筋肉を、5mMのEDTA及び0.5%TritonX-100を含有する、10容量の氷冷「標準」緩衝液(50mMのTris、pH7.4、0.1Mの酢酸カリウム、5mMのKCl、2mMのDTT、0.2mMのPMSF、10μMのロイペプチン、5μMのペプスタチン、及び0.5mMのアジ化ナトリウム)内でホモジナイズした。低速度の遠心分離(3000rpmを10分間)で筋原線維を回収し、TritonX-100を含有する緩衝液で2回洗浄することによって、細胞膜が確実に除去されるようにした。Tritonでの洗浄に続いて、2mM酢酸マグネシウムを含有する「標準」緩衝液で筋原線維を3回洗浄した。アッセイ緩衝液(12mMのPIPES、pH6.8、60mMのKCl、1mMのDTT)中で最後の洗浄を実施し、液体窒素中でのフラッシュ凍結のために10%ショ糖に移し、-80℃で保存した。
粉末の調製
1.ミンチ状にした筋肉約1000g当たりの容量を示す。
2.チーズクロスを予め切断し、水中で10分間沸騰する。排水し、乾燥させる。
3.予め冷却した肉粉砕機の中でニワトリ胸肉をミンチ状にする。
4.2Lの0.1MのKCl、0.15MのK-リン酸、pH6.5の中で、4℃で10分間撹拌しながら抽出する。5000rpmで、4℃で10分間、JLA内でスピンさせる。ペレットを収集する。
5.2Lの0.05MのNaHCO3を用いて、5分間撹拌しながらペレットを抽出する。5000rpm、4℃で10分間、JLA内でスピンさせる。ペレットを収集する。この抽出をもう一度繰り返す。
7.2LのH2Oを用いて、5分間撹拌しながら抽出する。10000rpmで、4℃で15分間、JLA内でスピンさせる。慎重にペレットを収集する。ペレットの一部は、もろくゼラチン状となる。
8.アセトンで5回抽出する(それぞれ2Lのアセトンで、撹拌しながら10分間)。チーズクロスを通して徐々に圧搾する。アセトン抽出はすべて室温で実施する。アセトンは、予め4℃に冷却しておくものとする。
9.乾燥:チーズクロス上に広げた濾過した残渣を大きなガラストレイに置き、覆いをかけて一晩放置する。残渣が乾燥したら、広口のプラスチックボトルに入れて、20℃で保存する。
(Zot & Potter(1981)Prep. Biochem. 11(4) pp. 381-395を参照)
1.心筋の左心室を解離する。できるだけ多くの心嚢組織及び脂肪を除去する。予め冷却した肉粉砕機内で粉砕する。秤量する。
2.5容量の抽出緩衝液を調製する(以下を参照)。ブレンダー内で肉を4回ホモジナイズし、15秒間隔でブレンド15秒を行う。すでに調製した5容量から取った1容量(重量/容量)の緩衝液を用いてこれを行う。ホモジネートを抽出緩衝液に戻し、十分に混合するまで撹拌する(5分間)。
3.大きなポリプロピレン濾過器の中で1層のチーズクロスを介して濾過する。上記のように、5容量の抽出緩衝液中に再懸濁させる。
4.ステップ3をさらに4回繰り返す。最後は、抽出緩衝液中に再懸濁せずに、ステップ5に進む。ペレットは、黄白色となる。
5.3容量(元の重量による)の95%冷エタノール中に再懸濁する。5分間撹拌し、上記の通りにチーズクロスを通して圧搾し、さらに2回繰り返す。
7.ステップ6を全部で3回繰り返す。
8.ガラストレイの中で、チーズクロス上の単層に一晩放置する。
9.乾燥したら、粉末を収集し、秤量し、広口のジャーの中で、4℃で保存する。
1.粉末1グラムにつき(10gにつき200ml)、20mlの緩衝液A(以下参照、以下のステップのそれぞれの使用の直前にBME及びATPを添加する)を用いて、粉末を抽出する(上述の通り)。150gの粉末に対して大型4Lビーカーを使用する。激しく混合して、粉末を溶解する。4℃で30分間撹拌する。
2.いくつかの層のチーズクロスを介して圧搾することによって、水和した粉末から抽出物を分離する。チーズクロスは、水気を1〜2分間マイクロ波処理することによって、予め滅菌しておくものとする。
3.同量の緩衝液Aで残渣を再抽出し、抽出物を合わせる。
4.10Krpm(4℃)で1時間、JLA10ローター(複数可)内でスピンさせる。2層のチーズクロスを介して上清を収集する。
5.ATPを0.2mMまで、及びMgCl2を50mMまで添加する。撹拌プレート上で、4℃で60分間撹拌することによって、アクチンの重合/パラ-クリスタルの形成を可能とする。
6.固体KClを0.6M(45g/l)までゆっくりと添加する。4℃で30分間撹拌する。
8.脱重合:緩衝液Aでペレットの表面を手早くすすぎ、洗浄剤を破棄する。各管内で少量の緩衝液Aを用いて氷上で予備インキュベートすることによりペレットを軟化させる(すべての管の最終の再懸濁液総量の半分未満を使用)。細胞スクレーパーを用いて最初に手作業で再懸濁させ、ペレットを合わせる。25mlピペット及び電動式ピペッターを用いて追加の緩衝液で管を洗浄し、アクチンを管の側面から積極的に除去する。氷上の冷緩衝液A中で、大型ダウンスでホモジナイズする。最初に抽出した粉末1グラム当たり3mlを使用する。
9.48時間に渡り、4回交換しながら緩衝液Aに対する透析を行う。
10.透析したアクチンを収集し、40Krpmで1.5時間(4℃)、45Tiローター内でスピンさせる。
11.上清を収集する(G-アクチン)。ゲル分析及びタンパク質濃度測定用に試料を保存する。
12.保存用G-アクチンを重合するため、KClを50mM(3Mストックから)まで、MgCl2を1mMまで、及びNaN3を0.02%(10%ストックから)まで添加する。4℃で保存する。冷凍してはならない。
緩衝液A:2mMのtris/HCl、0.2mMのCaCl2、0.5mM(36μl/L)の2-メルカプトエタノール、0.2mMのNa2ATP(新たに添加)、及び0.005%のNa-アジド;pH8.0。
(Margossian, S.S.及びLowey, S. (1982) Methods Enzymol. 85, 55-123;並びにGoldmann, W.H.及びGeeves, M.A. (1991) Anal. Biochem. 192, 55-58を参照)
溶液A:0.3MのKCl、0.15Mのリン酸カリウム、0.02MのEDTA、0.005MのMgCl2、0.001MのATP、pH6.5。
溶液B:1MのKCl、0.025MのEDTA、0.06Mのリン酸カリウム、pH6.5。
溶液C:0.6MのKCl、0.025Mのリン酸カリウム、pH6.5。
溶液D:0.6MのKCl、0.05Mのリン酸カリウム、pH6.5。
溶液E:0.15Mのリン酸カリウム、0.01MのEDTA、pH7.5。
溶液F:0.04MのKCl、0.01Mのリン酸カリウム、0.001MDTT、pH6.5。
溶液G:3MのKCl、0.01Mのリン酸カリウム、pH6.5。
1.約1000gの骨格筋、例えばウサギ骨格筋などを入手する。
2.2回粉砕する;撹拌しながら2Lの溶液Aで15分間抽出する;4Lの冷H2Oを添加し、ガーゼを介して濾過する;イオン強度0.04(約10倍)まで冷H2Oで希釈する;3時間放置する;7,000rpmで15分間、GSAローター内で沈殿物を収集する。
3.ペレットを220mlの溶液B中に分散させる;6Lの溶液Cに対して一晩透析する;約400ml等量の冷蒸留H2Oをゆっくりと添加する;30分間撹拌する;10,000rpmで10分間、GSAローター内で遠心分離する。
4.上清を19,000rpmで1時間遠心分離する。
5.イオン強度0.04(約8倍)まで上清を希釈する;ミオシンを一晩放置する;GSAローター内で、10,000rpmで10分間遠心分離することによって約5〜6Lの軽いミオシン沈殿物を収集する。
7.上清を5〜10mg/mlまで希釈し、溶液Eに対して十分に透析し、DEAE-セファデックスカラムに充填する。
8.溶液Eで予備平衡化する;500〜600gのミオシンを30ml/時間で塗布する;350mlの溶液Eで洗浄する;溶液E中の0〜0.5MのKCl(2×1リットル)の線形勾配で溶出する;10mlの画分を収集する;ミオシン画分(>0.1MのKCl)をプールする;溶液Fに対する一晩の透析により濃縮する;25,000rpmで30分間遠心分離する;上記のように保存する。
9.次いで、EDTAの存在下、キモトリプシン又はパパインでミオシンを切断し、ATPase活性に最適な低塩条件で可溶性のS1フラグメントを生成する(Margossian、上記を参考)。
ミオシンは、ウサギ腰筋の塩抽出物からの沈殿により調製し、可溶性のS1画分は、キモトリプシンでの消化により調製する(Margossian及びLowey, 1982)。
Claims (59)
- 式Iの化合物:
(式中、
R1は、水素、ハロゲン、CN、C1〜6アルキル、及びC(O)NRbRc から選択され、
R2は、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、及び5〜10員ヘテロアリールから選択され、前記C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール及び5〜10員ヘテロアリール基のそれぞれは、ハロゲン、CN、オキソ、(CH2)nORa、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル、及び(CH2)n5〜10員ヘテロアリールから選択される1、2、3、4又は5個の置換基で場合によって置換されており、前記C1〜6アルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル、及び(CH2)n5〜10員ヘテロアリール基のそれぞれは、1、2、3、4又は5個のRf置換基で場合によって置換されており、
R3は、水素、及びC1〜6アルキルから選択され、
R4は、水素、C1〜6アルキル、C(O)ORa、及びSO2Raから選択され、
R5及びR6は、それぞれ独立して、C 1〜6アルキルから選択され、
又は代替として、R5及びR6は、これらが結合している炭素原子と一緒になって、C3〜8シクロアルキル、3〜8員ヘテロシクロアルキルから選択される基を形成しており、それぞれは、ハロゲン、ORa、C(O)Ra、C(O)ORa、SO2Ra、及びC1〜6アルキルから選択される1、2又は3個の置換基で場合によって置換されており、
R7は、C 6〜10アリール及び5〜10員ヘテロアリールから選択され、それぞれは、ハロゲン、CN、オキソ、ORa、C(O)ORa、C(O)NRbRc、C 1〜6アルキル及びC1〜6ハロアルキルから選択される1、2、3、4又は5個の置換基で場合によって置換されており、前記C1〜6アルキルは、1、2、3、4又は5個のRf置換基で場合によって置換されており、
R8及びR9は、出現ごとに、それぞれ水素であり、
Xは、結合であり、
Raは、出現ごとに、独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C 3〜8シクロアルキル、3〜8員ヘテロシクロアルキル、C 6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリールから選択され、前記C1〜6アルキル、C 3〜8シクロアルキル、3〜8員ヘテロシクロアルキル、C 6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれは、1、2、3、4又は5個のRf置換基で場合によって置換されており、
Rb及びRcは、出現ごとに、それぞれ独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C 3〜8シクロアルキル及び3〜8員ヘテロシクロアルキルから選択され、前記C1〜6アルキル、C 3〜8シクロアルキル、及び3〜8員ヘテロシクロアルキル基のそれぞれは、1、2、3、4又は5個のRf置換基で場合によって置換されており、
Rdは、出現ごとに、独立して、水素及びC1〜6アルキルから選択され、
Reは、出現ごとに、独立して、水素、CN、及びC1〜6アルキルから選択され、
Rfは、出現ごとに、独立して、ハロゲン、CN、ORh、OC(O)Rh、NRiRj、NRdC(O)Rh、NRdC(O)ORh、C(O)Rh、C(O)ORh、C(O)NRiRj、S(O)Rh、SO2Rh、C 1〜6アルキル、C1〜6ハロアルキル、C 3〜8シクロアルキル及び3〜8員ヘテロシクロアルキルから選択され、前記C1〜6アルキル、C 3〜8シクロアルキル及び3〜8員ヘテロシクロアルキル基のそれぞれは、1、2、3、4又は5個のRk置換基で場合によって置換されており、
又は単一の炭素原子に結合している2個のRf置換基は、これら両方が結合している炭素原子と一緒になって、カルボニル基を形成しており、
Rhは、出現ごとに、独立して、水素、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリールから選択され、前記C1〜6アルキル、C2〜6アルケニル、C2〜6アルキニル、C3〜8シクロアルキル、C3〜8シクロアルケニル、3〜8員ヘテロシクロアルキル、3〜8員ヘテロシクロアルケニル、C6〜10アリール、C7〜11アラルキル及び5〜10員ヘテロアリール基のそれぞれは、1、2、3、4又は5個のRk置換基で場合によって置換されており、
Ri及びRjは、出現ごとに、それぞれ独立して、水素及びC1〜6アルキルから選択され、
Rkは、出現ごとに、独立して、ハロゲン、OH、NH2、及びOC(O)C1〜6アルキルから選択され、
mは、0又は1であり、
nは、出現ごとに、独立して、0、1又は2である)。 - mが0である、請求項1に記載の化合物、又は薬学的に許容されるその塩。
- mが1である、請求項1に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6がそれぞれC1〜6アルキルである、請求項1〜3のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6がそれぞれメチルである、請求項4に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6が、これらが結合している炭素原子と一緒になって、C3〜8シクロアルキル、及び3〜8員ヘテロシクロアルキルから選択される基を形成しており、それぞれが、ハロゲン、ORa、C(O)Ra、C(O)ORa、SO2Ra 及びC1〜6アルキルから選択される1又は2個の置換基で場合によって置換されている、請求項1〜3のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6が、これらが結合している炭素原子と一緒になって、ハロゲン、ORa、C(O)Ra、C(O)ORa、SO2Ra 及びC1〜6アルキルから選択される1又は2個の置換基で場合によって置換されているC3〜8シクロアルキルを形成している、請求項6に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6が、これらが結合している炭素原子と一緒になって、シクロプロピル、シクロブチル、シクロペンチル及びシクロヘキシルから選択される基を形成しており、それぞれが、ハロゲン、ORa、C(O)Ra、C(O)ORa、SO2Ra 及びC1〜6アルキルから選択される1又は2個の置換基で場合によって置換されている、請求項7に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6が、これらが結合している炭素原子と一緒になって、ハロゲン、ORa 及びC1〜6アルキルから選択される1又は2個の置換基で場合によって置換されているシクロブチルを形成している、請求項8に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6が、これらが結合している炭素原子と一緒になって、1個又は2個のハロゲンで場合によって置換されているシクロブチルを形成している、請求項9に記載の化合物、又は薬学的に許容されるその塩。
- R5及びR6が、これらが結合している炭素原子と一緒になって、シクロブチル、3-フルオロシクロブチル及び3,3-ジフルオロシクロブチルから選択される基を形成している、請求項10に記載の化合物、又は薬学的に許容されるその塩。
- Rm及びRnのうちの一方が水素であり、他方がハロゲンである、請求項12に記載の化合物。
- ハロゲン及びR7が、シクロブチル環上で互いに対してtrans配置にある、請求項13に記載の化合物。
- ハロゲン及びR7が、シクロブチル環上で互いに対してcis配置にある、請求項14に記載の化合物。
- Rm及びRnのうちの一方が水素であり、他方がフッ素である、請求項12〜15のいずれか一項に記載の化合物。
- R7が、ハロゲン、CN、ORa、C(O)ORa、C(O)NRbRc、C 1〜6アルキル及びC1〜6ハロアルキルから選択される、1、2、3、4又は5個の置換基で場合によって置換されているフェニルであり、前記C1〜6アルキルが、1又は2個のRf置換基で場合によって置換されている、請求項1〜16のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R7が、ハロゲン、CN、オキソ、ORa、C(O)ORa、C(O)NRbRc、C 1〜6アルキル及びC1〜6ハロアルキルから選択される、1、2、3、4又は5個の置換基で場合によって置換されている5〜10員ヘテロアリールであり、前記C1〜6アルキルが、1又は2個のRf置換基で場合によって置換されている、請求項1〜16のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R7が、ハロゲン、CN、オキソ、ORa、C(O)ORa、C(O)NRbRc、C 1〜6アルキル及びC1〜6ハロアルキルから選択される、1、2、3、4又は5個の置換基で場合によって置換されているピリジルであり、前記C1〜6アルキルが、1又は2個のRf置換基で場合によって置換されている、請求項18に記載の化合物、又は薬学的に許容されるその塩。
- R7が、ハロゲン、CN、オキソ、ORa、C(O)ORa、C(O)NRbRc、C 1〜6アルキル及びC1〜6ハロアルキルから選択される、1、2、3、4又は5個の置換基で場合によって置換されている2-ピリジルであり、前記C1〜6アルキルが、1又は2個のRf置換基で場合によって置換されている、請求項19に記載の化合物、又は薬学的に許容されるその塩。
- R2が、ハロゲン、CN、オキソ、(CH2)nORa、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリールから選択される、1、2、3、4又は5個の置換基で場合によって置換されているフェニルであり、前記C1〜6アルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRf置換基で場合によって置換されている、請求項1〜20のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R2が、ハロゲン、CN、オキソ、(CH2)nORa、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリールから選択される、1、2、3、4又は5個の置換基で場合によって置換されている5〜10員ヘテロアリールであり、前記C1〜6アルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリール基のそれぞれが、1、2、3、4又は5個のRf置換基で場合によって置換されている、請求項1〜20のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R2が、ピリジル、ピリミジル、ピラジル、ピリダジル、ピロリル、ピラゾリル、チオフェニル、チアゾリル、チアジアゾリル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、イミダゾリル、トリアゾリル及びテトラゾリルから選択され、それぞれが、ハロゲン、CN、オキソ、(CH2)nORa、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリールから選択される1、2、3又は4個の置換基で場合によって置換されており、前記C1〜6アルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリール基のそれぞれが、1又は2個のRf置換基で場合によって置換されている、請求項22に記載の化合物、又は薬学的に許容されるその塩。
- R2が、ピリジル、ピリミジル、ピラジル、ピリダジル、トリアジル、フラニル、ピロリル、ピラゾリル、チオフェニル、チアゾリル、イソチアゾリル、チアジアゾリル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、イミダゾリル、トリアゾリル及びテトラゾリルから選択され、それぞれが、(CH2)nC(O)ORa及び(CH2)nC(O)NRbRcから選択される置換基で場合によって置換されており、かつハロゲン、CN、オキソ、(CH2)nORa、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリールから選択される1、2又は3個のさらなる置換基で場合によって置換されており、前記C1〜6アルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリール基のそれぞれが、1又は2個のRf置換基で場合によって置換されている、請求項22に記載の化合物、又は薬学的に許容されるその塩。
- R2が、フラニル、ピロリル、ピラゾリル、チオフェニル、チアゾリル、イソチアゾリル、チアジアゾリル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、イミダゾリル、トリアゾリル及びテトラゾリルから選択され、それぞれが、(CH2)nC(O)NRbRcで場合によって置換されている、請求項22に記載の化合物、又は薬学的に許容されるその塩。
- R2が、ピリジル、ピリミジル、ピラジル、ピリダジル、トリアジル、フラニル、ピロリル、ピラゾリル、チオフェニル、チアゾリル、イソチアゾリル、チアジアゾリル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、イミダゾリル、トリアゾリル及びテトラゾリルから選択され、それぞれが、(CH2)nNRdC(O)Raで場合によって置換されており、ここで、Raは、ハロゲン、(CH 2 ) n OR a 、(CH 2 ) n NR b R c 、及びC 1〜6 ハロアルキルから選択される1、2又は3個のさらなる置換基で場合によって置換されているC1〜6アルキルである、請求項22に記載の化合物、又は薬学的に許容されるその塩。
- R2が、フラニル、ピロリル、ピラゾリル、チオフェニル、チアゾリル、イソチアゾリル、チアジアゾリル、オキサゾリル、イソオキサゾリル、オキサジアゾリル、イミダゾリル、トリアゾリル及びテトラゾリルから選択され、それぞれが、(CH2)nNRdC(O)Raで場合によって置換されており、ここで、Raは、C1〜6アルキル、C1〜6アルキル-OH及びC1〜6アルキル-NH2から選択される、請求項22に記載の化合物、又は薬学的に許容されるその塩。
- R2が、インドリル、インダゾリル、ベンズイミダゾリル、ベンズオキサゾリル及びベンゾイソオキサゾリルから選択され、それぞれが、ハロゲン、CN、オキソ、(CH2)nORa、(CH2)nNRbRc、(CH2)nNRdC(O)Ra、(CH2)nNRdC(O)ORa、(CH2)nNRdC(O)NRbRc、(CH2)nNRdC(NRe)NRbRc、(CH2)nNRdS(O)Ra、(CH2)nNRdSO2Ra、(CH2)nNRdSO2NRbRc、(CH2)nC(O)Ra、(CH2)nC(O)ORa、(CH2)nC(O)NRbRc、(CH2)nC(S)NRbRc、(CH2)nC(NRe)NRbRc、(CH2)nSO2Ra、(CH2)nSO2NRbRc、C1〜6アルキル、C1〜6ハロアルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリールから選択される1、2、3又は4個の置換基で場合によって置換されており、前記C1〜6アルキル、C2〜6アルケニル、(CH2)n3〜8員ヘテロシクロアルキル及び(CH2)n5〜10員ヘテロアリール基のそれぞれが、1又は2個のRf置換基で場合によって置換されている、請求項22に記載の化合物、又は薬学的に許容されるその塩。
- R1が、水素、CN及びメチルから選択される、請求項1〜28のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R1が水素である、請求項29に記載の化合物、又は薬学的に許容されるその塩。
- R3が、水素及びメチルから選択される、請求項1〜30のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- R3が水素である、請求項31に記載の化合物、又は薬学的に許容されるその塩。
- R4が水素である、請求項1〜32のいずれか一項に記載の化合物、又は薬学的に許容されるその塩。
- mが0であり、
R 2 が、ハロゲン、CN、オキソ、(CH 2 ) n OR a 、(CH 2 ) n NR b R c 、(CH 2 ) n NR d C(O)R a 、(CH 2 ) n NR d C(O)OR a 、(CH 2 ) n NR d C(O)NR b R c 、(CH 2 ) n NR d S(O)R a 、(CH 2 ) n NR d SO 2 R a 、(CH 2 ) n NR d SO 2 NR b R c 、(CH 2 ) n C(O)R a 、(CH 2 ) n C(O)OR a 、(CH 2 ) n C(O)NR b R c 、(CH 2 ) n SO 2 R a 、(CH 2 ) n SO 2 NR b R c 、C 1〜6 アルキル、C 1〜6 ハロアルキル、及びC 2〜6 アルケニル(前記C 1〜6 アルキル、及びC 2〜6 アルケニルのそれぞれは、1、2、3、4又は5個のR f 置換基で場合によって置換されている)から選択される1、2、3、4又は5個の置換基で場合によって置換されている、フェニル及び5〜10員ヘテロアリールから選択され、
R 4 が、水素であり、
R 5 が、メチルであり、
R 6 が、メチルであり、かつ
R 7 が、フェニル及びピリジルから選択され、それぞれは、ハロゲン、CN、OR a 、C 1〜6 アルキル、及びC 1〜6 ハロアルキルから選択される1、2又は3個の置換基で場合によって置換されている、
請求項1に記載の化合物、または薬学的に許容されるその塩。 - mが0であり、
R 2 が、ハロゲン、CN、オキソ、(CH 2 ) n OR a 、(CH 2 ) n NR b R c 、(CH 2 ) n NR d C(O)R a 、(CH 2 ) n NR d C(O)OR a 、(CH 2 ) n NR d C(O)NR b R c 、(CH 2 ) n NR d S(O)R a 、(CH 2 ) n NR d SO 2 R a 、(CH 2 ) n NR d SO 2 NR b R c 、(CH 2 ) n C(O)R a 、(CH 2 ) n C(O)OR a 、(CH 2 ) n C(O)NR b R c 、(CH 2 ) n SO 2 R a 、(CH 2 ) n SO 2 NR b R c 、C 1〜6 アルキル、C 1〜6 ハロアルキル、及びC 2〜6 アルケニル(前記C 1〜6 アルキル、及びC 2〜6 アルケニルのそれぞれは、1、2、3、4又は5個のR f 置換基で場合によって置換されている)から選択される1、2、3、4又は5個の置換基で場合によって置換されている、フェニル及び5〜10員ヘテロアリールから選択され、
R 4 が、水素であり、
R 5 及びR 6 が、これらが結合している炭素原子と一緒になって、1又は2個のハロゲンで場合によって置換されたシクロブチル基を形成しており、かつ
R 7 が、フェニル及びピリジルから選択され、それぞれは、ハロゲン、CN、OR a 、C 1〜6 アルキル、及びC 1〜6 ハロアルキルから選択される1、2又は3個の置換基で場合によって置換されている、
請求項1に記載の化合物、または薬学的に許容されるその塩。 - mが1であり、
R 2 が、ハロゲン、CN、オキソ、(CH 2 ) n OR a 、(CH 2 ) n NR b R c 、(CH 2 ) n NR d C(O)R a 、(CH 2 ) n NR d C(O)OR a 、(CH 2 ) n NR d C(O)NR b R c 、(CH 2 ) n NR d S(O)R a 、(CH 2 ) n NR d SO 2 R a 、(CH 2 ) n NR d SO 2 NR b R c 、(CH 2 ) n C(O)R a 、(CH 2 ) n C(O)OR a 、(CH 2 ) n C(O)NR b R c 、(CH 2 ) n SO 2 R a 、(CH 2 ) n SO 2 NR b R c 、C 1〜6 アルキル、C 1〜6 ハロアルキル、及びC 2〜6 アルケニル(前記C 1〜6 アルキル、及びC 2〜6 アルケニルのそれぞれは、1、2、3、4又は5個のR f 置換基で場合によって置換されている)から選択される1、2、3、4又は5個の置換基で場合によって置換されている、フェニル及び5〜10員ヘテロアリールから選択され、
R 4 が、水素であり、
R 5 が、メチルであり、
R 6 が、メチルであり、
R 7 が、フェニル及びピリジルから選択され、それぞれは、ハロゲン、CN、OR a 、C 1〜6 アルキル、及びC 1〜6 ハロアルキルから選択される1、2又は3個の置換基で場合によって置換されており、
R 8 が、水素であり、かつ
R 9 が、水素である、
請求項1に記載の化合物、または薬学的に許容されるその塩。 - mが1であり、
R 2 が、ハロゲン、CN、オキソ、(CH 2 ) n OR a 、(CH 2 ) n NR b R c 、(CH 2 ) n NR d C(O)R a 、(CH 2 ) n NR d C(O)OR a 、(CH 2 ) n NR d C(O)NR b R c 、(CH 2 ) n NR d S(O)R a 、(CH 2 ) n NR d SO 2 R a 、(CH 2 ) n NR d SO 2 NR b R c 、(CH 2 ) n C(O)R a 、(CH 2 ) n C(O)OR a 、(CH 2 ) n C(O)NR b R c 、(CH 2 ) n SO 2 R a 、(CH 2 ) n SO 2 NR b R c 、C 1〜6 アルキル、C 1〜6 ハロアルキル、及びC 2〜6 アルケニル(前記C 1〜6 アルキル、及びC 2〜6 アルケニルのそれぞれは、1、2、3、4又は5個のR f 置換基で場合によって置換されている)から選択される1、2、3、4又は5個の置換基で場合によって置換されている、フェニル及び5〜10員ヘテロアリールから選択され、
R 4 が、水素であり、
R 5 及びR 6 が、これらが結合している炭素原子と一緒になって、1又は2個のハロゲンで場合によって置換されたシクロブチル基を形成しており、
R 7 が、フェニル及びピリジルから選択され、それぞれは、ハロゲン、CN、OR a 、C 1〜6 アルキル、及びC 1〜6 ハロアルキルから選択される1、2又は3個の置換基で場合によって置換されており、
R 8 が、水素であり、かつ
R 9 が、水素である、
請求項1に記載の化合物、または薬学的に許容されるその塩。 - 4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- 4-フルオロ-3-[6-({[(trans)-3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- 4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- [6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミン、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- [6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- [6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- [6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(trans)-3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-ヒドロキシアセトアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- 2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-メチルプロパンアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- (2S)-2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)プロパンアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- (2R)-2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)プロパンアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- (2S)-2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-3-ヒドロキシ-3-メチルブタンアミド、又は薬学的に許容されるその塩である、請求項1に記載の化合物。
- 以下の化合物又は薬学的に許容されるその塩から選択される、請求項1に記載の化合物:
3-{6-[(1-メチル-1-フェニルエチル)アミノ]ピリダジン-3-イル}ベンズアミド;
3-{6-[(1-メチル-1-フェニルエチル)アミノ]ピリダジン-3-イル}ベンゼンカルボニトリル;
3-{6-[(1-メチル-1-(2-ピリジル)エチル)アミノ]ピリダジン-3-イル}ベンズアミド;
4-{6-[(1-メチル-1-フェニルエチル)アミノ]ピリダジン-3-イル}ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)(1-メチル-1-フェニルエチル)アミン;
[6-(6-アミノ(3-ピリジル))ピリダジン-3-イル](1-メチル-1-フェニルエチル)アミン;
(1-メチル-1-フェニルエチル)(6-フェニルピリダジン-3-イル)アミン;
3-(6-{[1-(4-フルオロフェニル)-イソプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[1-(3-フルオロフェニル)-イソプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
4-フルオロ-3-(6-{[1-(4-フルオロフェニル)-イソプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[1-(3-クロロ(2-ピリジル))-イソプロピル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
4-フルオロ-3-(6-{[1-メチル-1-(6-オキソ(2-ヒドロピリジル))エチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-[6-({1-[6-(ジフルオロメトキシ)(2-ピリジル)]-イソプロピル}アミノ)ピリダジン-3-イル]-4-フルオロベンズアミド;
3-[6-({1-[6-(ジフルオロメトキシ)(2-ピリジル)]-イソプロピル}アミノ)ピリダジン-3-イル]ベンズアミド;
{3-[6-({1-[6-(ジフルオロメトキシ)(2-ピリジル)]-イソプロピル}アミノ)ピリダジン-3-イル]フェニル}(メチルスルホニル)アミン;
2-[6-({1-[6-(ジフルオロメトキシ)(2-ピリジル)]-イソプロピル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-カルボキサミド;
4-フルオロ-3-(6-{[1-(3-フルオロ(2-ピリジル))-イソプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
2-(6-{[1-(3-クロロ(2-ピリジル))-イソプロピル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-カルボキサミド;
6-(6-{[1-(3-クロロ(2-ピリジル))-イソプロピル]アミノ}ピリダジン-3-イル)イミダゾ[2,1-b]1,3-チアゾリン-3-カルボキサミド;及び
2-[2-(6-{[1-(3-クロロ(2-ピリジル))-イソプロピル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-イル]アセトアミド。 - 以下の化合物又は薬学的に許容されるその塩から選択される、請求項1に記載の化合物:
3-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)[(4-フルオロフェニル)シクロブチル]アミン;
[6-(2-アミノピリミジン-5-イル)ピリダジン-3-イル][(4-フルオロフェニル)シクロブチル]アミン;
アミノ-N-[4-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)フェニル]アミド;
3-(6-{[(2-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[(3-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-{6-[(2-ピリジルシクロブチル)アミノ]ピリダジン-3-イル}ベンズアミド;
(フェニルシクロブチル)(6-フェニルピリダジン-3-イル)アミン;
3-{6-[(フェニルシクロブチル)アミノ]ピリダジン-3-イル}ベンズアミド;
3-(6-{[(3-フルオロ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[(5-フルオロ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
4-フルオロ-3-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
[(4-フルオロフェニル)シクロブチル][6-(6-メトキシ(2-ピリジル))ピリダジン-3-イル]アミン;
(6-ベンゾイミダゾール-5-イルピリダジン-3-イル)[(4-フルオロフェニル)シクロブチル]アミン;
[(4-フルオロフェニル)シクロブチル](6-ピラゾール-4-イルピリダジン-3-イル)アミン;
3-{6-[(1,3-チアゾール-2-イルシクロブチル)アミノ]ピリダジン-3-イル}ベンズアミド;
4-フルオロ-3-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[(4-メトキシ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
[6-(3-フルオロ(4-ピリジル))ピリダジン-3-イル][(4-フルオロフェニル)シクロブチル]アミン;
[(4-フルオロフェニル)シクロブチル](6-(4-ピリジル)ピリダジン-3-イル)アミン;
4-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ピリジン-2-カルボニトリル;
4-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ピリジン-2-カルボキサミド;
[4-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)フェニル](メチルスルホニル)アミン;
[(4-フルオロフェニル)シクロブチル][6-(2-メトキシ(3-ピリジル))ピリダジン-3-イル]アミン;
[(4-フルオロフェニル)シクロブチル]{6-[2-(2,2,2-トリフルオロエトキシ)(3-ピリジル)]ピリダジン-3-イル}アミン;
3-(6-{[(4-クロロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[(4-シアノフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[(3-クロロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
[3-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)フェニル](メチルスルホニル)アミン;
3-(6-{[(4-カルバモイルフェニル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
[(4-フルオロフェニル)シクロブチル][6-(2-メチル(4-ピリジル))ピリダジン-3-イル]アミン;
[(4-フルオロフェニル)シクロブチル][6-(2-メトキシ(4-ピリジル))ピリダジン-3-イル]アミン;
3-(6-{[(6-メトキシ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
4-フルオロ-3-(6-{[(6-メトキシ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
[3-(6-{[(6-メトキシ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル](メチルスルホニル)アミン;
[3-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル](メチルスルホニル)アミン;
アミノ-N-[4-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル]アミド;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)[(3-フルオロ(2-ピリジル))シクロブチル]アミン;
(6-ベンゾイミダゾール-6-イルピリダジン-3-イル)[(3-フルオロ(2-ピリジル))シクロブチル]アミン;
3-[6-({[6-(ジフルオロメトキシ)-2-ピリジル]シクロブチル}アミノ)ピリダジン-3-イル]ベンズアミド;
3-[6-({[6-(ジフルオロメトキシ)(2-ピリジル)]シクロブチル}アミノ)ピリダジン-3-イル]-4-フルオロベンズアミド;
{3-[6-({[6-(ジフルオロメトキシ)(2-ピリジル)]シクロブチル}アミノ)ピリダジン-3-イル]フェニル}(メチルスルホニル)アミン;
4-フルオロ-3-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)安息香酸;
[4-フルオロ-3-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)フェニル]-N-(2-ヒドロキシ-2-メチルプロピル)カルボキサミド;
3-(6-{[(3-ブロモ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
4-クロロ-3-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
[4-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)(2-ピリジル)]-N-メチルカルボキサミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)[(3-フルオロ(2-ピリジル))シクロブチル]アミン;
[6-(6-フルオロ(1H-インダゾール-5-イル))ピリダジン-3-イル][(3-フルオロ(2-ピリジル))シクロブチル]アミン;
アミノ-N-[4-フルオロ-3-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル]アミド;
アミノ[4-フルオロ-3-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル]スルホンアミド;
アミノ[3-フルオロ-4-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル]スルホンアミド;
アミノ-N-[3-フルオロ-4-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)フェニル]アミド;
3-(6-{[(4-シアノ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
2-({[6-(3-カルバモイル-6-フルオロフェニル)ピリダジン-3-イル]アミノ}シクロブチル)ピリジン-4-カルボキサミド;
3-(6-{[(5-シアノ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
3-(6-{[(6-シアノ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
6-({[6-(3-カルバモイル-6-フルオロフェニル)ピリダジン-3-イル]アミノ}シクロブチル)ピリジン-2-カルボキサミド;
4-フルオロ-3-(6-{[(3-ヒドロキシ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
4-フルオロ-3-(6-{[(3-メトキシ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-[6-({[3-(ジフルオロメトキシ)(2-ピリジル)]シクロブチル}アミノ)ピリダジン-3-イル]-4-フルオロベンズアミド;
3-[6-({[3-(ジフルオロメトキシ)-2-ピリジル]シクロブチル}アミノ)ピリダジン-3-イル]ベンズアミド;
{3-[6-({[3-(ジフルオロメトキシ)(2-ピリジル)]シクロブチル}アミノ)ピリダジン-3-イル]フェニル}(メチルスルホニル)アミン;
4-フルオロ-3-(6-{[(5-メトキシ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-[6-({[5-(ジフルオロメトキシ)(2-ピリジル)]シクロブチル}アミノ)ピリダジン-3-イル]-4-フルオロベンズアミド;
4-フルオロ-3-(6-{[(5-ヒドロキシ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンズアミド;
4-フルオロ-3-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)ベンゼンカルボニトリル;
[(3-フルオロ(2-ピリジル))シクロブチル](6-フェニルピリダジン-3-イル)アミン;
(6-シクロヘキシルピリダジン-3-イル)[(3-フルオロ(2-ピリジル))シクロブチル]アミン;
(6-シクロヘキサ-1-エニルピリダジン-3-イル)[(3-フルオロ(2-ピリジル))シクロブチル]アミン;
4-フルオロ-3-(6-{[(3-フルオロ(2-ピリジル))シクロペンチル]アミノ}ピリダジン-3-イル)ベンズアミド;
2-(6-{[(3-フルオロ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-カルボキサミド;
5-(6-{[(3-フルオロ(2-ピリジル))シクロブチル]アミノ}ピリダジン-3-イル)-2-ヒドロキシベンズアミド;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][(3-フルオロ(2-ピリジル))シクロブチル]アミン;
2-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-カルボキサミド;
5-(6-{[(3-フルオロ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)チオフェン-2-カルボキサミド;
5-(6-{[(4-フルオロフェニル)シクロブチル]アミノ}ピリダジン-3-イル)チオフェン-2-カルボキサミド;及び
5-(6-{[(3-フルオロ-2-ピリジル)シクロブチル]アミノ}ピリダジン-3-イル)チオフェン-2-カルボン酸。 - 以下の化合物又は薬学的に許容されるその塩から選択される、請求項1に記載の化合物:
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-カルボニトリル;
メチル5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-カルボキシレート;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-カルボキサミド;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-ピラゾール-4-イルピリダジン-3-イル)アミン;
3-(6-{[2-(2-クロロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[2-(4-クロロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[2-(2,4-ジフルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンゼンカルボニトリル;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
3-(6-{[2-(2-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
(6-(1H-インダゾール-4-イル)ピリダジン-3-イル)[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロベンゾイミダゾール-2-オン;
3-(6-{[2-(3-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
(6-(1H-1,2,3,4-テトラアゾール-5-イル)ピリダジン-3-イル)[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
5-(6-{[2-(2-クロロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-カルボキサミド;
5-(6-{[2-(2-クロロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-カルボニトリル;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(3-アミノ(1H-インダゾール-7-イル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(3-アミノベンゾ[3,4-d]イソオキサゾール-5-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(3-アミノベンゾ[d]イソオキサゾール-7-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(2-クロロフェニル)-2-メチルプロピル](6-(3-ピリジル)ピリダジン-3-イル)アミン;
[2-(2-クロロフェニル)-2-メチルプロピル](6-ピリミジン-5-イルピリダジン-3-イル)アミン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}-5-メチルピリダジン-3-イル)ベンゼンカルボニトリル;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}-5-メチルピリダジン-3-イル)ベンズアミド;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}-4-メチルピリダジン-3-イル)ベンゼンカルボニトリル;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}-4-メチルピリダジン-3-イル)ベンズアミド;
[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]-N-(2-ヒドロキシエチル)カルボキサミド;
N-(2,3-ジヒドロキシプロピル)[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]カルボキサミド;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニルピペリジルケトン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニルモルホリン-4-イルケトン;
N-(2-アミノエチル)[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]カルボキサミド;
tert-ブチル4-{[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]カルボニル}ピペラジンカルボキシレート;
2-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(1-メチル(1H-インダゾール-6-イル))ピリダジン-3-イル]アミン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニルピペラジニルケトン;
[6-(3-アミノ-1-メチル(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
5-(6-{[2-(2-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロベンゾイミダゾール-2-オン;
[6-(3-アミノ(1H-インダゾール-6-イル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(3-アミノベンゾ[d]イソオキサゾール-6-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
3-フルオロ-5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(5-シアノ-6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
6-(3-カルバモイルフェニル)-3-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-4-カルボキサミド;
5-[6-({2-[2-(ヒドロキシメチル)フェニル]-2-メチルプロピル}アミノ)ピリダジン-3-イル]-3-ヒドロベンゾイミダゾール-2-オン;
5-{6-[(2-メチル-2-フェニルプロピル)アミノ]ピリダジン-3-イル}-3-ヒドロベンゾイミダゾール-2-オン;
N-{3-[(tert-ブトキシ)カルボニルアミノ]プロピル}[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]カルボキサミド;
N-(3-アミノプロピル)[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]カルボキサミド;
(6-ベンゾイミダゾール-5-イルピリダジン-3-イル)[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(2-メチルベンゾイミダゾール-5-イル)ピリダジン-3-イル]アミン;
[6-(2-アミノベンゾイミダゾール-5-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]-N-メチルカルボキサミド;
N-[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-2-ピリジル]アセトアミド;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(2-メチルベンゾオキサゾール-5-イル)ピリダジン-3-イル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(2-メチルベンゾオキサゾール-6-イル)ピリダジン-3-イル]アミン;
3-(6-{[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[2-(5-フルオロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロベンゾオキサゾール-2-オン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニルフェニルケトン;
4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニルフェニルケトン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(3-ヨード(1H-インダゾール-5-イル))ピリダジン-3-イル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-(4-1,2,5,6-テトラヒドロピリジル)ピリダジン-3-イル)アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-ピラゾール-3-イルピリダジン-3-イル)アミン;
1-アセチル-4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,2,5,6-テトラヒドロピリジン;
メチル4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,2,5,6-テトラヒドロピリジンカルボキシレート;
4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1-(メチルスルホニル)-1,2,5,6-テトラヒドロピリジン;
4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,2,5,6-テトラヒドロピリジンカルボキサミド;
(tert-ブトキシ)-N-(2-{[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1H-インダゾール-3-イル)]アミノ}エチル)カルボキサミド;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-ピロロ[3,2-b]ピリジン-6-イルピリダジン-3-イル)アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-ピラゾロ[5,4-b]ピリジン-5-イルピリダジン-3-イル)アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロベンゾオキサゾール-2-オン;
(6-{3-[(2-アミノエチル)アミノ](1H-インダゾール-5-イル)}ピリダジン-3-イル)[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
4-フルオロ-3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(3-メチル(1H-インダゾール-6-イル))ピリダジン-3-イル]アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-メチル-2-(2-メチルフェニル)プロピル]アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-カルボニトリル;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-カルボキサミド;
[4-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]メタン-1-オール;
{[4-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]メチル}ジメチルアミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(3-ビニル(1H-インダゾール-5-イル))ピリダジン-3-イル]アミン;
[6-(3-エチル(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,2,4-オキサジアゾール-5-カルボキサミド;
[6-(3-アミノ(1H-インダゾール-6-イル))ピリダジン-3-イル][2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(5-フルオロ(2-ピリジル))-2-メチルプロピル]アミン;
[6-(3-アミノ(1H-インダゾール-6-イル))ピリダジン-3-イル][2-(5-フルオロ(2-ピリジル))-2-メチルプロピル]アミン;
1-[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-イル]エタン-1,2-ジオール;
2-アミノ-6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロピリミジン-4-オン;
N-[6-(2-アミノ-6-オキソヒドロピリミジン-4-イル)ピリダジン-3-イル](tert-ブトキシ)-N-[2-(4-フルオロフェニル)-2-メチルプロピル]カルボキサミド;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロキナゾリン-4-オン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル](2-メチル-2-(1,3-オキサゾール-2-イル)プロピル)アミン;
エチル2-フルオロ-5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンゾエート;
2-アミノ-6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロキナゾリン-4-オン;
4-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)ベンゼンカルボニトリル;
4-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)ベンズアミド;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{2-[4-(アミノメチル)フェニル]-2-メチルプロピル}アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-カルボキサミジン;
2-[4-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]プロパン-2-オール;
[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]メタン-1-オール;
2-[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-イル]プロパン-2-オール;
3-(6-{[2-(3,5-ジフルオロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-イル]メタン-1-オール;
{[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]メチル}ジメチルアミン;
3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)ベンゼンカルボニトリル;
3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)ベンズアミド;
2-[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]プロパン-2-オール;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(3,5-ジフルオロ(2-ピリジル))-2-メチルプロピル]アミン;
N-[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-イル]アセトアミド;
[6-(3-アミノピラゾロ[5,4-b]ピリジン-5-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]-N-メチルカルボキサミド;
[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]-N,N-ジメチルカルボキサミド;
[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1H-インダゾール-3-イル)](メチルスルホニル)アミン;
[2-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]メタン-1-オール;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{2-[3-(アミノメチル)フェニル]-2-メチルプロピル}アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-7-カルボキサミド;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-(3-メトキシフェニル)-2-メチルプロピル]アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][2-メチル-2-(4-メチルフェニル)プロピル]アミン;
2-[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]エタン-1-オール;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミン;
N-[6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンゾイミダゾール-2-イル]アセトアミド;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,3-ジヒドロキナゾリン-2,4-ジオン;
2-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-4-カルボキサミド;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-2-カルボキサミド;
3-(6-{(tert-ブトキシ)-N-[2-(4-フルオロフェニル)-2-メチルプロピル]カルボニルアミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{(tert-ブトキシ)-N-[2-(4-フルオロフェニル)-2-メチルプロピル]カルボニルアミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
2-フルオロ-4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)安息香酸;
メチル3-アミノ-5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾールカルボキシレート;
メチル5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-(メトキシカルボニルアミノ)-1H-インダゾールカルボキシレート;
N-[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1H-インダゾール-3-イル)]メトキシカルボキサミド;
[3-アミノ-5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1H-インダゾリル)]-N,N-ジメチルカルボキサミド;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3,3-ジメチルインドリン-2-オン;
2-アミノ-7-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロキナゾリン-4-オン;
3-{6-[(2-メチル-2-ピリミジン-2-イルプロピル)アミノ]ピリダジン-3-イル}ベンズアミド;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-{3-[(メチルエチル)アミノ](1H-インダゾール-5-イル)}ピリダジン-3-イル)アミン;
[6-(2-アミノピリミジン-5-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル]{6-[3-(メチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(2-メトキシピリミジン-5-イル)ピリダジン-3-イル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(2-メトキシ(3-ピリジル))ピリダジン-3-イル]アミン;
{6-[3-(エチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-フェニルピリダジン-3-イル)アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ヒドロピリジン-2-オン;
[6-(2-アミノ(4-ピリジル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(4-アミノフェニル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(3-アミノフェニル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-2-オール;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-3-ヒドロピリミジン-2-オン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,3,4-オキサジアゾリン-2-オン;
[6-(6-アミノ(3-ピリジル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(5-アミノピラゾール-3-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(6-メトキシ(2-ピリジル))ピリダジン-3-イル]アミン;
N-[4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)イミダゾール-2-イル]アセトアミド;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-2-カルボニトリル;
[6-(2-アミノイミダゾール-4-イル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-2-カルボキサミド;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-2-オール;
{6-[6-(アミノメチル)(3-ピリジル)]ピリダジン-3-イル}[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(2-フルオロフェニル)ピリダジン-3-イル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(3-フルオロフェニル)ピリダジン-3-イル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(4-フルオロフェニル)ピリダジン-3-イル]アミン;
[6-(2-クロロフェニル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(3-クロロフェニル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[6-(4-クロロフェニル)ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
4-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンゼンカルボニトリル;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-(3-ピリジル)ピリダジン-3-イル)アミン;
[6-(6-アミノ(2-ピリジル))ピリダジン-3-イル][2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
N-{[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-2-ピリジル]メチル}アセトアミド;
N-{[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)(2-ピリジル)]メチル}メトキシカルボキサミド;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-(2-ピリジル)ピリダジン-3-イル)アミン;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-カルボキサミド;
[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]メタン-1-オール;
(tert-ブトキシ)-N-{[3-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)フェニル]メチル}カルボキサミド;
{6-[3-(アミノメチル)フェニル]ピリダジン-3-イル}[2-(4-フルオロフェニル)-2-メチルプロピル]アミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(5-メトキシ(2-ピリジル))ピリダジン-3-イル]アミン;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)ピリジン-3-オール;
[2-(4-フルオロフェニル)-2-メチルプロピル](6-{3-[(2,2,2-トリフルオロエチル)アミノ](1H-インダゾール-5-イル)}ピリダジン-3-イル)アミン;
[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1H-インダゾール-3-イル)]ジメチルアミン;
[2-(4-フルオロフェニル)-2-メチルプロピル][6-(3-{[2-(フェニルメトキシ)エチル]アミノ}(1H-インダゾール-5-イル))ピリダジン-3-イル]アミン;
2-{[5-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1H-インダゾール-3-イル]アミノ}エタン-1-オール;
2-(6-{[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-カルボキサミド;
[6-(3-(2H-1,2,3,4-テトラアゾール-5-イル)フェニル)ピリダジン-3-イル][2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミン;
2-[2-(6-{[1-(3-フルオロ(2-ピリジル))-イソプロピル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-イル]アセトアミド;
((2S)ピロリジン-2-イル)-N-{[2-(6-{[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1,3-チアゾール-5-イル)]メチル}カルボキサミド;
3-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンズアミド;
3-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)-4-フルオロベンズアミド;
3-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンゼンカルボニトリル;
3-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)-4-フルオロベンゼンカルボニトリル;
2-[2-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-イル]アセトアミド;
2-アミノ-N-{[2-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)(1,3-チアゾール-5-イル)]メチル}-2-メチルプロパンアミド;
6-(6-{[2-(3-クロロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)イミダゾ[2,1-b]1,3-チアゾリン-3-カルボキサミド;
(tert-ブトキシ)-N-[6-(2,3-ジオキソ(1,4-ジヒドロキノキサリン-6-イル))ピリダジン-3-イル]-N-[2-(4-フルオロフェニル)-2-メチルプロピル]カルボキサミド;
{2-[3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェニル]エチル}ジメチルアミン;
3-(2-{[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]アミノ}-tert-ブチル)フェノール;
6-(6-{[2-(4-フルオロフェニル)-2-メチルプロピル]アミノ}ピリダジン-3-イル)-1,4-ジヒドロキノキサリン-2,3-ジオン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{2-[2-(メトキシメチル)フェニル]-2-メチルプロピル}アミン;
3-(6-{(tert-ブトキシ)-N-[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]カルボニルアミノ}ピリダジン-3-イル)ベンズアミド;
(tert-ブトキシ)-N-[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]-N-[6-(2-ヒドロキシベンゾイミダゾール-5-イル)ピリダジン-3-イル]カルボキサミド;及び
5-(6-{[2-(3-フルオロ(2-ピリジル))-2-メチルプロピル]アミノ}ピリダジン-3-イル)ベンゾイミダゾール-2-オール。 - 以下の化合物又は薬学的に許容されるその塩から選択される、請求項1に記載の化合物:
3-[6-({[(4-フルオロフェニル)シクロプロピル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
5-[6-({[(4-フルオロフェニル)シクロプロピル]メチル}アミノ)ピリダジン-3-イル]ピリジン-3-カルボキサミド
5-[6-({[(4-フルオロフェニル)シクロプロピル]メチル}アミノ)ピリダジン-3-イル]ピリジン-3-カルボニトリル;
3-[6-({[(2-クロロフェニル)シクロプロピル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
5-[6-({[(4-フルオロフェニル)シクロプロピル]メチル}アミノ)ピリダジン-3-イル]-3-ヒドロベンゾイミダゾール-2-オン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(4-フルオロフェニル)シクロプロピル]メチル}アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(2-フルオロフェニル)シクロプロピル]メチル}アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(2-フルオロフェニル)シクロブチル]メチル}アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(4-フルオロフェニル)シクロブチル]メチル}アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(2-フルオロフェニル)シクロペンチル]メチル}アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(4-フルオロフェニル)シクロヘキシル]メチル}アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][(フェニルシクロプロピル)メチル]アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][(フェニルシクロブチル)メチル]アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル][(2,2-ジメチル-1-フェニルシクロプロピル)メチル]アミン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(4-フルオロフェニル)シクロペンチル]メチル}アミン;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
{[(4-フルオロフェニル)シクロブチル]メチル}[6-(2-メトキシピリミジン-5-イル)ピリダジン-3-イル]アミン;
5-[6-({[(4-フルオロフェニル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-3-ヒドロピリミジン-2-オン;
[6-(3-アミノ(1H-インダゾール-5-イル))ピリダジン-3-イル]{[(5-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
3-[6-({[(5-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[(6-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[(6-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
4-フルオロ-3-[6-({[(6-メトキシ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
4-フルオロ-3-(6-{[(2-ピリジルシクロブチル)メチル]アミノ}ピリダジン-3-イル)ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)[(2-ピリジルシクロブチル)メチル]アミン;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)[(2-ピリジルシクロブチル)メチル]アミン;
2-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
3-フルオロ-4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
6-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-2-オール;
6-({[(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-2-オール;
4-フルオロ-3-[6-({[(6-ヒドロキシ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
2-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-4-オール;
4-フルオロ-3-[6-({[(4-メトキシ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[(4-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[(4-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
2-({[(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-4-オール;
4-フルオロ-3-[6-({[(4-ヒドロキシ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-3-ヒドロベンゾイミダゾール-2-オン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-ピラゾール-4-イルピリダジン-3-イル)アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(1-メチルピラゾール-4-イル)ピリダジン-3-イル]アミン;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼンスルホンアミド;
{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}(メチルスルホニル)アミン;
{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}(メチルスルホニル)アミン;
4-フルオロ-3-[6-({[(3-メトキシ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[(3-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[(3-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
4-フルオロ-3-[6-({[(5-メトキシ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[(5-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[(5-メトキシ(2-ピリジル))シクロブチル]メチル}アミン;
3-{[(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)アミノ]メチル}-3-(2-ピリジル)シクロブタン-1-オール;
3-{[(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)アミノ]メチル}-3-(2-ピリジル)シクロブタン-1-オール;
3-[6-({[(4-フルオロフェニル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-メチルベンズアミド;
6-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-3-カルボニトリル;
6-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-3,3-ジメチルインドリン-2-オン;
3-[6-({[(4-シアノ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
2-[({[6-(3-カルバモイルフェニル)ピリダジン-3-イル]アミノ}メチル)シクロブチル]ピリジン-4-カルボキサミド;
3-[6-({[(4-シアノ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-フルオロベンズアミド;
2-[({[6-(3-カルバモイル-6-フルオロフェニル)ピリダジン-3-イル]アミノ}メチル)シクロブチル]ピリジン-4-カルボキサミド;
2-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-4-カルボニトリル;
2-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-4-カルボキサミド;
3-[6-({[(6-シアノ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
6-[({[6-(3-カルバモイルフェニル)ピリダジン-3-イル]アミノ}メチル)シクロブチル]ピリジン-2-カルボキサミド;
6-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-2-カルボニトリル;
6-({[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}シクロブチル)ピリジン-2-カルボキサミド;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[(4-フルオロフェニル)シクロブチル]メチル}アミン;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[(4-フルオロフェニル)シクロブチル]メチル}アミン;
4-フルオロ-3-[6-({[(1-メチル-6-オキソ(2-ヒドロピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
3-(6-{[(2-ピリジルシクロブチル)メチル]アミノ}ピリダジン-3-イル)ベンズアミド;
メチル3-(3-フルオロ(2-ピリジル))-3-{[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}アゼチジンカルボキシレート;
メチル3-({[6-(3-カルバモイルフェニル)ピリダジン-3-イル]アミノ}メチル)-3-(3-フルオロ(2-ピリジル))アゼチジンカルボキシレート;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[3-(メチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}アミン;
2-フルオロ-5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]安息香酸;
{2-フルオロ-5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチルカルボキサミド;
N-{5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1H-インダゾール-3-イル}アセトアミド;
2-アミノ-N-{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1H-インダゾール-3-イル)}アセトアミド;
{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1H-インダゾール-3-イル)}(メチルスルホニル)アミン;
3-アミノ-5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1H-インダゾールカルボキサミド;
[6-(3-アミノフェニル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(4-アミノフェニル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(6-{3-[(2-アミノエチル)アミノ](1H-インダゾール-5-イル)}ピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
アミノ{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミジン;
アミノ{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミジン;
3-(6-{[(ピラジン-2-イルシクロブチル)メチル]アミノ}ピリダジン-3-イル)ベンズアミド;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル)[(ピラジン-2-イルシクロブチル)メチル]アミン;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)[(ピラジン-2-イルシクロブチル)メチル]アミン;
アミノ-N-{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼン-1,3-ジカルボン酸;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼン-1,3-ジカルボキサミド;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼンカルボキサミジン;
3-[6-({[1-アセチル-3-(3-フルオロ(2-ピリジル))アゼチジン-3-イル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
1-アセチル-3-(3-フルオロ(2-ピリジル))-3-{[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}アゼチジン;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[3-(3-フルオロ(2-ピリジル))アゼチジン-3-イル]メチル}アミン;
3-[6-({[3-(3-フルオロ-2-ピリジル)アゼチジン-3-イル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
3-(3-フルオロ(2-ピリジル))-3-{[(6-(1H-インダゾール-5-イル)ピリダジン-3-イル)アミノ]メチル}-1-(メチルスルホニル)アゼチジン;
3-[6-({[3-(3-フルオロ(2-ピリジル))-1-(メチルスルホニル)アゼチジン-3-イル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[3-(3-フルオロ(2-ピリジル))アゼチジン-3-イル]メチル}(メチルスルホニル)アミン;
アミノ{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1H-インダゾール-3-イル)}カルボキサミジン;
3-[6-({[3-(4-フルオロフェニル)オキセタン-3-イル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
{6-[3-(エチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
N-{4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾール-2-イル}アセトアミド;
[6-(2-アミノイミダゾール-4-イル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-{3-[(メチルエチル)アミノ](1H-インダゾール-5-イル)}ピリダジン-3-イル)アミン;
{6-[3-(エチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}[(2-ピリジルシクロブチル)メチル]アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[2-(トリフルオロメトキシ)フェニル]ピリダジン-3-イル}アミン;
{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}メタン-1-オール;
[6-(5-アミノ(2-ピリジル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(6-アミノ(3-ピリジル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(4-アミノ-3-フルオロフェニル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(6-ベンゾトリアゾール-6-イルピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドリン-2-オン;
(6-ベンゾイミダゾール-5-イルピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
N-{3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アセトアミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(4-モルホリン-4-イルフェニル)ピリダジン-3-イル]アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(2-メチルピリミジン-5-イル)ピリダジン-3-イル]アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-ピリミジン-2-イルピリダジン-3-イル)アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-ピラジン-2-イルピリダジン-3-イル)アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-フェニルピリダジン-3-イル)アミン;
N-{4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アセトアミド;
[6-(2-アミノピリミジン-5-イル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
N-{5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}アセトアミド;
N-{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}メトキシカルボキサミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(5-メトキシ(2-ピリジル))ピリダジン-3-イル]アミン;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリジン-3-オール;
{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}(メチルスルホニル)アミン;
[6-(2,3-ジフルオロフェニル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(3-フルオロ(2-ピリジル))ピリダジン-3-イル]アミン;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドリン-2-オン;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1H-2-ヒドロインダゾール-3-オン;
N-{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}(メチルアミノ)カルボキサミド;
N-{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}(メチルアミノ)カルボキサミド;
tert-ブチル4-{5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}ピペラジンカルボキシレート;
2-({5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}アミノ)アセトアミド;
{6-[2-(アミノメチル)-5-フルオロフェニル]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{6-[2-(アミノメチル)フェニル]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{6-[4-(アミノメチル)フェニル]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(2-ピペラジニルピリミジン-5-イル)ピリダジン-3-イル]アミン;
[6-(3-クロロ(2-ピリジル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(2-メチル(3-ピリジル))ピリダジン-3-イル]アミン;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリジン-2-カルボニトリル;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリジン-2-カルボキサミド;
メチル3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリジン-2-カルボキシレート;
2-{3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ピリジル}プロパン-2-オール;
アミノ-N-{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アミド;
2-アミノ-2-{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アセトアミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-ピリダジン-4-イルピリダジン-3-イル)アミン;
3-[6-({[3,3-ジフルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
(6-(1H-インダゾール-5-イル)ピリダジン-3-イル){[3,3-ジフルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-(メチルエチル)-1H-2-ヒドロインダゾール-3-オン;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-(メチルエチル)-1H-2-ヒドロインダゾール-3-オン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-(2-ピリジル)ピリダジン-3-イル)アミン;
{3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ピリジル}メタン-1-オール;
アミノ-N-{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](2-ピリジル)}アミド;
1-アミノ-1-{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-2-メチルプロパン-2-オール;
アミノ-N-{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}アミド;
(6-(1H-インダゾール-6-イル)ピリダジン-3-イル){[3,3-ジフルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(2-アミノ(3-ピリジル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(6-アミノ-5-フルオロ(3-ピリジル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドリン-2-オン;
アミノ-N-{4-[6-({[3,3-ジフルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アミド;
(6-シクロヘキサ-1-エニルピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(6-シクロヘキシルピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(2S,1R)-2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]シクロプロパンカルボキサミド;
アミノ-N-{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]シクロヘキシル}アミド;
アミノ-N-{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]シクロヘキシル}アミド;
アミノ-N-{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]シクロブチル}アミド;
アミノ-N-{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]シクロブチル}アミド;
アミノ-N-{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]シクロヘキサ-3-エニル}アミド;
フェニルメチル3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]アゼチジンカルボキシレート;
(6-アゼチジン-3-イルピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
メチル3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]アゼチジンカルボキシレート;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]アゼチジンカルボキサミド;
1-アセチル-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]アゼチジン;
エチル5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソオキサゾール-3-カルボキシレート;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソオキサゾール-3-カルボン酸;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソオキサゾール-3-カルボキサミド;
アミノ-N-{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1H-インダゾール-3-イル)}アミド;
4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-メチルイミダゾール-2-カルボキサミド;
4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシベンズアミド;
4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシベンズアミド;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシ安息香酸;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシ安息香酸;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-オキサゾール-2-カルボキサミド;
4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾール-2-カルボキサミド;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソオキサゾール-5-カルボキサミド;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピラゾール-5-カルボキサミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-メチルピラゾール-5-カルボキサミド;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-メチルピラゾール-3-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-オキサゾール-5-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-4-カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,2,4-オキサジアゾール-3-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-イミダゾリン-5-カルボキサミド;
メチル2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-イミダゾリン-5-カルボキシレート;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-イミダゾリン-5-カルボン酸;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-オキサゾール-4-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-カルボキサミド;
メチル2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-オキサゾール-4-カルボキシレート;
メチル2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-4-カルボキシレート;
メチル2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-オキサゾール-5-カルボキシレート;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾール-4-カルボキサミド;
メチル2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾール-4-カルボキシレート;
4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-2-カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-2-カルボキサミド;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,2,4-オキサジアゾール-5-カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4H-1,2,4-トリアゾール-3-カルボキサミド;
メチル2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-メチルイミダゾール-4-カルボキシレート;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-メチルイミダゾール-4-カルボキサミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1-メチルイミダゾール-5-カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]チオフェン-2-カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3,4-チアジアゾール-2-カルボキサミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-(1,3-チアゾール-2-イル)ピリダジン-3-イル)アミン;
(6-(2H-1,2,3,4-テトラアゾール-5-イル)ピリダジン-3-イル){[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3,4-オキサジアゾール-2-カルボキサミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-メチル-1,3-チアゾール-5-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-カルボン酸;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-カルボニトリル;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]チオフェン-2-カルボン酸;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシ-1,3-チアゾール-5-カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-3-ピラゾリノ[3,4-d]1,3-チアゾール-3-オン;
{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メタン-1-オール;
[6-(5-(2H-1,2,3,4-テトラアゾール-5-イル)(1,3-チアゾール-2-イル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
5-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}-1,3,4-オキサジアゾリン-2-オン;
エチル3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-ヒドロキシピラゾール-4-カルボキシレート;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-3-ピラゾリン-5-オン;
3-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}-1,2,4-トリアゾリン-5-オン;
3-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}-1,2,4-オキサジアゾリン-5-オン;
エチル2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシ-1,3-チアゾール-5-カルボキシレート;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-メトキシ-1,3-チアゾール-5-カルボキサミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-メトキシ-1,3-チアゾール-5-カルボン酸;
1-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}エタン-1-オール;
2,2,2-トリフルオロ-1-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}エタン-1-オール;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-(メチルエチル)カルボキサミド;
エチル2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-4-カルボキシレート;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-3-ピロリノ[3,4-d]1,3-チアゾール-6-オン;
1-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}エタン-1-オン;
2-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}プロパン-2-オール;
1,1,1-トリフルオロ-2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}プロパン-2-オール;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-メチルカルボキサミド;
3-(6-{[(2-ピリジルシクロブチル)メチル]アミノ}ピリダジン-3-イル)ベンゼンカルボニトリル;
3-(6-{メチル[(2-ピリジルシクロブチル)メチル]アミノ}ピリダジン-3-イル)ベンズアミド;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピラジン-2-カルボニトリル;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピラジン-2-カルボキサミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシ-1,3-チアゾール-5-カルボニトリル;
2-(6-{[(2-ピリジルシクロブチル)メチル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-カルボキサミド;
2-(6-{[(2-ピリジルシクロブチル)メチル]アミノ}ピリダジン-3-イル)-1,3-チアゾール-5-カルボン酸;
3-{5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-チエニル}-1,2,4-トリアゾリン-5-オン;
3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,2,4-トリアゾリン-5-オン;
アミノ{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メタン-1-チオン;
2,2,2-トリフルオロ-1-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}エタン-1,1-ジオール;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[5-(2,2,2-トリフルオロエチル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}アミン;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]チオフェン-2-カルボニトリル;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]チオフェノ[2,3-c]3-ピロリン-6-オン;
{6-[5-(1-アミノ-2,2,2-トリフルオロエチル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(2-アミノピリミジン-4-イル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
2-{5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,2,3,4-テトラアゾール-2-イル}アセトアミド;
{6-[2-(2-アミノエチル)(1,2,3,4-テトラアゾール-5-イル)]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[6-(3-(2H-1,2,3,4-テトラアゾール-5-イル)フェニル)ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
3-{3-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-1,2,4-トリアゾリン-5-オン;
3-{4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-1,2,4-トリアゾリン-5-オン;
{6-[5-(アミノメチル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
N-((2-(6-((1-(3-フルオロピリジン-2-イル)シクロブチル)メチルアミノ)ピリダジン-3-イル)チアゾール-5-イル)メチル)-2-メチルプロパン-2-スルフィンアミド;
{6-[5-(アミノエチル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{6-[5-(3-アミノオキセタン-3-イル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-4-カルボキサミド;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-(2-ヒドロキシエチル)カルボキサミド;
エチル5-クロロ-2-[5-クロロ-6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-4-カルボキシレート;
N-{4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}アセトアミド;
{4-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-イル}(メチルスルホニル)アミン;
(2E)-3-アミノ-3-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-2-アザプロパ-2-エンニトリル;
N-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)アセトアミド;
({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)(メチルスルホニル)アミン;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)メトキシカルボキサミド;
2,2-ジフルオロ-1-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}エタン-1-オール;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)モルホリン-4-イルケトン;
N-(2-アミノエチル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
N-(2,3-ジヒドロキシプロピル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-ピロリジン-3-イルカルボキサミド;
2-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}アセトアミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(5-ピラゾール-4-イル(1,3-チアゾール-2-イル))ピリダジン-3-イル]アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(5-ピラゾール-3-イル(1,3-チアゾール-2-イル))ピリダジン-3-イル]アミン;
4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-2-カルボキサミド;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]ピリミジン-4-カルボキサミド;
N-(カルバモイルメチル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
4-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}カルボニル)ピペラジン-2-カルボキサミド;
[6-(5-クロロ(1,3-チアゾリノ[5,4-b]ピリジン-2-イル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-(1,3-チアゾリノ[5,4-b]ピリジン-2-イル)ピリダジン-3-イル)アミン;
[6-(5-アミノ(1,3-チアゾリノ[5,4-b]ピリジン-2-イル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
アミノ{4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}スルホンアミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)3-ヒドロキシピロリジニルケトン;
4-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}カルボニル)-1,4-チアザペルヒドロイン-1,1-ジオン;
N-(1,1-ジオキソチオラン-3-イル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-[2-(メチルスルホニル)エチル]カルボキサミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)3-ヒドロキシピペリジルケトン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-ピラゾロ[5,4-d]1,3-チアゾール-5-イルピリダジン-3-イル)アミン;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)4-ヒドロキシピペリジルケトン;
4-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}カルボニル)ピペラジン-2-オン;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-(オキソラン-2-イルメチル)カルボキサミド;
1-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}カルボニル)ピペリジン-3-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾリノ[5,4-b]ピリジン-5-カルボキサミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(5-メトキシ(1,3-チアゾリノ[5,4-b]ピリジン-2-イル))ピリダジン-3-イル]アミン;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾリノ[5,4-b]ピリジン-5-オール;
N-((2R)-2,3-ジヒドロキシプロピル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
N-((2S)-2,3-ジヒドロキシプロピル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
N-(2-アミノ-3,3,3-トリフルオロプロピル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
N-(3-アミノ-2,2-ジフルオロプロピル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N,N-ジメチルカルボキサミド;
N-(2,2-ジフルオロ-3-ヒドロキシプロピル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-(2-オキソピロリジン-3-イル)カルボキサミド;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)アセトアミド;
((2S)ピロリジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
((2R)ピロリジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-(3-ピロリノ[3,4-d]1,3-チアゾール-2-イル)ピリダジン-3-イル)アミン;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-(メチルスルホニル)-3-ピロリノ[3,4-d]1,3-チアゾール;
2-[({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)アミノ]アセトアミド;
((2S)-5-オキソピロリジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-ヒドロキシ-2-メチルプロパンアミド;
N-((3S)ピロリジン-3-イル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
N-((3R)ピロリジン-3-イル){2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}カルボキサミド;
((3S)モルホリン-3-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)ピラゾール-5-イルカルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)イミダゾール-2-イルカルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)ピラゾール-4-イルカルボキサミド;
((4S)-2-オキソイミダゾリジン-4-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
((3S)-6-オキソ(3-ピペリジル))-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
2H-1,2,3-トリアゾール-4-イル-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
(2S)-2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-3-ヒドロキシプロパンアミド;
(2R)-2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-3-ヒドロキシプロパンアミド;
((2S)-4-アセチルピペラジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
[(2S)-4-(メチルスルホニル)ピペラジン-2-イル]-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
((3S)モルホリン-3-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
1H-1,2,4-トリアゾール-5-イル-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
((2R)-6-オキソ(2-ピペリジル))-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)イミダゾール-5-イルカルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)(2-ヒドロキシイミダゾール-5-イル)カルボキサミド;
((3R)-1,1-ジオキソ(1,4-チアザペルヒドロイン-3-イル))-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
((2S)-4,4-ジフルオロピロリジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
tert-ブチル(2S)-4,4-ジフルオロ-2-[N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルバモイル]ピロリジンカルボキシレート;
((2S)-4,4-ジフルオロ-1-ホルミルピロリジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
((2R,4R)-4-フルオロピロリジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-メチルプロパンアミド;
アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)アミド;
((3S)-1,1-ジオキソ(1,4-チアザペルヒドロイン-3-イル))-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
N-({2-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)アセトアミド;
N-({2-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)アセトアミド;
4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼンカルボニトリル;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシベンズアミド;
4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]安息香酸;
N-((2R)-2,3-ジヒドロキシプロピル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-((3R)ピロリジン-3-イル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-((3S)ピロリジン-3-イル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
[6-(3-(2H-1,2,3,4-テトラアゾール-5-イル)フェニル)ピリダジン-3-イル]{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-スルホンアミド;
(アミノシクロプロピル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
(N-{1-[N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルバモイル]-イソプロピル}カルバモイルオキシ)エチル2-メチルプロパノエート;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]安息香酸;
3-(6-{[(3-フルオロ-1-(2-ピリジル)シクロブチル)メチル]アミノ}ピリダジン-3-イル)安息香酸;
3-(6-{[(3-フルオロ-1-(2-ピリジル)シクロブチル)メチル]アミノ}ピリダジン-3-イル)安息香酸;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼンカルボニトリル;
N-((2S)-2,3-ジヒドロキシプロピル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
メチル4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゾエート;
{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチルカルボキサミド;
{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(メチルエチル)カルボキサミド;
メチル3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゾエート;
メチルエチル4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゾエート;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾ[2,1-b]1,3-チアゾリン-3-カルボキサミド;
6-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾ[2,1-b]1,3-チアゾリン-3-カルボン酸;
6-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]イミダゾ[2,1-b]1,3-チアゾリン-3-カルボキサミド;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼンスルホンアミド;
{5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1H-インダゾール-3-イル)}(メチルスルホニル)アミン;
{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[3-(メチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}アミン;
{6-[3-(エチルアミノ)(1H-インダゾール-5-イル)]ピリダジン-3-イル}{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
エチル2-フルオロ-5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゾエート;
2-フルオロ-5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]安息香酸;
2-{4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アセトアミド;
メチル2-{4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}アセテート;
N-({4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}メチル)アセトアミド;
N-({3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}メチル)アセトアミド;
{2-フルオロ-5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチルカルボキサミド;
N-エチル{2-フルオロ-5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
メチル5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-(メチルアミノ)ベンゾエート;
エチル5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-(メチルアミノ)ベンゾエート;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}メタン-1-オール;
((2S)アゼチジン-2-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
エチル2-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-4-イル}アセテート;
2-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-4-イル}アセトアミド;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-2-メチルプロパンニトリル;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-2-メチルプロパンアミド;
3-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}プロパンアミド;
3-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}プロパン酸;
メチル3-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}プロパノエート;
2-アミノ-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-メチル-N-メチルプロパンアミド;
2-{2-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}アセトアミド;
2-{2-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}酢酸;
(3-アミノオキセタン-3-イル)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)カルボキサミド;
{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチルカルボキサミド;
{4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチルカルボキサミド;
N-({5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-2-イル}メチル)アセトアミド;
N-({4-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-2-イル}メチル)アセトアミド;
2-{2-[6-({[1-(3-クロロ(2-ピリジル))-3-フルオロシクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}アセトアミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチルカルボキサミド;
2-{2-[6-({[(3-クロロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}アセトアミド;
2-{2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}酢酸;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-メチルアセトアミド;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N,N-ジメチルアセトアミド;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-メチル-2-(メチルアミノ)プロパンアミド;
N-エチル{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-(2-フルオロエチル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-(2,2-ジフルオロエチル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(2,2,2-トリフルオロエチル)カルボキサミド;
{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N,N-ジメチルカルボキサミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシ安息香酸;
{3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシフェニル}-N-メチルカルボキサミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシベンズアミド;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシピリジン-3-カルボニトリル;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシピリジン-3-カルボキサミド;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-オキソヒドロピリジン-3-カルボン酸;
5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-オキソヒドロピリジン-3-カルボキサミド;
5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシ安息香酸;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-[2-ヒドロキシ-1-(ヒドロキシメチル)エチル]カルボキサミド;
{5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシフェニル}-N-メチルカルボキサミド;
5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロキシフェニル}-N-メチルカルボキサミド;
{5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](2-チエニル)}-N-メチルカルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4,5,6-トリヒドロシクロペンタ[1,2-d]1,3-チアゾール-4-カルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4,5,6-トリヒドロシクロペンタ[1,2-d]1,3-チアゾール-4-カルボン酸;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-(4,5,6,7-テトラヒドロ-1,3-チアゾロ[5,4-c]ピリジン-2-イル)ピリダジン-3-イル)アミン;
N-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](4,5,6-トリヒドロシクロペンタ[2,3-d]1,3-チアゾール-4-イル)}メトキシカルボキサミド;
2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4,5,6,7-テトラヒドロ-1,3-チアゾロ[5,4-c]ピリジン-5-カルボキサミド;
5-アセチル-2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4,5,6,7-テトラヒドロ-1,3-チアゾロ[5,4-c]ピリジン;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-(メチルスルホニル)-4,5,6,7-テトラヒドロ-1,3-チアゾロ[5,4-c]ピリジン;
{5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシフェニル}-N,N-ジメチルカルボキサミド;
4-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソインドリン-1-オン;
5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソインドリン-1-オン;
6-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]イソインドリン-1-オン;
[6-(6-アミノ(4,5,6,7-テトラヒドロベンゾチアゾール-2-イル))ピリダジン-3-イル]{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
アミノ-N-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](4,5,6,7-テトラヒドロベンゾチアゾール-6-イル)}アミド;
N-{3-フルオロ-4-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}(メチルアミノ)カルボキサミド;
N-{4-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-メチル(メチルアミノ)カルボキサミド;
2-{2-[6-({[1-(3-クロロ(2-ピリジル))-3-フルオロシクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-メチルアセトアミド;
N-{4-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}(メチルアミノ)カルボキサミド;
2-{2-[6-({[(3-クロロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-メチルアセトアミド;
N-シクロプロピル{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
5-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-8-ヒドロ-3-ピラゾリノ[1,5-a]ピリミジン-7-オン;
7-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-ヒドロ-4-イミダゾリノ[1,2-a]ピリミジン-5-オン;
{4-フルオロ-5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシフェニル}-N-メチルカルボキサミド;
4-フルオロ-5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4-メチル-3-ピラゾリン-5-オン;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-4,4-ジメチル-2-ピラゾリン-5-オン;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]ベンゼンカルボニトリル;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]ベンズアミド;
N-シクロブチル{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]ベンズアミド;
N-(3,3-ジフルオロシクロブチル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]-1,3-チアゾール-5-カルボキサミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-5-メチルピリダジン-3-イル]ベンズアミド;
N-シクロプロピル{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
[6-(2-アミノピリミジン-5-イル)ピリダジン-3-イル]{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
N-アゼチジン-3-イル{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-(1-アセチルアゼチジン-3-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-[1-(メチルスルホニル)アゼチジン-3-イル]カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(2-ヒドロキシ-2-メチルプロピル)カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(1-メチルアゼチジン-3-イル)カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-オキセタン-3-イルカルボキサミド;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]-1,3-チアゾール-5-イル}酢酸;
{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]-1,3-チアゾール-5-イル}メタン-1-オール;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル](1,3-チアゾール-5-イル)}-N-メチルアセトアミド;
2-{2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)-4-メチルピリダジン-3-イル]-1,3-チアゾール-5-イル}アセトアミド;
{4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(1-メチルアゼチジン-3-イル)カルボキサミド;
N-(1-アセチルアゼチジン-3-イル){4-フルオロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(3-ヒドロキシシクロブチル)カルボキサミド;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[5-(ピペラジニルメチル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[5-(モルホリン-4-イルメチル)(1,3-チアゾール-2-イル)]ピリダジン-3-イル}アミン;
4-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)-1,4-チアザペルヒドロイン-1,1-ジオン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}(6-{5-[(4-メチルピペラジニル)メチル](1,3-チアゾール-2-イル)}ピリダジン-3-イル)アミン;
{[(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(5-{[4-(2,2,2-トリフルオロエチル)ピペラジニル]メチル}(1,3-チアゾール-2-イル))ピリダジン-3-イル]アミン;
1-アセチル-4-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)ピペラジン;
1-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-4-(メチルスルホニル)ピペラジン;
[(2S)-1-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)ピペラジン-2-イル]メタン-1-オール;
[(2R)-1-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)ピペラジン-2-イル]メタン-1-オール;
N-(2H-3,4,5,6-テトラヒドロピラン-4-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-(3-ヒドロキシ-3-メチルシクロブチル)カルボキサミド;
N-((3S)オキソラン-3-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-((3R)オキソラン-3-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-((3S,4S)-4-ヒドロキシ-1,1-ジオキソチオラン-3-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
N-(1,1-ジオキソチオラン-3-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
5-アミノ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンゼンカルボニトリル;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-(トリフルオロメチル)ベンズアミド;
5-クロロ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-ヒドロキシベンズアミド;
5-アミノ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]ベンズアミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシフェニル}-N-メチルカルボキサミド;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンゼンカルボニトリル;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシベンゼンカルボニトリル;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシ安息香酸;
5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシベンズアミド;
N-(1,1-ジオキソチエタン-3-イル){3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}カルボキサミド;
4-フルオロ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
4-フルオロ-5-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンズアミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]フェニル}-N-[(ヒドロキシシクロプロピル)メチル]カルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-メチルフェニル}-N-メチルカルボキサミド;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-5-メチルベンズアミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシ-5-メチルベンズアミド;
3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシ-5-メチルベンゼンカルボニトリル;
5-ブロモ-3-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシベンゼンカルボニトリル;
3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-メトキシベンズアミド;
{5-ブロモ-3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシフェニル}-N-メチルカルボキサミド;
{3-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]-2-ヒドロキシ-5-メチルフェニル}-N-メチルカルボキサミド;
メチル5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドール-2-カルボキシレート;
5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドール-2-カルボキサミド;
5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドール-2-カルボン酸;
{5-[6-({[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル]インドール-2-イル}-N-メチルカルボキサミド;
[6-(6-アミノ(3-ピリジル))ピリダジン-3-イル]{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}{6-[6-(メチルアミノ)(3-ピリジル)]ピリダジン-3-イル}アミン;
{6-[6-(シクロプロピルアミノ)(3-ピリジル)]ピリダジン-3-イル}{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
{6-[6-アミノ-5-(トリフルオロメチル)(3-ピリジル)]ピリダジン-3-イル}{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
[N-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)カルバモイル]メチルアセテート;
[N-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)カルバモイル]メチル(2S)-2-アミノ-3-メチルブタノエート;
[N-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)カルバモイル]メチル(2S)-2-アミノプロパノエート;
{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}[6-(6-メトキシ-5-メチル(3-ピリジル))ピリダジン-3-イル]アミン;
[6-(6-アミノ-5-メチル(3-ピリジル))ピリダジン-3-イル]{[3-フルオロ-1-(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミン;
(2S)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-ヒドロキシプロパンアミド;
(2R)-N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-ヒドロキシプロパンアミド;
2-[({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)アミノ]エタン-1-オール;
N-({2-[6-({[(3-フルオロ(2-ピリジル))シクロブチル]メチル}アミノ)ピリダジン-3-イル](1,3-チアゾール-5-イル)}メチル)-2-ヒドロキシ-N-メチルアセトアミド;
[N-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)カルバモイル]メチル(2S)-2-((2S)-2-アミノプロパノイルアミノ)プロパノエート;及び
[N-({2-[6-({[(3-フルオロ-2-ピリジル)シクロブチル]メチル}アミノ)ピリダジン-3-イル]-1,3-チアゾール-5-イル}メチル)カルバモイル]メチル(2S)-2-((2S)-2-アミノ-3-メチルブタノイルアミノ)-3-メチルブタノエート。 - 請求項1〜53のいずれか一項に記載の化合物、又は薬学的に許容されるその塩を含む医薬組成物。
- 経口、舌下、皮下、非経口、静脈内、鼻腔内、局所的、経皮的、腹腔内、筋肉内、肺内、経膣、直腸、又は眼内の投与用に製剤化されている、請求項54に記載の医薬組成物。
- 経口投与用に製剤化されている、請求項54に記載の医薬組成物。
- 神経筋障害、筋肉消耗状態、筋肉ミオパシー、リハビリテーション関連の欠損、末梢血管疾患、末梢動脈疾患、虚弱、筋萎縮及び疲労、メタボリックシンドローム、慢性疲労症候群並びに肥満から選択される疾患又は状態の治療用の医薬の調製のための、請求項1〜53のいずれか一項に記載の化合物、又は薬学的に許容されるその塩の使用。
- 筋萎縮性側索硬化症(ALS)、脊髄性筋萎縮症(SMA)及び重症筋無力症から選択される疾患の治療用の医薬の調製のための、請求項1〜53のいずれか一項に記載の化合物、又は薬学的に許容されるその塩の使用。
- 末梢血管疾患及び末梢動脈疾患から選択される疾患の治療用の医薬の調製のための、請求項1〜53のいずれか一項に記載の化合物、又は薬学的に許容されるその塩の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32753810P | 2010-04-23 | 2010-04-23 | |
US61/327,538 | 2010-04-23 | ||
US41230210P | 2010-11-10 | 2010-11-10 | |
US61/412,302 | 2010-11-10 | ||
PCT/US2011/033605 WO2011133882A1 (en) | 2010-04-23 | 2011-04-22 | Certain amino-pyridazines, compositions thereof, and methods of their use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016076999A Division JP6470224B2 (ja) | 2010-04-23 | 2016-04-07 | 特定のアミノピリダジン、その組成物、及びこれらの使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013525376A JP2013525376A (ja) | 2013-06-20 |
JP5918217B2 true JP5918217B2 (ja) | 2016-05-18 |
Family
ID=44834527
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013506327A Active JP5918217B2 (ja) | 2010-04-23 | 2011-04-22 | 特定のアミノピリダジン、その組成物、及びこれらの使用方法 |
JP2016076999A Active JP6470224B2 (ja) | 2010-04-23 | 2016-04-07 | 特定のアミノピリダジン、その組成物、及びこれらの使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016076999A Active JP6470224B2 (ja) | 2010-04-23 | 2016-04-07 | 特定のアミノピリダジン、その組成物、及びこれらの使用方法 |
Country Status (22)
Country | Link |
---|---|
US (3) | US8969346B2 (ja) |
EP (2) | EP3127541B1 (ja) |
JP (2) | JP5918217B2 (ja) |
KR (2) | KR101960642B1 (ja) |
CN (2) | CN103002897B (ja) |
AR (1) | AR081626A1 (ja) |
AU (3) | AU2011242569B2 (ja) |
BR (1) | BR112012026950B1 (ja) |
CA (1) | CA2796390C (ja) |
CL (1) | CL2012002945A1 (ja) |
CO (1) | CO6630154A2 (ja) |
EA (1) | EA024881B1 (ja) |
EC (1) | ECSP12012292A (ja) |
HK (1) | HK1181662A1 (ja) |
IL (2) | IL222465A (ja) |
MX (1) | MX343264B (ja) |
MY (1) | MY191829A (ja) |
NZ (2) | NZ603593A (ja) |
PH (1) | PH12017501192B1 (ja) |
SG (2) | SG184954A1 (ja) |
TW (1) | TWI501963B (ja) |
WO (1) | WO2011133882A1 (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
EP2585455B1 (en) | 2010-06-24 | 2019-08-07 | The Regents of the University of California | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms |
GB2497476B (en) * | 2010-09-06 | 2018-01-10 | Guangzhou Inst Biomed & Health | Amide Compounds |
BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
EP3243815B1 (en) * | 2011-10-28 | 2019-07-10 | Inhibitaxin Limited | Pyridazine derivatives useful in therapy |
EA201491060A1 (ru) * | 2011-11-28 | 2014-09-30 | Новартис Аг | Новые производные трифторметилоксадиазола и их применение для лечения заболевания |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
CA2868507A1 (en) * | 2012-04-02 | 2013-10-10 | Cytokinetics, Inc. | Methods for improving diaphragm function |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
EP2970240B1 (en) | 2013-03-14 | 2018-01-10 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
US20160184305A1 (en) | 2013-07-31 | 2016-06-30 | Novartis Ag | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating smn-deficiency-related conditions |
CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
WO2015157005A1 (en) | 2014-04-10 | 2015-10-15 | E I Du Pont De Nemours And Company | Substituted tolyl fungicide mixtures |
DK3137622T3 (da) | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
AU2015338946B2 (en) | 2014-10-31 | 2020-06-11 | The General Hospital Corporation | Potent gamma-secretase modulators |
KR101720851B1 (ko) * | 2015-01-29 | 2017-03-28 | 포항공과대학교 산학협력단 | 세포의 지질막에서 유래된 나노소포체 및 이의 용도 |
KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
HUE058820T2 (hu) | 2016-02-12 | 2022-09-28 | Cytokinetics Inc | Tetrahidroizokinolin származékok |
SG11201811161YA (en) | 2016-07-14 | 2019-01-30 | Pfizer | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme |
KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
SG10202002990XA (en) | 2017-08-04 | 2020-05-28 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
WO2019074749A1 (en) * | 2017-10-09 | 2019-04-18 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED CYCLOBUTYLPYRIMIDINE AND CYCLOBUTYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) |
US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CA3087051A1 (en) * | 2017-12-26 | 2019-07-04 | Cytokinetics, Incorporated | Process for the preparation of an amino-pyrimidine and intermediates thereof |
AU2019205944A1 (en) | 2018-01-05 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
JP2021518413A (ja) | 2018-03-20 | 2021-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | キナーゼ阻害剤化合物及び組成物ならびに使用方法 |
BR112021008905A2 (pt) * | 2018-11-06 | 2021-08-10 | Edgewise Therapeutics, Inc. | compostos de piridazinona e usos dos mesmos |
AR116978A1 (es) | 2018-11-06 | 2021-06-30 | Fmc Corp | Fungicidas de tolilo sustituido |
EP3877367A1 (en) | 2018-11-06 | 2021-09-15 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
MX2021005348A (es) | 2018-11-06 | 2021-08-11 | Edgewise Therapeutics Inc | Compuestos de piridazinonas y usos de los mismos. |
US20220064146A1 (en) * | 2018-12-31 | 2022-03-03 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
WO2021007477A1 (en) | 2019-07-11 | 2021-01-14 | E-Scape Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
WO2021071981A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
WO2021071983A1 (en) * | 2019-10-08 | 2021-04-15 | Skyhawk Therapeutics, Inc. | Compounds for modulating splicing |
UY39189A (es) | 2020-05-06 | 2021-12-31 | Fmc Corp | Fungicidas de tolilo sustituido y sus mezclas |
EP4274824A1 (en) * | 2021-01-08 | 2023-11-15 | IFM Due, Inc. | Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity |
CN112772662B (zh) * | 2021-01-13 | 2022-02-15 | 南方科技大学 | 小分子化合物在促进植物生长发育中的应用 |
KR20220150625A (ko) | 2021-05-04 | 2022-11-11 | 주식회사 엘지화학 | 함질소헤테로고리 화합물의 제조방법, 함질소헤테로고리 화합물, 및 이를 포함하는 의약품 또는 농업용품 |
CN116410140A (zh) * | 2022-01-07 | 2023-07-11 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
GB202206054D0 (en) * | 2022-04-26 | 2022-06-08 | Cerevance Ltd | Novel Compounds |
WO2024006956A2 (en) * | 2022-06-30 | 2024-01-04 | Dana-Farber Cancer Institute, Inc. | Deubiquitinase inhibitors and methods of use thereof |
WO2024064745A1 (en) | 2022-09-21 | 2024-03-28 | Cytokinetics, Incorporated | Synthesis of reldesemtiv |
Family Cites Families (256)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH361573A (de) | 1957-07-12 | 1962-04-30 | Cilag Chemie Aktiengesellschaf | Verfahren zur Herstellung neuer 5-Aminomethyl-pyrimidine |
US3239345A (en) | 1965-02-15 | 1966-03-08 | Estrogenic compounds and animal growth promoters | |
NL155156B (nl) * | 1968-07-11 | 1977-11-15 | Philips Nv | Schakelinrichting voor het in een televisieweergeefinrichting opwekken van een beeldregelfrequente zaagtandvormige stroom met een rasterfrequent varierende amplitude. |
US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
GB1345880A (en) * | 1971-06-18 | 1974-02-06 | Cepbepe | Pyridazine derivatives |
US4036979A (en) | 1974-01-25 | 1977-07-19 | American Cyanamid Company | Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate |
US4157392A (en) | 1977-05-17 | 1979-06-05 | Diamond Shamrock Corporation | Pharmacologically active substituted 1,2,4-triazines |
HU175471B (hu) * | 1977-06-13 | 1980-08-28 | Gyogyszerkutato Intezet | Sposob poluchenija novykh proizvodnykh 3-skobka-1-pirazolil-skobka zakryta-piridazina |
DE2730467A1 (de) | 1977-07-06 | 1979-01-18 | Basf Ag | Benzylpyrimidine, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
FR2510997A1 (fr) * | 1981-08-10 | 1983-02-11 | Sanofi Sa | Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant |
FR2540115B1 (fr) | 1983-01-28 | 1985-06-07 | Sanofi Sa | Derive de la pyridazine ayant une action psychotrope, son mode de preparation et les medicaments en contenant |
US4565814A (en) | 1983-01-28 | 1986-01-21 | Sanofi | Pyridazine derivatives having a psychotropic action and compositions |
EP0254259A3 (en) | 1986-07-21 | 1989-11-23 | Otsuka Pharmaceutical Factory, Inc. | P-aminophenol derivatives |
JPS63165376A (ja) | 1986-12-27 | 1988-07-08 | Nippon Soda Co Ltd | オキサ(チア)ジアゾ−ル誘導体その製造方法及び殺ダニ剤 |
CN1027537C (zh) | 1987-06-25 | 1995-02-01 | 伊莱利利公司 | 制备除草和杀虫的尿素类的新方法 |
JPH03502329A (ja) | 1988-01-28 | 1991-05-30 | ポリゲン ホールディング コーポレイション | 成長ホルモン放出活性を有するポリペプチド化合物類 |
AU628322B2 (en) | 1988-01-28 | 1992-09-17 | Eastman Kodak Company | Polypeptide compounds having growth hormone releasing activity |
JPH01261381A (ja) | 1988-04-12 | 1989-10-18 | Nippon Soda Co Ltd | オキサ(チア)ジアゾール誘導体、その製造方法及び殺ダニ剤 |
FR2636628B1 (fr) | 1988-08-25 | 1990-12-28 | Sanofi Sa | Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant |
JPH02164863A (ja) | 1988-12-15 | 1990-06-25 | Otsuka Pharmaceut Co Ltd | p−アミノフェノール誘導体の製造方法 |
US5631255A (en) | 1989-02-07 | 1997-05-20 | Sanofi | Pyridazine derivatives |
FR2663326B2 (fr) * | 1989-11-17 | 1992-10-16 | Sanofi Sa | Derives de la pyridazine, procede de preparation et compositions pharmaceutiques en contenant. |
US5461053A (en) * | 1989-02-07 | 1995-10-24 | Sanofi | Pyridazine derivatives |
GR900100380A (el) | 1989-05-20 | 1991-10-10 | Fisons Plc | Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης. |
IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
GB9008123D0 (en) | 1990-04-10 | 1990-06-06 | Lilly Industries Ltd | Pharmaceutical compounds |
US5208248A (en) | 1991-01-11 | 1993-05-04 | Merck Sharpe & Dohme, Ltd. | Indazole-substituted five-membered heteroaromatic compounds |
US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
JP2651755B2 (ja) | 1991-03-01 | 1997-09-10 | 富士写真フイルム株式会社 | ハロゲン化銀カラー写真感光材料 |
WO1992016527A1 (en) | 1991-03-22 | 1992-10-01 | Nippon Soda Co., Ltd. | 2-substituted pyridine derivative, production thereof, and agrohorticultural bactericide |
US5114958A (en) | 1991-05-09 | 1992-05-19 | Warner-Lambert Company | 1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents |
FR2676444B1 (fr) | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
JPH06509574A (ja) | 1991-08-03 | 1994-10-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht↓4レセプターアンタゴニスト |
US5663146A (en) | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
JPH05117255A (ja) | 1991-10-25 | 1993-05-14 | Nippon Soda Co Ltd | オキサジアゾール及びチアジアゾール誘導体、その製法 |
JPH07500116A (ja) | 1992-03-26 | 1995-01-05 | ダウエランコ | 殺菌剤としてのn−複素環式ニトロアニリン |
US5654322A (en) | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
WO1994028898A1 (en) | 1993-06-15 | 1994-12-22 | Pfizer Inc. | H2-antagonists as immune stimulants in bacterial infections of cattle or swine |
ZW8594A1 (en) | 1993-08-11 | 1994-10-12 | Bayer Ag | Substituted azadioxacycbalkenes |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
DE4424788A1 (de) | 1993-12-22 | 1995-06-29 | Bayer Ag | Arylessigsäurederivate |
US6008257A (en) | 1994-01-28 | 1999-12-28 | Bayer Aktiengesellschaft | Hydroxamic-acid derivatives, method of preparing them and their use as fungicides |
GB9405347D0 (en) | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
PT779884E (pt) | 1994-09-09 | 2000-10-31 | Bayer Ag | Derivados de imidoacidos e sua utilizacao como pesticidas |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US6096895A (en) | 1995-05-17 | 2000-08-01 | E. I. Du Pont De Nemours And Company | Heterocyclic dihydrazole compounds and their use for controlling fungal plant diseases |
TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
KR19990028230A (ko) | 1995-06-20 | 1999-04-15 | 미리암 디. 메코너헤이 | 살절지동물성 및 살진균성 시클릭 아미드 |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
US5834468A (en) | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
DE19525969A1 (de) | 1995-07-17 | 1997-01-23 | Bayer Ag | Etherderivate |
US20070173465A9 (en) | 1995-10-11 | 2007-07-26 | Monahan Sean D | Expression of zeta negative and zeta positive nucleic acids using a dystrophin gene |
CN1056370C (zh) | 1995-10-17 | 2000-09-13 | 化学工业部沈阳化工研究院 | 具有除草活性的4-芳氧(硫或氨)基嘧啶衍生物及其制备 |
EP0873361B1 (en) | 1995-12-13 | 2006-11-02 | The Regents Of The University Of California | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand |
US6114537A (en) | 1996-02-26 | 2000-09-05 | Apotex Inc. | Process for scavenging thiols |
US5854265A (en) | 1996-04-03 | 1998-12-29 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
CA2249639A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
EP0891357A1 (en) | 1996-04-03 | 1999-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2250204A1 (en) | 1996-04-03 | 1997-10-09 | Neville J. Anthony | Inhibitors of farnesyl-protein transferase |
JP2000507592A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5874452A (en) | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
TW414795B (en) | 1996-07-01 | 2000-12-11 | Yamanouchi Pharma Co Ltd | A thiophene derivative and the pharmaceutical composition |
BR9711816A (pt) | 1996-08-01 | 1999-08-31 | Du Pont | Composto, composição fungicida, método para controlar doenças de plantas causadas pelos agentes patogênicos f·ngicos de plantas, composição artropodicida e método para controlar artrópodes. |
WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
HRP980093A2 (en) | 1997-02-28 | 1998-12-31 | Lilly Co Eli | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds |
DE19725450A1 (de) | 1997-06-16 | 1998-12-17 | Hoechst Schering Agrevo Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
US6699853B2 (en) | 1997-06-16 | 2004-03-02 | Hoechst Schering Agrevo Gmbh | 4-haloalkyl-3-heterocyclylpyridines, 4-haloalkyl-5-heterocyclyl-pyrimidines and 4-trifluoromethyl-3-oxadiazolylpyridines, processes for their preparation, compositions comprising them, and their use as pesticides |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
GB9716446D0 (en) | 1997-08-05 | 1997-10-08 | Agrevo Uk Ltd | Fungicides |
WO1999042455A1 (en) | 1998-02-19 | 1999-08-26 | Tularik Inc. | Antiviral agents |
US6506782B1 (en) | 1998-02-27 | 2003-01-14 | Athena Neurosciences, Inc. | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
DE19824175A1 (de) | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
PL346247A1 (en) | 1998-08-18 | 2002-01-28 | Ucb Sa | Muscarinic agonists and antagonists |
WO2000024725A1 (en) | 1998-10-26 | 2000-05-04 | Vertex Pharmaceuticals Incorporated | Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase |
EP1126833A4 (en) | 1998-10-29 | 2004-09-08 | Trega Biosciences Inc | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES CONTAINING THESE DERIVATIVES |
US20040053900A1 (en) * | 1998-12-23 | 2004-03-18 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy |
GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
EP1394150B1 (en) | 1999-02-24 | 2011-01-19 | F. Hoffmann-La Roche AG | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
JP2000281579A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | オキサジアゾリル−1,4−ジヒドロピリジン誘導体を含有するプロテオグリカン生成促進剤 |
US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US7202051B1 (en) | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
US6743599B1 (en) | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
EP1206935A4 (en) | 1999-07-23 | 2008-07-30 | Shionogi & Co | TH2 DIFFERENTIAL INHIBITION |
AU6994600A (en) | 1999-08-12 | 2001-03-13 | Basf Aktiengesellschaft | Substituted benzoxazoles |
EP1078632A1 (en) * | 1999-08-16 | 2001-02-28 | Sanofi-Synthelabo | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
JP4144978B2 (ja) | 1999-09-09 | 2008-09-03 | 富士フイルム株式会社 | 1,2,4−チアジアゾール誘導体の合成法 |
US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
GB9927844D0 (en) | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
CA2388529A1 (en) | 1999-11-29 | 2001-06-07 | Pierre Ducray | Pesticidal n-heteroaryl alpha-alkoximino-carboxamides |
PT1254135E (pt) | 1999-12-02 | 2005-03-31 | Novartis Ag | Compostos organicos |
US6602872B1 (en) * | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
AU2010601A (en) | 1999-12-16 | 2001-07-03 | Novartis Ag | Organic compounds |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
US20020002171A1 (en) | 2000-01-28 | 2002-01-03 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
US7078536B2 (en) | 2001-03-14 | 2006-07-18 | Genesoft Pharmaceuticals, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
MXPA02009763A (es) | 2000-04-04 | 2003-03-27 | Shionogi & Co | Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa. |
AU2001244610A1 (en) | 2000-04-05 | 2001-10-23 | Shionogi And Co., Ltd. | Oil-in-water microemulsions containing tricyclic compounds or preconcentrates thereof |
CA2410393A1 (en) | 2000-06-23 | 2002-01-03 | Dupont Pharmaceuticals Company | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor xa inhibitors |
AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
PE20020384A1 (es) | 2000-07-21 | 2002-05-28 | Schering Corp | PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C |
EP1180512A1 (en) | 2000-08-04 | 2002-02-20 | Aventis Cropscience S.A. | Fungicidal phenylimine derivatives |
EP1178036A1 (en) | 2000-08-04 | 2002-02-06 | Aventis Cropscience S.A. | Fungicidal phenylimidate derivatives |
FR2812633A1 (fr) | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
EP1178035B1 (en) | 2000-08-04 | 2008-07-30 | Bayer CropScience S.A. | Fungicidal phenylimine derivatives |
AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
US6667326B1 (en) | 2000-11-16 | 2003-12-23 | Novartis Animal Health Us, Inc. | Pesticidal aminoheterocyclamide compounds |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
JP2002212169A (ja) | 2001-01-12 | 2002-07-31 | Sumitomo Pharmaceut Co Ltd | 5員複素芳香環化合物 |
EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
CA2435143A1 (en) | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Halogen compounds having thrombopoietin receptor agonism |
JP4175113B2 (ja) | 2001-03-14 | 2008-11-05 | 小野薬品工業株式会社 | Ep1アンタゴニストを有効成分として含有するうつ病の治療剤 |
US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
JP2002305083A (ja) | 2001-04-04 | 2002-10-18 | Mitsubishi Chemicals Corp | 有機電界発光素子 |
RU2003138074A (ru) | 2001-06-08 | 2005-02-20 | Цитови Инк. (US) | Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
US6825221B2 (en) | 2001-10-18 | 2004-11-30 | Allergan, Inc. | Arylsulfanyl and heteroarylsulfanyl derivatives for treating pain |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
AU2002354056A1 (en) | 2001-11-19 | 2003-06-10 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary frequency |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
US20040110757A1 (en) | 2002-03-21 | 2004-06-10 | Thomas Arrhenius | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
AU2003222648A1 (en) | 2002-05-13 | 2003-12-02 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
US7232616B2 (en) | 2002-06-13 | 2007-06-19 | Tsinghua University | Organic electroluminescent materials and devices made from such materials |
CA2489458A1 (en) | 2002-06-14 | 2003-12-24 | Altana Pharma Ag | Substituted diaminopyrimidines |
ES2373226T3 (es) | 2002-06-28 | 2012-02-01 | Astellas Pharma Inc. | Derivado de diaminopirimidincarboxamida. |
DK1539724T3 (da) | 2002-08-07 | 2008-02-11 | Neuraxon Inc | Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet |
IL166510A0 (en) | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
EP1537116B1 (en) | 2002-09-04 | 2010-06-02 | Schering Corporation | Pyrazolopyrimidines suitable for the treatment of cancer diseases |
AU2003266668A1 (en) | 2002-09-30 | 2004-04-23 | Banyu Pharmaceutical Co., Ltd. | 2-aminobenzimidazole derivative |
JP4688498B2 (ja) | 2002-11-04 | 2011-05-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体 |
BR0316191A (pt) | 2002-11-11 | 2005-09-27 | Bayer Healthcare Ag | Derivados de amino alcano de fenila ou heteroarila como antagonistas de receptor de ip |
CA2507699A1 (en) | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
US20040147561A1 (en) | 2002-12-27 | 2004-07-29 | Wenge Zhong | Pyrid-2-one derivatives and methods of use |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
CN100345853C (zh) * | 2003-01-24 | 2007-10-31 | 田边制药株式会社 | 吡唑并嘧啶化合物及其制备方法 |
TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
JP2006523184A (ja) | 2003-02-22 | 2006-10-12 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 液晶としてのシアノピリドン誘導体 |
US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
PL1635824T3 (pl) | 2003-06-03 | 2010-01-29 | Novartis Ag | 5-Członowe heterocykliczne inhibitory P-38 |
US20050004133A1 (en) | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
PT1354876E (pt) | 2003-06-13 | 2005-06-30 | Servier Lab | Novo processo de sintese do acido (2s,3as,7as)-per-hidroindole-2-carboxilico e dos seus esteres e aplicacao a sintese do perindopril |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
JP2007512230A (ja) | 2003-08-20 | 2007-05-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用な(4−アミノ−1,2,5−オキサジアゾール−4−イル)−ヘテロ芳香族化合物 |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
EP2609919A3 (en) | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
TWI316955B (en) | 2003-11-19 | 2009-11-11 | Chisso Corp | Photo-polymerization liquid composition,polymer or polymer co mposition and optical compensation device thereof |
WO2005051932A1 (ja) | 2003-11-28 | 2005-06-09 | Nippon Soda Co., Ltd. | アリール複素環誘導体および農園芸用殺菌剤および殺虫剤 |
GB0328295D0 (en) | 2003-12-05 | 2004-01-07 | Muscagen Ltd | Therapeutic compounds |
US20070191336A1 (en) | 2003-12-24 | 2007-08-16 | Flynn Daniel L | Anti-inflammatory medicaments |
US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
CN1918128B (zh) | 2004-02-13 | 2011-01-26 | 万有制药株式会社 | 稠环4-氧代-嘧啶衍生物 |
US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
AU2005225471B2 (en) | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
JPWO2005095364A1 (ja) | 2004-03-30 | 2008-02-21 | 第一三共株式会社 | フェノキシ酢酸誘導体及びそれを用いた医薬 |
EP1749827A4 (en) | 2004-03-30 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | ANTITUMOR AGENTS |
US7423147B2 (en) | 2004-03-31 | 2008-09-09 | Janssen Pharmaceutical, N.V. | Pyridine compounds as histamine H3 modulators |
AU2005231375A1 (en) | 2004-03-31 | 2005-10-20 | Janssen Pharmaceutica, N.V. | Non-imidazole heterocyclic compounds as histamine H3 receptor modulators |
CN101014597A (zh) | 2004-04-02 | 2007-08-08 | 沃泰克斯药物股份有限公司 | 可用作rock和其他蛋白激酶抑制剂的吖吲哚 |
US7439369B2 (en) | 2004-06-22 | 2008-10-21 | Loa Alamos National Security, Llc | Method and system for hydrogen evolution and storage |
CA2577061C (en) | 2004-08-23 | 2014-02-18 | Eli Lilly And Company | Histamine h3 receptor agents, preparation and therapeutic uses |
US7718801B2 (en) | 2004-08-31 | 2010-05-18 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazole derivative |
EP2592075B1 (en) * | 2004-11-02 | 2015-04-29 | Northwestern University | Pyridazine compounds for the treatment of inflammatory diseases |
EP1809290A2 (en) * | 2004-11-03 | 2007-07-25 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
JP2008520738A (ja) | 2004-11-22 | 2008-06-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピラジンおよびピラゾロピラジン |
ES2450566T3 (es) | 2004-11-30 | 2014-03-25 | Amgen Inc. | Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer |
US20070123572A1 (en) | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines |
CA2590939C (en) | 2004-12-17 | 2011-10-18 | Amgen Inc. | Aminopyrimidine compounds and methods of use |
JP2008526777A (ja) | 2005-01-05 | 2008-07-24 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ユビキチンリガーゼインヒビター |
ATE499370T1 (de) | 2005-01-19 | 2011-03-15 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3- aminderivate und verwandte verbindungen als p2y1- rezeptor-hemmer zur behandlung thromboembolischer erkrankungen |
WO2006081388A2 (en) * | 2005-01-25 | 2006-08-03 | Neurogen Corporation | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues |
ATE451363T1 (de) | 2005-01-26 | 2009-12-15 | Schering Corp | 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs |
AU2006210513C1 (en) | 2005-02-04 | 2012-10-25 | Senomyx, Inc. | Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
DE602006001515D1 (de) | 2005-02-16 | 2008-07-31 | Astrazeneca Ab | Chemische verbindungen |
JP2006274133A (ja) | 2005-03-30 | 2006-10-12 | Fuji Photo Film Co Ltd | 液晶組成物、位相差板及び楕円偏光板 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
MX2007015427A (es) | 2005-06-07 | 2008-04-16 | Pharmacopeia Inc | Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres. |
EP2233470B1 (en) | 2005-07-04 | 2011-12-07 | High Point Pharmaceuticals, LLC | Histamine H3 receptor antagonists |
WO2007012642A1 (de) | 2005-07-29 | 2007-02-01 | Basf Aktiengesellschaft | 7-amino-6-thiadiazolyl- und -oxadiazolyl- 1 , 2 , 4-triazolo [1 , 5 -a] pyrimidin- verbindungen und ihre verwendung zur bekämpfung von schadpilzen |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7345178B2 (en) | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
RU2008110949A (ru) | 2005-08-23 | 2009-09-27 | Айрм Ллк (Bm) | Соединения и композиции-иммуносупрессанты |
JP2007093919A (ja) | 2005-09-28 | 2007-04-12 | Fujifilm Corp | 光学ローパスフィルター、およびその製造方法 |
JP2007093918A (ja) | 2005-09-28 | 2007-04-12 | Fujifilm Corp | 光学ローパスフィルター、およびその製造方法 |
WO2007037010A1 (ja) | 2005-09-29 | 2007-04-05 | Daiichi Pharmaceutical Co., Ltd. | フェノキシ酢酸誘導体及びそれを用いた医薬 |
JP5243960B2 (ja) | 2005-10-21 | 2013-07-24 | ダウ アグロサイエンシィズ エルエルシー | 殺菌活性を有するチエノ−ピリミジン化合物 |
US7531482B2 (en) | 2005-10-21 | 2009-05-12 | Dow Agrosciences Llc | Thieno-pyrimidine compounds having fungicidal activity |
AU2006307953A1 (en) * | 2005-10-26 | 2007-05-03 | Boehringer Ingelheim International Gmbh | (Hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds |
DK2404919T3 (da) | 2005-11-08 | 2013-11-04 | Vertex Pharma | Heterocyclisk forbindelse, der er egnet som modulator af ATP-bindende kassettetransportører |
ES2700433T3 (es) | 2005-12-13 | 2019-02-15 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus |
US20070197505A1 (en) | 2005-12-15 | 2007-08-23 | Morgan Bradley P | Certain chemical entities, compositions and methods |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
WO2007076460A2 (en) | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
US7951803B2 (en) | 2006-03-09 | 2011-05-31 | Pharmacopeia, Llc | 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders |
JP5243696B2 (ja) * | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
SI2007752T1 (sl) | 2006-03-31 | 2010-12-31 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidini in pirazini kot modulatorji histamin H4 receptorja |
KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
AU2007240860A1 (en) | 2006-04-19 | 2007-11-01 | Merck Serono Sa | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors |
WO2007130383A2 (en) * | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
MX2008013511A (es) | 2006-04-28 | 2008-10-28 | Shionogi & Co | Derivados de amina que tienen actividad antagonista del receptor neuropeptido y y5. |
WO2007127475A2 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Pyridazines for demyelinating diseases and neuropathic pain |
EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
US8435774B2 (en) | 2006-06-28 | 2013-05-07 | Qiagen Gmbh | Enhancing reactivation of thermostable reversibly inactivated enzymes |
AU2007271089A1 (en) | 2006-07-07 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents |
WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
SI2583970T1 (sl) * | 2006-08-02 | 2016-03-31 | Cytokinetics, Inc. | Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine |
CA2660699A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridine compounds for treating gpr119 related disorders |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008071646A1 (en) * | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds |
DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
WO2009011285A1 (ja) | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | ヘテロアリールベンゼン化合物 |
GB0720444D0 (en) * | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
WO2009131958A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising triazine derivatives |
WO2009131947A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyridazine derivatives |
UY31865A (es) | 2008-06-04 | 2010-01-29 | Astrazeneca Ab | Derivados de urea heterocíclicos y métodos para la utilización de los mismos |
US8183267B2 (en) | 2008-06-09 | 2012-05-22 | Awd. Pharma Gmbh & Co. Kg | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
MX2011000081A (es) | 2008-06-30 | 2011-03-02 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina. |
US20100025641A1 (en) | 2008-08-04 | 2010-02-04 | Fujifilm Corporation | Infrared region selective reflection coat and infrared region selective reflection film |
EP2326627A1 (en) | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
KR20120002581A (ko) | 2009-03-30 | 2012-01-06 | 아스텔라스세이야쿠 가부시키가이샤 | 피리미딘 화합물 |
WO2011032169A2 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
NZ611529A (en) * | 2010-12-23 | 2015-06-26 | Pfizer | Glucagon receptor modulators |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
CA2868507A1 (en) | 2012-04-02 | 2013-10-10 | Cytokinetics, Inc. | Methods for improving diaphragm function |
SG11201406359TA (en) | 2012-04-11 | 2014-11-27 | Cytokinetics Inc | Improving resistance to skeletal muscle fatigue |
DK3137622T3 (da) | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
ES2750751T3 (es) | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
-
2011
- 2011-04-20 AR ARP110101387A patent/AR081626A1/es active IP Right Grant
- 2011-04-22 NZ NZ603593A patent/NZ603593A/en unknown
- 2011-04-22 EP EP16166061.8A patent/EP3127541B1/en active Active
- 2011-04-22 JP JP2013506327A patent/JP5918217B2/ja active Active
- 2011-04-22 CN CN201180021470.0A patent/CN103002897B/zh active Active
- 2011-04-22 US US13/642,207 patent/US8969346B2/en active Active
- 2011-04-22 EA EA201201377A patent/EA024881B1/ru unknown
- 2011-04-22 WO PCT/US2011/033605 patent/WO2011133882A1/en active Application Filing
- 2011-04-22 NZ NZ627973A patent/NZ627973A/en unknown
- 2011-04-22 EP EP11772778.4A patent/EP2563365B1/en active Active
- 2011-04-22 MX MX2012012259A patent/MX343264B/es active IP Right Grant
- 2011-04-22 BR BR112012026950-0A patent/BR112012026950B1/pt active IP Right Grant
- 2011-04-22 AU AU2011242569A patent/AU2011242569B2/en active Active
- 2011-04-22 CN CN201710354789.4A patent/CN107266419B/zh active Active
- 2011-04-22 KR KR1020187002999A patent/KR101960642B1/ko active IP Right Grant
- 2011-04-22 SG SG2012077871A patent/SG184954A1/en unknown
- 2011-04-22 TW TW100113965A patent/TWI501963B/zh active
- 2011-04-22 SG SG10201700219XA patent/SG10201700219XA/en unknown
- 2011-04-22 KR KR1020127029537A patent/KR101825735B1/ko active IP Right Grant
- 2011-04-22 MY MYPI2012004644A patent/MY191829A/en unknown
- 2011-04-22 CA CA2796390A patent/CA2796390C/en active Active
-
2012
- 2012-10-15 IL IL222465A patent/IL222465A/en active IP Right Grant
- 2012-10-22 CL CL2012002945A patent/CL2012002945A1/es unknown
- 2012-10-24 CO CO12189887A patent/CO6630154A2/es active IP Right Grant
- 2012-11-09 EC ECSP12012292 patent/ECSP12012292A/es unknown
-
2013
- 2013-08-02 HK HK13109022.8A patent/HK1181662A1/zh unknown
-
2015
- 2015-01-12 US US14/594,274 patent/US9604965B2/en active Active
-
2016
- 2016-04-07 JP JP2016076999A patent/JP6470224B2/ja active Active
- 2016-04-26 AU AU2016202617A patent/AU2016202617B2/en active Active
-
2017
- 2017-02-27 IL IL250824A patent/IL250824B/en active IP Right Grant
- 2017-03-20 US US15/463,288 patent/US10076519B2/en active Active
- 2017-06-23 PH PH12017501192A patent/PH12017501192B1/en unknown
-
2018
- 2018-03-19 AU AU2018201953A patent/AU2018201953B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5918217B2 (ja) | 特定のアミノピリダジン、その組成物、及びこれらの使用方法 | |
US10272030B2 (en) | Amino-pyrimidine skeletal muscle modulators | |
US9278962B2 (en) | Certain heterocycles, compositions thereof, and methods for their use | |
EP2560488A1 (en) | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20131113 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131113 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140310 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150529 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160407 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5918217 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |